| Other |
laboratory biomarker analysis |
419 |
2012 |
| Drug |
cisplatin |
263 |
2015 |
| Drug |
nivolumab |
171 |
2018 |
| Drug |
pembrolizumab |
169 |
2014 |
| placebo |
placebo |
166 |
2014 |
| Drug |
carboplatin |
164 |
2014 |
| Drug |
paclitaxel |
159 |
2015 |
| Drug |
sorafenib |
113 |
2015 |
| Other |
pharmacological study |
111 |
2006 |
| Other |
quality-of-life assessment |
110 |
2015 |
| Radiation |
radiotherapy |
110 |
2014 |
| Biological |
bevacizumab |
108 |
2006 |
| Drug |
docetaxel |
95 |
2015 |
| Drug |
cetuximab |
91 |
2014 |
| Other |
questionnaire administration |
86 |
2014 |
| Drug |
gemcitabine |
81 |
2014 |
| Drug |
durvalumab |
66 |
2018 |
| Biological |
ipilimumab |
66 |
2014 |
| Drug |
sunitinib |
54 |
2010 |
| Drug |
capecitabine |
48 |
2015 |
| Procedure |
tace |
44 |
2017 |
| Drug |
gemcitabine hydrochloride |
43 |
2015 |
| Drug |
cabozantinib |
40 |
2018 |
| Drug |
everolimus |
40 |
2014 |
| Drug |
fluorouracil |
40 |
2014 |
| Drug |
cyclophosphamide |
39 |
2018 |
| Drug |
tremelimumab |
39 |
2014 |
| Drug |
atezolizumab |
37 |
2018 |
| Radiation |
intensity-modulated radiation therapy |
37 |
2014 |
| Procedure |
therapeutic conventional surgery |
37 |
2019 |
| Drug |
avelumab |
36 |
2017 |
| Drug |
oxaliplatin |
35 |
2010 |
| Drug |
lenvatinib |
33 |
2018 |
| Procedure |
computed tomography |
28 |
2018 |
| Drug |
pazopanib |
28 |
2010 |
| Procedure |
positron emission tomography |
28 |
2018 |
| Drug |
sorafenib tosylate |
28 |
2006 |
| Drug |
erlotinib hydrochloride |
27 |
2008 |
| Drug |
olaparib |
26 |
2014 |
| Drug |
5-fluorouracil |
25 |
2010 |
| Drug |
etoposide |
25 |
2017 |
| Drug |
nab-paclitaxel |
24 |
2017 |
| Drug |
temsirolimus |
24 |
2006 |
| Drug |
chemotherapy |
22 |
2014 |
| Drug |
irinotecan |
22 |
2017 |
| Drug |
erlotinib |
20 |
2010 |
| Radiation |
sbrt |
20 |
2018 |
| Drug |
sunitinib malate |
20 |
2018 |
| Drug |
doxorubicin |
19 |
2018 |
| Drug |
doxorubicin hydrochloride |
19 |
2009 |
| Radiation |
imrt |
19 |
2019 |
| Radiation |
stereotactic body radiation therapy |
19 |
2018 |
| Drug |
enzalutamide |
18 |
2014 |
| Drug |
pemetrexed |
18 |
2010 |
| Drug |
5-fu |
17 |
2018 |
| Drug |
axitinib |
17 |
2009 |
| Procedure |
ct-scan |
17 |
2019 |
| Drug |
veliparib |
17 |
2012 |
| Other |
best supportive care |
15 |
2010 |
| Drug |
cabozantinib s-malate |
15 |
2014 |
| Procedure |
conventional surgery |
15 |
2018 |
| Radiation |
external beam radiation therapy |
15 |
2017 |
| Other |
questionnaire |
15 |
2020 |
| Radiation |
radiation |
15 |
2016 |
| Biological |
ramucirumab |
15 |
2019 |
| Drug |
toripalimab |
15 |
2019 |
| Biological |
trastuzumab |
15 |
2017 |
| Drug |
afatinib |
14 |
2019 |
| Drug |
apatinib |
14 |
2017 |
| Drug |
fludarabine |
14 |
2018 |
| Drug |
letrozole |
14 |
2018 |
| Drug |
rad001 |
14 |
2011 |
| Procedure |
surgery |
14 |
2014 |
| Drug |
vismodegib |
14 |
2009 |
| Radiation |
3-dimensional conformal radiation therapy |
13 |
2009 |
| Drug |
cemiplimab |
13 |
2019 |
| Drug |
lapatinib ditosylate |
13 |
2013 |
| Procedure |
radiofrequency ablation |
13 |
2009 |
| Drug |
sorafenib (nexavar, bay43-9006) |
13 |
2009 |
| Drug |
dexamethasone |
12 |
2009 |
| Drug |
gefitinib |
12 |
2009 |
| Procedure |
magnetic resonance imaging |
12 |
2018 |
| Drug |
pazopanib hydrochloride |
12 |
2011 |
| Drug |
pegylated liposomal doxorubicin hydrochloride |
12 |
2015 |
| Drug |
abiraterone acetate |
11 |
2012 |
| Drug |
cabazitaxel |
11 |
2018 |
| Drug |
cediranib maleate |
11 |
2010 |
| Biological |
filgrastim |
11 |
2010 |
| Drug |
irinotecan hydrochloride |
11 |
2016 |
| Drug |
leucovorin |
11 |
2017 |
| Drug |
prednisone |
11 |
2012 |
| Procedure |
rfa |
11 |
2010 |
| Drug |
tamoxifen citrate |
11 |
2011 |
| Drug |
topotecan hydrochloride |
11 |
2015 |
| Drug |
trametinib |
11 |
2017 |
| Procedure |
transarterial chemoembolization |
11 |
2016 |
| Drug |
akt inhibitor mk2206 |
10 |
2011 |
| Drug |
dasatinib |
10 |
2014 |
| Radiation |
intensity-modulated radiotherapy |
10 |
2012 |
| Radiation |
internal radiation therapy |
10 |
2018 |
| Drug |
methotrexate |
10 |
2014 |
| Device |
pet |
10 |
2018 |
| Drug |
sirolimus |
10 |
2010 |
| Drug |
vorinostat |
10 |
2010 |
| Procedure |
biopsy |
9 |
2018 |
| Drug |
bortezomib |
9 |
2010 |
| Biological |
cixutumumab |
9 |
2010 |
| Other |
educational intervention |
9 |
2013 |
| Drug |
entinostat |
9 |
2018 |
| Drug |
fulvestrant |
9 |
2018 |
| Drug |
metformin |
9 |
2014 |
| Diagnostic Test |
mri |
9 |
2013 |
| Drug |
palbociclib |
9 |
2017 |
| Drug |
panitumumab |
9 |
2012 |
| Drug |
photodynamic therapy |
9 |
2009 |
| Biological |
shr-1210 |
9 |
2017 |
| Radiation |
stereotactic body radiation therapy (sbrt) |
9 |
2018 |
| Biological |
aldesleukin |
8 |
2009 |
| Drug |
anlotinib |
8 |
2019 |
| Drug |
berzosertib |
8 |
2015 |
| Procedure |
cytoreductive surgery |
8 |
2009 |
| Drug |
folfiri |
8 |
2008 |
| Biological |
pegfilgrastim |
8 |
2010 |
| Drug |
pemetrexed disodium |
8 |
2017 |
| Drug |
sintilimab |
8 |
2018 |
| Drug |
anastrozole |
7 |
2018 |
| Other |
best available therapy |
7 |
2016 |
| Drug |
ccrt |
7 |
2015 |
| Drug |
celecoxib |
7 |
2018 |
| Drug |
epacadostat |
7 |
2017 |
| Procedure |
hepatic arterial infusion chemotherapy |
7 |
2016 |
| Drug |
imiquimod |
7 |
2019 |
| Drug |
ixabepilone |
7 |
2009 |
| Drug |
leucovorin calcium |
7 |
2017 |
| Drug |
mitomycin c |
7 |
2018 |
| Drug |
nedaplatin |
7 |
2020 |
| Drug |
nimotuzumab |
7 |
2018 |
| Drug |
osimertinib |
7 |
2018 |
| Drug |
paclitaxel albumin-stabilized nanoparticle formulation |
7 |
2014 |
| Radiation |
proton beam radiation therapy |
7 |
2012 |
| Drug |
regorafenib |
7 |
2014 |
| Drug |
selumetinib |
7 |
2012 |
| Drug |
standard care |
7 |
2015 |
| Drug |
talazoparib |
7 |
2017 |
| Biological |
talimogene laherparepvec |
7 |
2018 |
| Drug |
temozolomide |
7 |
2018 |
| Drug |
abemaciclib |
6 |
2019 |
| Drug |
copanlisib |
6 |
2018 |
| Behavioral |
exercise intervention |
6 |
2017 |
| Drug |
il-2 |
6 |
2018 |
| Radiation |
intensity modulated radiation therapy |
6 |
2014 |
| Drug |
interleukin-2 |
6 |
2018 |
| Drug |
lenalidomide |
6 |
2010 |
| Device |
microwave ablation |
6 |
2018 |
| Drug |
mitomycin |
6 |
2009 |
| Drug |
mk-3475 |
6 |
2014 |
| Drug |
niraparib |
6 |
2013 |
| Drug |
pdr001 |
6 |
2019 |
| Other |
pharmacogenomic study |
6 |
2017 |
| Drug |
ribociclib |
6 |
2018 |
| Drug |
sapanisertib |
6 |
2017 |
| Radiation |
stereotactic body radiotherapy |
6 |
2018 |
| Radiation |
stereotactic radiosurgery |
6 |
2013 |
| Drug |
tislelizumab |
6 |
2018 |
| Drug |
vinflunine |
6 |
2014 |
| Radiation |
yttrium y 90 glass microspheres |
6 |
2014 |
| Drug |
adavosertib |
5 |
2018 |
| Drug |
apatinib mesylate |
5 |
2020 |
| Procedure |
biospecimen collection |
5 |
2018 |
| Procedure |
blood draw |
5 |
2018 |
| Radiation |
brachytherapy |
5 |
2018 |
| Drug |
camrelizumab |
5 |
2020 |
| Drug |
cediranib |
5 |
2016 |
| Procedure |
chemoembolization |
5 |
2015 |
| Other |
clinical observation |
5 |
2014 |
| Drug |
crizotinib |
5 |
2015 |
| Diagnostic Test |
ct scan |
5 |
2011 |
| Biological |
dalantercept |
5 |
2011 |
| Other |
diagnostic laboratory biomarker analysis |
5 |
2011 |
| Drug |
fludarabine phosphate |
5 |
2018 |
| Radiation |
fludeoxyglucose f-18 |
5 |
2018 |
| Drug |
gemcitabine/cisplatin |
5 |
2018 |
| Procedure |
hepatic resection |
5 |
2014 |
| Procedure |
hipec |
5 |
2020 |
| Drug |
kg |
5 |
2018 |
| Drug |
medi4736 |
5 |
2014 |
| Drug |
melphalan |
5 |
2017 |
| Drug |
nintedanib |
5 |
2014 |
| Other |
patient observation |
5 |
2018 |
| Procedure |
peripheral blood stem cell transplantation |
5 |
2000 |
| Other |
pharmacokinetic study |
5 |
2017 |
| Biological |
recombinant ephb4-hsa fusion protein |
5 |
2017 |
| Radiation |
rt |
5 |
2019 |
| Drug |
rucaparib |
5 |
2017 |
| Drug |
sitravatinib |
5 |
2017 |
| Radiation |
stereotactic body radiotherapy (sbrt) |
5 |
2018 |
| Drug |
su011248 |
5 |
2007 |
| Procedure |
surgical resection |
5 |
2008 |
| Drug |
tadalafil |
5 |
2015 |
| Drug |
tipiracil hydrochloride |
5 |
2017 |
| Drug |
tivozanib |
5 |
2019 |
| Procedure |
transcatheter arterial chemoembolization |
5 |
2008 |
| Procedure |
transoral robotic surgery |
5 |
2011 |
| Drug |
trifluridine |
5 |
2017 |
| Drug |
trifluridine/tipiracil hydrochloride |
5 |
2017 |
| Biological |
ziv-aflibercept |
5 |
2014 |
| Procedure |
adjuvant therapy |
4 |
2006 |
| Drug |
amg 386 |
4 |
2009 |
| Drug |
anlotinib hydrochloride |
4 |
2019 |
| Drug |
bavituximab |
4 |
2018 |
| Behavioral |
behavioral dietary intervention |
4 |
2013 |
| Drug |
belinostat |
4 |
2009 |
| Drug |
binimetinib |
4 |
2015 |
| Drug |
brivanib |
4 |
2009 |
| Drug |
cobimetinib |
4 |
2017 |
| Other |
counseling intervention |
4 |
2010 |
| Drug |
cyclosporine |
4 |
1999 |
| Other |
cytology specimen collection procedure |
4 |
2015 |
| Dietary Supplement |
dietary intervention |
4 |
2016 |
| Drug |
dovitinib |
4 |
2010 |
| Drug |
eribulin mesylate |
4 |
2016 |
| Radiation |
external beam radiotherapy |
4 |
2010 |
| Drug |
folfox protocol |
4 |
2016 |
| Drug |
folfox4 |
4 |
2013 |
| Procedure |
g cream |
4 |
2007 |
| Drug |
hydroxyurea |
4 |
2014 |
| Drug |
ifosfamide |
4 |
2009 |
| Radiation |
intensity-modulated radiation therapy (imrt) |
4 |
2016 |
| Other |
internet-based intervention |
4 |
2015 |
| Radiation |
intraoperative radiotherapy |
4 |
2015 |
| Drug |
lde225 |
4 |
2011 |
| Drug |
lipiodol |
4 |
2016 |
| Drug |
metformin hydrochloride |
4 |
2014 |
| Drug |
mitotane |
4 |
2018 |
| Procedure |
nephrectomy |
4 |
2018 |
| Biological |
nivolumab/ipilimumab |
4 |
2016 |
| Drug |
pep005 |
4 |
2007 |
| Biological |
pertuzumab |
4 |
2017 |
| Procedure |
pet/ct |
4 |
2014 |
| Behavioral |
quality of life assessment |
4 |
2011 |
| Procedure |
radical cystectomy |
4 |
2016 |
| Biological |
sargramostim |
4 |
2016 |
| Drug |
systemic chemotherapy |
4 |
2011 |
| Procedure |
tai |
4 |
2017 |
| Behavioral |
telephone-based intervention |
4 |
2013 |
| Drug |
tivantinib |
4 |
2012 |
| Drug |
tpf induction chemotherapy |
4 |
2014 |
| Procedure |
transarterial chemoembolization (tace) |
4 |
2018 |
| Drug |
valproic acid |
4 |
2017 |
| Drug |
vinorelbine |
4 |
2010 |
| Drug |
vitamin c |
4 |
2017 |
| Drug |
5-fluorouracil (5-fu) |
3 |
2011 |
| Drug |
5-fu) |
3 |
2017 |
| Radiation |
accelerated partial breast irradiation |
3 |
2015 |
| Drug |
adi-peg 20 |
3 |
2014 |
| Drug |
adjuvant chemotherapy |
3 |
2014 |
| Drug |
alisertib |
3 |
2009 |
| Biological |
anti-ox40 antibody pf-04518600 |
3 |
2017 |
| Drug |
apalutamide |
3 |
2019 |
| Drug |
arq 197 |
3 |
2008 |
| Drug |
atorvastatin |
3 |
2017 |
| Drug |
avastin |
3 |
2008 |
| Drug |
axitinib (ag-013736) |
3 |
2010 |
| Drug |
azd1775 |
3 |
2015 |
| Drug |
bbi608 |
3 |
2015 |
| Procedure |
blood |
3 |
2014 |
| Other |
blood sample |
3 |
2013 |
| Drug |
brigatinib |
3 |
2018 |
| Drug |
brivanib alaninate |
3 |
2010 |
| Drug |
byl719 |
3 |
2014 |
| Biological |
car-gpc3 t cells |
3 |
2017 |
| Biological |
car-t cell immunotherapy |
3 |
2017 |
| Drug |
cb-839 |
3 |
2016 |
| Other |
chemoradiotherapy |
3 |
2016 |
| Drug |
cisplatin (induction chemotherapy) |
3 |
2015 |
| Drug |
cisplatin/carboplatin |
3 |
2010 |
| Drug |
cisplatinum |
3 |
2017 |
| Other |
communication intervention |
3 |
2017 |
| Procedure |
cryoablation |
3 |
2015 |
| Biological |
cytokine-induced killer cells |
3 |
2017 |
| Drug |
decitabine |
3 |
2015 |
| Drug |
diphenhydramine |
3 |
2017 |
| Biological |
durvalumab / tremelimumab |
3 |
2017 |
| Drug |
exemestane |
3 |
2018 |
| Drug |
famitinib |
3 |
2011 |
| Drug |
fgfr inhibitor azd4547 |
3 |
2015 |
| Drug |
fluciclovine f18 |
3 |
2019 |
| Drug |
folinic acid |
3 |
2015 |
| Drug |
gallium ga 68-labeled psma-11 |
3 |
2019 |
| Drug |
gamma-secretase inhibitor ro4929097 |
3 |
2010 |
| Drug |
gemcitabine/cisplatin (induction chemotherapy) |
3 |
2015 |
| Drug |
goserelin acetate |
3 |
2014 |
| Drug |
guadecitabine |
3 |
2018 |
| Procedure |
hepatectomy |
3 |
2018 |
| Drug |
hpph |
3 |
2010 |
| Drug |
hydroxychloroquine |
3 |
2019 |
| Drug |
hyperthermic intraperitoneal chemotherapy |
3 |
2014 |
| Radiation |
hypofractionated radiation therapy |
3 |
2017 |
| Radiation |
image guided radiation therapy |
3 |
2012 |
| Drug |
imiquimod 5% cream |
3 |
2017 |
| Biological |
immuncell-lc |
3 |
2016 |
| Other |
immunohistochemistry staining method |
3 |
2008 |
| Drug |
indocyanine green |
3 |
2013 |
| Other |
informational intervention |
3 |
2020 |
| Radiation |
intensity modulated radiation therapy (imrt) |
3 |
2019 |
| Radiation |
intensity modulated radiotherapy (imrt) |
3 |
2014 |
| Drug |
ipi-549 |
3 |
2019 |
| Drug |
itraconazole |
3 |
2014 |
| Drug |
lapatinib |
3 |
2011 |
| Procedure |
laser therapy |
3 |
2017 |
| Drug |
liposomal irinotecan |
3 |
2017 |
| Procedure |
liver resection |
3 |
2018 |
| Drug |
ly2157299 |
3 |
2014 |
| Procedure |
lymph node biopsy |
3 |
2014 |
| Procedure |
metastasectomy |
3 |
2018 |
| Drug |
methylprednisolone |
3 |
1999 |
| Drug |
mln0128 |
3 |
2016 |
| Biological |
modified vaccinia virus ankara vaccine expressing p53 |
3 |
2014 |
| Drug |
mycophenolate mofetil |
3 |
2000 |
| Biological |
navitoclax |
3 |
2014 |
| Drug |
neoadjuvant chemotherapy |
3 |
2016 |
| Procedure |
neoadjuvant therapy |
3 |
2011 |
| Drug |
nexavar (sorafenib, bay43-9006) |
3 |
2008 |
| Drug |
niclosamide |
3 |
2016 |
| Procedure |
nonmyeloablative allogeneic hematopoietic stem cell transplantation |
3 |
2000 |
| Other |
observation |
3 |
2012 |
| Drug |
onalespib |
3 |
2016 |
| Biological |
oncolytic measles virus encoding thyroidal sodium iodide symporter |
3 |
2015 |
| Drug |
paclitaxel poliglumex |
3 |
2005 |
| Drug |
paclitaxel/cisplatin |
3 |
2012 |
| Drug |
pei |
3 |
2016 |
| Drug |
pf |
3 |
2017 |
| Radiation |
photon beam radiation therapy |
3 |
2012 |
| Drug |
pipac |
3 |
2017 |
| Drug |
poly iclc |
3 |
2018 |
| Radiation |
proton beam therapy |
3 |
2012 |
| Radiation |
radical radiotherapy |
3 |
2016 |
| Radiation |
radium ra 223 dichloride |
3 |
2017 |
| Biological |
recombinant interferon alfa-2b |
3 |
2018 |
| Drug |
retifanlimab |
3 |
2018 |
| Drug |
ribavirin |
3 |
2016 |
| Drug |
rintatolimod |
3 |
2018 |
| Drug |
s-1 |
3 |
2018 |
| Other |
saline |
3 |
2011 |
| Drug |
savolitinib |
3 |
2016 |
| Drug |
sodium thiosulfate |
3 |
2019 |
| Drug |
spartalizumab |
3 |
2019 |
| Radiation |
stereotactic ablative radiotherapy |
3 |
2013 |
| Radiation |
stereotactic body radiation |
3 |
2019 |
| Drug |
suramin |
3 |
2004 |
| Drug |
taselisib |
3 |
2015 |
| Drug |
tegafur |
3 |
2018 |
| Drug |
thalidomide |
3 |
2007 |
| Drug |
tipifarnib |
3 |
2015 |
| Drug |
tivozanib (av-951) |
3 |
2009 |
| Drug |
topotecan |
3 |
2016 |
| Radiation |
total-body irradiation |
3 |
2000 |
| Drug |
tpf |
3 |
2018 |
| Drug |
tpf/ccrt |
3 |
2018 |
| Drug |
trc105 |
3 |
2011 |
| Biological |
trebananib |
3 |
2012 |
| Biological |
utomilumab |
3 |
2017 |
| Drug |
vandetanib |
3 |
2015 |
| Device |
18f-fdg pet |
2 |
2020 |
| Drug |
18f-fluoromisonidazole |
2 |
2015 |
| Drug |
5fu |
2 |
2008 |
| Drug |
68ganota-anti-her2 vhh1 |
2 |
2017 |
| Drug |
abbv-181 |
2 |
2019 |
| Drug |
abbv-368 |
2 |
2019 |
| Drug |
abexinostat |
2 |
2018 |
| Biological |
abi-007 |
2 |
2011 |
| Drug |
abr-217620 |
2 |
2003 |
| Drug |
abraxane |
2 |
2006 |
| Drug |
abt-869 |
2 |
2007 |
| Drug |
acalabrutinib |
2 |
2015 |
| Drug |
adv-tk |
2 |
2014 |
| Drug |
afatinib dimaleate |
2 |
2015 |
| Drug |
afimoxifene |
2 |
2009 |
| Biological |
ags-003 |
2 |
2008 |
| Drug |
ags-16c3f |
2 |
2015 |
| Biological |
ak105 |
2 |
2019 |
| Drug |
albumin-bound paclitaxel |
2 |
2019 |
| Drug |
alpelisib |
2 |
2017 |
| Drug |
amifostine |
2 |
2006 |
| Drug |
amifostine trihydrate |
2 |
2006 |
| Drug |
antiandrogen therapy |
2 |
2018 |
| Drug |
apatinib mesylate tablet |
2 |
2020 |
| Biological |
apl-501 |
2 |
2017 |
| Drug |
arq 501 |
2 |
2006 |
| Procedure |
assessment for surgical evaluation |
2 |
2014 |
| Drug |
atezolizumab (mpdl3280a), an engineered anti-pd-l1 antibody |
2 |
2013 |
| Drug |
atg-008 |
2 |
2018 |
| Drug |
atiprimod |
2 |
2008 |
| Drug |
azacitidine |
2 |
2011 |
| Drug |
azd9150 |
2 |
2013 |
| Drug |
bbi503 |
2 |
2014 |
| Biological |
bcg solution |
2 |
2017 |
| Biological |
bempegaldesleukin |
2 |
2018 |
| Drug |
bibf 1120 |
2 |
2009 |
| Device |
biliary stent |
2 |
2016 |
| Drug |
bintrafusp alfa |
2 |
2019 |
| Drug |
bupropion hydrochloride |
2 |
2017 |
| Drug |
busulfan |
2 |
2012 |
| Drug |
capecitabine adjuvant chemotherapy |
2 |
2014 |
| Drug |
capecitabine(aibin) |
2 |
2013 |
| Drug |
capivasertib |
2 |
2015 |
| Drug |
carboplatin/paclitaxel/pelvic radiation therapy |
2 |
2005 |
| Procedure |
care |
2 |
2013 |
| Biological |
carotuximab (trc105) |
2 |
2015 |
| Drug |
cc-486 |
2 |
2014 |
| Drug |
cci-779 |
2 |
2005 |
| Drug |
ccrt/pf |
2 |
2017 |
| Drug |
cddp |
2 |
2019 |
| Drug |
cf102 |
2 |
2014 |
| Other |
chemoradiation |
2 |
2016 |
| Drug |
chidamide |
2 |
2016 |
| Drug |
cisplatin/doxorubicin |
2 |
2014 |
| Device |
computed tomography perfusion imaging |
2 |
2018 |
| Radiation |
concurrent cisplatin |
2 |
2013 |
| Device |
cone-beam computed tomography |
2 |
2018 |
| Drug |
copanlisib hydrochloride |
2 |
2015 |
| Other |
correlative studies |
2 |
2014 |
| Other |
counseling |
2 |
2016 |
| Procedure |
cryosurgery |
2 |
2015 |
| Biological |
cv8102 |
2 |
2017 |
| Device |
cyberknife |
2 |
2010 |
| Procedure |
cytoreductive surgery (crs) |
2 |
2014 |
| Drug |
cytoxan |
2 |
2016 |
| Drug |
dabrafenib |
2 |
2013 |
| Drug |
dabrafenib mesylate |
2 |
2013 |
| Drug |
ddp |
2 |
2019 |
| Biological |
dec-205 |
2 |
2012 |
| Biological |
dec-205/ny-eso-1 fusion protein cdx-1401 |
2 |
2012 |
| Drug |
dinaciclib |
2 |
2013 |
| Drug |
docetaxel-pm |
2 |
2018 |
| Drug |
docetaxel, cisplatin, fluorouracil |
2 |
2020 |
| Drug |
docetaxel/cisplatin |
2 |
2012 |
| Drug |
doxil |
2 |
2015 |
| Drug |
durvalumab/tremelimumab |
2 |
2018 |
| Procedure |
dynamic contrast-enhanced magnetic resonance imaging |
2 |
2008 |
| Drug |
ef5 |
2 |
2014 |
| Other |
embolization |
2 |
2010 |
| Drug |
enfortumab vedotin |
2 |
2019 |
| Behavioral |
enhanced usual care |
2 |
2015 |
| Drug |
enmd-2076 |
2 |
2014 |
| Drug |
entecavir |
2 |
2009 |
| Drug |
enzastaurin |
2 |
2008 |
| Other |
eortc qlq-30 |
2 |
2018 |
| Drug |
epirubicin hydrochloride |
2 |
2012 |
| Drug |
erdafitinib |
2 |
2015 |
| Procedure |
esophagectomy |
2 |
2019 |
| Drug |
everolimus (rad001) |
2 |
2008 |
| Radiation |
external beam radiotherapy (ebrt) |
2 |
2009 |
| Procedure |
fdg-pet |
2 |
2013 |
| Procedure |
fdg-pet/ct |
2 |
2013 |
| Drug |
ficlatuzumab |
2 |
2014 |
| Drug |
floxuridine |
2 |
2013 |
| Radiation |
fludeoxyglucose f 18 |
2 |
2010 |
| Other |
fluorothymidine f-18 |
2 |
2010 |
| Drug |
fluorouracil (5-fu) |
2 |
2015 |
| Drug |
fmiso |
2 |
2017 |
| Dietary Supplement |
folic acid |
2 |
2016 |
| Drug |
g-202 |
2 |
2013 |
| Biological |
g-csf |
2 |
2005 |
| Drug |
galunisertib |
2 |
2015 |
| Drug |
gdc-0980 |
2 |
2011 |
| Drug |
gemcitabine/carboplatin |
2 |
2010 |
| Biological |
glycosylated recombinant human interleukin-7 |
2 |
2013 |
| Biological |
gm-csf |
2 |
2010 |
| Drug |
gp |
2 |
2017 |
| Drug |
h101 |
2 |
2018 |
| Drug |
haic of folfox |
2 |
2019 |
| Procedure |
hepatectomy alone |
2 |
2014 |
| Combination Product |
hepatic arterial infusion |
2 |
2017 |
| Radiation |
high-dose rate brachytherapy |
2 |
2015 |
| Drug |
hmn14 (labetuzumab) |
2 |
2002 |
| Procedure |
hyperthermia treatment |
2 |
2013 |
| Drug |
ibi305 |
2 |
2019 |
| Drug |
ibrutinib |
2 |
2015 |
| Drug |
icotinib |
2 |
2012 |
| Drug |
idarubicin |
2 |
2009 |
| Biological |
ido1 inhibitor bms-986205 |
2 |
2018 |
| Drug |
ima901 |
2 |
2010 |
| Drug |
imatinib mesylate |
2 |
2003 |
| Other |
immunologic technique |
2 |
2010 |
| Drug |
immunotherapy |
2 |
2018 |
| Biological |
imp321 |
2 |
2017 |
| Drug |
imrt combine with cisplatin concurrent chemotherapy |
2 |
2014 |
| Drug |
imrt combine with cisplatin concurrent chemotherapy/capecitabine adjuvant chemotherapy |
2 |
2014 |
| Radiation |
imrt/concurrent cisplatin |
2 |
2013 |
| Drug |
inc280 |
2 |
2016 |
| Drug |
incb024360 |
2 |
2014 |
| Drug |
indomethacin |
2 |
2016 |
| Drug |
interferon alfa |
2 |
2003 |
| Drug |
interferon alfa-2a |
2 |
2007 |
| Drug |
interferon alpha-2b |
2 |
2006 |
| Procedure |
interventional therapy |
2 |
2015 |
| Drug |
intraperitoneal oxaliplatin |
2 |
2010 |
| Radiation |
iodine i-131 |
2 |
2014 |
| placebo |
ipilimumab placebo |
2 |
2017 |
| Drug |
iressa (zd1839) |
2 |
2005 |
| Biological |
jx-594 |
2 |
2011 |
| Drug |
ketoconazole |
2 |
2018 |
| Drug |
kn046 |
2 |
2019 |
| Procedure |
laparoscopic surgery |
2 |
2016 |
| Procedure |
laser ablation |
2 |
2018 |
| Drug |
lenvatinib pill |
2 |
2018 |
| Drug |
ljm716 |
2 |
2012 |
| Biological |
ln-145 |
2 |
2017 |
| Procedure |
lt |
2 |
2014 |
| Procedure |
lumpectomy |
2 |
2016 |
| Other |
lymphatic mapping |
2 |
2009 |
| Drug |
m2 |
2 |
2011 |
| Procedure |
magnetic resonance elastography |
2 |
2019 |
| Biological |
mapatumumab |
2 |
2008 |
| Procedure |
mastectomy |
2 |
2016 |
| Drug |
medi4736 / tremelimumab |
2 |
2015 |
| Drug |
megestrol acetate |
2 |
2008 |
| Drug |
mfolfox6 (oxaliplatin, calcium folinate, |
2 |
2017 |
| Drug |
mfolfox6 (oxaliplatin, calcium folinate,/5-fu) |
2 |
2017 |
| Biological |
mg4101 |
2 |
2013 |
| Device |
microwave ablation (mwa) |
2 |
2018 |
| Biological |
mirvetuximab soravtansine |
2 |
2016 |
| Drug |
mitomycin-c |
2 |
2015 |
| Drug |
mk-2206 |
2 |
2011 |
| Diagnostic Test |
mr |
2 |
2018 |
| Biological |
multi-epitope folate receptor alpha peptide vaccine |
2 |
2016 |
| Biological |
n-803 |
2 |
2017 |
| Device |
nbi endoscopy |
2 |
2014 |
| Biological |
necitumumab |
2 |
2017 |
| Procedure |
neck dissection |
2 |
2014 |
| Drug |
nedisertib |
2 |
2019 |
| Drug |
neulasta |
2 |
2011 |
| Biological |
nk cells |
2 |
2014 |
| Biological |
ny-eso-1 fusion protein cdx-1401 |
2 |
2012 |
| Biological |
oblimersen sodium |
2 |
2004 |
| Drug |
octreotide acetate |
2 |
2010 |
| Drug |
octreotide depot |
2 |
2006 |
| Procedure |
open surgery |
2 |
2014 |
| Procedure |
operation |
2 |
2009 |
| Device |
optical coherence tomography |
2 |
2014 |
| Drug |
oxaliplatin(aiheng) |
2 |
2013 |
| Drug |
oxycodone |
2 |
2016 |
| Drug |
p276-00 |
2 |
2009 |
| Drug |
paclitaxel liposome |
2 |
2018 |
| Drug |
patidegib |
2 |
2016 |
| Drug |
patidegib topical gel, 2% |
2 |
2018 |
| Drug |
patidegib topical gel, vehicle |
2 |
2018 |
| Drug |
pd-1 |
2 |
2019 |
| Drug |
pd-1 blocking antibody |
2 |
2019 |
| Combination Product |
pd-1 mab |
2 |
2018 |
| Procedure |
pdt with metvix 160 mg |
2 |
2007 |
| Biological |
peg-pei-cholesterol lipopolymer-encased il-12 dna plasmid vector gen-1 |
2 |
2011 |
| Biological |
pegylated recombinant human arginase i |
2 |
2010 |
| Procedure |
peit |
2 |
2009 |
| Drug |
pelvic radiation therapy |
2 |
2005 |
| Drug |
pemigatinib |
2 |
2019 |
| Procedure |
percutaneous ethanol injection therapy |
2 |
2006 |
| Other |
pet scan |
2 |
2010 |
| Drug |
pevonedistat |
2 |
2019 |
| Biological |
pexastimogene devacirepvec (pexa vec) |
2 |
2017 |
| Drug |
pf-00299804 |
2 |
2011 |
| Drug |
pf-06801591 |
2 |
2019 |
| Other |
pharmacogenomic studies |
2 |
2011 |
| Procedure |
photodynamic therapy with metvix 160 mg |
2 |
2007 |
| Procedure |
photodynamic therapy with metvix 160 mg/g cream |
2 |
2007 |
| Drug |
pirarubicin |
2 |
2016 |
| placebo |
placebo pill |
2 |
2018 |
| Drug |
porfimer sodium |
2 |
2018 |
| Procedure |
positron emission tomography/computed tomography |
2 |
2019 |
| Radiation |
post-operative radiotherapy |
2 |
2014 |
| Radiation |
postoperative radiotherapy |
2 |
2016 |
| Drug |
pralatrexate |
2 |
2010 |
| Drug |
pravastatin |
2 |
2011 |
| Drug |
propranolol |
2 |
2011 |
| Genetic |
protein expression analysis |
2 |
2008 |
| Radiation |
proton radiation therapy |
2 |
2011 |
| Radiation |
proton therapy |
2 |
2009 |
| Procedure |
psychosocial assessment |
2 |
2013 |
| Procedure |
psychosocial assessment/care |
2 |
2013 |
| Drug |
pt2977 |
2 |
2018 |
| Procedure |
punch biopsy |
2 |
2014 |
| Procedure |
radiofrequency ablation (rfa) |
2 |
2019 |
| Radiation |
radiotherapy (rt) |
2 |
2018 |
| Drug |
raltitrexed |
2 |
2017 |
| Drug |
recombinant vaccinia gm-csf; rac vac gm-csf (jx-594) |
2 |
2011 |
| Drug |
refametinib (bay86-9766) |
2 |
2013 |
| Device |
reflectance confocal microscopy |
2 |
2014 |
| Biological |
regn2810 |
2 |
2017 |
| Radiation |
reirradiation |
2 |
2014 |
| Drug |
remetinostat |
2 |
2017 |
| Biological |
reolysin |
2 |
2009 |
| Drug |
rg3 |
2 |
2016 |
| Biological |
rilotumumab |
2 |
2009 |
| Drug |
rituximab |
2 |
2013 |
| Drug |
rogaratinib (bay1163877) |
2 |
2018 |
| Drug |
romidepsin |
2 |
2012 |
| Drug |
rucaparib camsylate |
2 |
2018 |
| Procedure |
sentinel node biopsy |
2 |
2012 |
| Device |
separable clustered electrodes |
2 |
2018 |
| Procedure |
single photon emission computed tomography |
2 |
2017 |
| Drug |
sintilimab injection |
2 |
2019 |
| Device |
sir-spheres |
2 |
2017 |
| Drug |
sonidegib |
2 |
2019 |
| Drug |
sorafenib / pravastatin |
2 |
2013 |
| Dietary Supplement |
soy isoflavones |
2 |
2013 |
| Radiation |
spect |
2 |
2018 |
| Dietary Supplement |
sugar pill |
2 |
2011 |
| Drug |
sunitinib (sutent) |
2 |
2008 |
| Procedure |
surgery group |
2 |
2014 |
| Procedure |
surgical excision |
2 |
2014 |
| Drug |
tace drug protocol |
2 |
2016 |
| Drug |
tacrolimus |
2 |
2014 |
| Combination Product |
tak-228 |
2 |
2017 |
| Drug |
talaporfin sodium |
2 |
2006 |
| Drug |
tamoxifen |
2 |
2018 |
| Drug |
tasquinimod |
2 |
2014 |
| Drug |
taxotere |
2 |
2005 |
| Drug |
tc 99m ec20 |
2 |
2012 |
| Drug |
tegafur-uracil |
2 |
2017 |
| Drug |
tepotinib |
2 |
2013 |
| Drug |
tetrathiomolybdate |
2 |
2005 |
| Drug |
tg4050 |
2 |
2019 |
| Biological |
therapeutic allogeneic lymphocytes |
2 |
2000 |
| Biological |
therapeutic autologous dendritic cells |
2 |
2013 |
| Drug |
thermodox |
2 |
2014 |
| Drug |
tivozanib hydrochloride |
2 |
2015 |
| Drug |
tkm-080301 |
2 |
2014 |
| Drug |
tlr8 agonist vtx-2337 |
2 |
2011 |
| Drug |
transarterial chemoembolisation (tace) |
2 |
2018 |
| Biological |
trastuzumab emtansine |
2 |
2017 |
| Drug |
triapine |
2 |
2015 |
| Procedure |
tumor biopsy |
2 |
2017 |
| Drug |
ulinastatin |
2 |
2017 |
| Procedure |
ultrasound imaging |
2 |
2009 |
| Device |
uni-deb |
2 |
2018 |
| Drug |
vehicle gel |
2 |
2016 |
| Drug |
vinblastine |
2 |
2019 |
| Drug |
vincristine sulfate |
2 |
2018 |
| Drug |
vinorelbine tartrate |
2 |
2006 |
| Dietary Supplement |
vitamin d |
2 |
2018 |
| Drug |
vtx-2337 |
2 |
2013 |
| Radiation |
whole-brain radiotherapy |
2 |
2015 |
| Radiation |
whole breast irradiation |
2 |
2016 |
| Biological |
wild-type reovirus |
2 |
2011 |
| Drug |
with cisplatin |
2 |
2018 |
| Drug |
x4p-001 |
2 |
2016 |
| Procedure |
yttrium-90 microsphere radioembolization |
2 |
2017 |
| Dietary Supplement |
zinc |
2 |
2019 |
| Diagnostic Test |
“epi procolon 2.0 ce” test from epigenomics, inc (berlin, germany) |
1 |
2017 |
| Drug |
(rt |
1 |
2010 |
| Drug |
[18f]f-arag pet scan, baseline |
1 |
2017 |
| Drug |
[18f]f-arag pet scan, baseline / post anti-pd-1 therapy. |
1 |
2017 |
| Diagnostic Test |
[68ga]dotatate-pet |
1 |
2018 |
| Diagnostic Test |
[68ga]dotatate-pet/mri |
1 |
2018 |
| Drug |
[f-18] vm4-037 |
1 |
2009 |
| Drug |
1 |
1 |
2007 |
| Drug |
1.7ml |
1 |
2019 |
| Drug |
100 âµg doxorubicin-containing mna |
1 |
2018 |
| Device |
1064 multiplex laser |
1 |
2014 |
| Drug |
111-in-dota-cg250 |
1 |
2005 |
| Drug |
111in-cp04 |
1 |
2017 |
| Drug |
111in-cp04 with co-administration of gelofusine |
1 |
2017 |
| Drug |
111in-cp04 with co-administration of gelofusine/gelaspan |
1 |
2017 |
| Procedure |
11carbon-acetate-pet |
1 |
2004 |
| Drug |
12.5mg sunitinib with cisplatin |
1 |
2011 |
| Drug |
12.5mg sunitinib with cisplatin/gemcitabine |
1 |
2011 |
| Drug |
123i-iodometomidate |
1 |
2007 |
| Drug |
124-iodine-cg250 (124i-cg250) |
1 |
2008 |
| Drug |
124icg250 |
1 |
2012 |
| Drug |
13-cis retino acid |
1 |
2005 |
| Drug |
131 i-lipiodol |
1 |
2005 |
| Biological |
131i-chtnt-1 |
1 |
2016 |
| Biological |
131i-chtnt-1/b |
1 |
2016 |
| Drug |
177-lu-dota-cg250 |
1 |
2005 |
| Drug |
18-f fdg |
1 |
2014 |
| Drug |
188re-sss lipiodol |
1 |
2010 |
| Drug |
18f-al-nota-prgd2 pet |
1 |
2015 |
| Drug |
18f-al-nota-prgd2 pet/ct |
1 |
2015 |
| Drug |
18f-dcfpyl |
1 |
2016 |
| Device |
18f-fdg-pet |
1 |
2012 |
| Device |
18f-fdg pet/ct, mri |
1 |
2020 |
| Other |
18f-fdg pet/with ct with iodinated contrast injection |
1 |
2015 |
| Other |
18f-fdg pet/with ct without injection |
1 |
2015 |
| Drug |
18f-fludeoxyglucose (18f-fdg) |
1 |
2013 |
| Procedure |
18f-fluorodeoxyglucose-pet (fdg-pet) |
1 |
2004 |
| Drug |
18f-fluoromethylcholine |
1 |
2011 |
| Drug |
18f-fpprgd2 |
1 |
2013 |
| Drug |
18f-î±vî²6-bp |
1 |
2017 |
| Diagnostic Test |
18fdg-pet |
1 |
2019 |
| Diagnostic Test |
18fdg-pet/ct |
1 |
2019 |
| Radiation |
18fdg pet |
1 |
2018 |
| Drug |
2 |
1 |
2007 |
| Other |
2 cycles cisplatin-5-fluorouracil |
1 |
2015 |
| Drug |
2.5mg |
1 |
2011 |
| Drug |
2.5mg/kg bevacizumab alternating with cisplatin/gemcitabine |
1 |
2011 |
| Drug |
200 âµg doxorubicin-containing mna |
1 |
2018 |
| Radiation |
23f) of neoadjuvant chemoradiation |
1 |
2017 |
| Biological |
240mg anti-pd-1 mab js001 q3w |
1 |
2016 |
| Drug |
25 âµg doxorubicin-containing mna |
1 |
2018 |
| Radiation |
25 gy |
1 |
2015 |
| Biological |
2503 |
1 |
2017 |
| Drug |
25mg sunitinib alternating with cisplatin |
1 |
2011 |
| Drug |
25mg sunitinib alternating with cisplatin/gemcitabine |
1 |
2011 |
| Radiation |
28f) of neoadjuvant chemoradiation |
1 |
2017 |
| Device |
2940-nm er:yag afl pretreatment |
1 |
2016 |
| Radiation |
3-dcrt |
1 |
2017 |
| Radiation |
3-dcrt/imrt radiation |
1 |
2017 |
| Radiation |
3-dimensional conformal accelerated partial breast irradiation |
1 |
2017 |
| Radiation |
3-dimensional ultrasound-guided radiation therapy |
1 |
2015 |
| Drug |
3 cycles of neoadjuvant chemotherapy with concurrent chemoradiotherapy |
1 |
2019 |
| Biological |
3 mg |
1 |
2016 |
| Biological |
3 mg/kg anti-pd-1 mab js001 q2w |
1 |
2016 |
| Radiation |
30 gy over 3 weeks |
1 |
2017 |
| Biological |
360 mg anti-pd-1 mab js001 q3w |
1 |
2016 |
| Radiation |
39.6 gy radiation |
1 |
2013 |
| Procedure |
3d-crt |
1 |
2016 |
| Radiation |
3d-printing template-assisted ct-guided i-125 seed implantation |
1 |
2020 |
| Radiation |
3d conformal radiation therapy |
1 |
2013 |
| Diagnostic Test |
3d ultrasound |
1 |
2015 |
| Radiation |
3dcrt |
1 |
2009 |
| Radiation |
3dcrt/imrt |
1 |
2009 |
| Other |
4 cycles cisplatin-5-fluorouracil |
1 |
2015 |
| Drug |
4 cycles of neoadjuvant chemotherapy with definitive radiotherapy |
1 |
2019 |
| Drug |
40 mg |
1 |
2015 |
| Device |
40um embozene tandem microspheres |
1 |
2016 |
| Drug |
4sc-201 |
1 |
2009 |
| Drug |
4sc-201(resminostat) |
1 |
2011 |
| Drug |
5-azacitadine |
1 |
2014 |
| Drug |
5-flourouracil, interferon-a, il-2 |
1 |
2006 |
| Drug |
5-flourouracil, interferon-a, il-2/thalidomide |
1 |
2006 |
| Drug |
5-fluoro-uracil |
1 |
2015 |
| Drug |
5-fluorouracil (5fu) |
1 |
2016 |
| Drug |
5-fluorouracil (tpf) (only until feb 2009) |
1 |
2007 |
| Drug |
5-fluorouracil) |
1 |
2013 |
| Drug |
5% dextrose solution |
1 |
2008 |
| Drug |
50 âµg doxorubicin-containing mna |
1 |
2018 |
| Radiation |
50 gy |
1 |
2015 |
| Drug |
52.6ml gemcitabine instillation |
1 |
2017 |
| Device |
595 |
1 |
2014 |
| Device |
595/1064 multiplex laser |
1 |
2014 |
| Drug |
5fluorouracil |
1 |
2017 |
| Drug |
5fluorouracil bolus |
1 |
2016 |
| Drug |
5fluorouracil continu |
1 |
2016 |
| Drug |
6 weeks bcg instillation |
1 |
2017 |
| Drug |
68 ga-imp-288 |
1 |
2012 |
| Other |
68ga-nota-ae105 pet |
1 |
2016 |
| Other |
68ga-nota-ae105 pet/ct |
1 |
2016 |
| Drug |
68ga-psma-11 pet |
1 |
2019 |
| Drug |
68ga-psma-11 pet/mri |
1 |
2019 |
| Diagnostic Test |
68ga-psma-pet |
1 |
2019 |
| Diagnostic Test |
68ga-psma-pet/ct |
1 |
2019 |
| Drug |
68gallium citrate |
1 |
2016 |
| Drug |
7-hydroxystaurosporine |
1 |
2002 |
| Drug |
7.5mg |
1 |
2011 |
| Drug |
7.5mg/kg bevacizumab alternating with cisplatin/gemcitabine |
1 |
2011 |
| Drug |
75 approved agents |
1 |
2016 |
| Drug |
89zr-bevacizumab |
1 |
2013 |
| Drug |
89zr-dfo-atezolizumab |
1 |
2019 |
| Diagnostic Test |
89zr-girentuximab |
1 |
2018 |
| Combination Product |
a (pembrolizumab |
1 |
2017 |
| Combination Product |
a (pembrolizumab/rt) |
1 |
2017 |
| Drug |
a combination of anti-pd-1 antibody camrelizumab |
1 |
2019 |
| Drug |
a combination of anti-pd-1 antibody camrelizumab/albumin-bound paclitaxel |
1 |
2019 |
| Behavioral |
a healthy diet |
1 |
2014 |
| Behavioral |
a healthy diet, |
1 |
2014 |
| Drug |
a steroid-free immunosuppression protocol |
1 |
2010 |
| Drug |
• tf2 |
1 |
2012 |
| Drug |
• tf2/68 ga-imp-288 |
1 |
2012 |
| Drug |
a166 |
1 |
2018 |
| Drug |
ab122 |
1 |
2018 |
| Drug |
ab928 |
1 |
2018 |
| Drug |
abbv-085 |
1 |
2015 |
| Drug |
abbv-399 |
1 |
2018 |
| Drug |
abbv-927 |
1 |
2019 |
| Biological |
abi-007/carboplatin/trastuzumab |
1 |
1999 |
| Drug |
abiraterone acetate, prednisolone |
1 |
2014 |
| Device |
ablation |
1 |
2016 |
| Device |
ablation with the nanoknife low energy direct current (ledc) system |
1 |
2010 |
| Other |
ablation) |
1 |
2012 |
| Procedure |
ablative chemoembolization (ace) |
1 |
2018 |
| Drug |
abr-217620/naptumomab estafenatox |
1 |
2007 |
| Drug |
abt-510 |
1 |
2003 |
| Drug |
abt-510/thrombospondin-1 mimetic |
1 |
2003 |
| Drug |
abt-888 |
1 |
2011 |
| Drug |
abx-egf |
1 |
2005 |
| Drug |
abx196 |
1 |
2019 |
| Radiation |
accelerated fractionation (afx) radiotherapy |
1 |
2017 |
| Radiation |
accelerated radiotherapy |
1 |
2005 |
| Behavioral |
acceptance |
1 |
2015 |
| Behavioral |
acceptance/commitment therapy |
1 |
2015 |
| Dietary Supplement |
acetogenins |
1 |
2014 |
| Drug |
acetylcysteine |
1 |
2014 |
| Drug |
acp-196 in combination with pembrolizumab |
1 |
2015 |
| Diagnostic Test |
act-hla |
1 |
2017 |
| Behavioral |
active comparator: progressive resistance training (prt) |
1 |
2014 |
| Behavioral |
active comparator: progressive resistance training (prt)/a healthy diet |
1 |
2014 |
| Device |
acupuncture therapy |
1 |
2016 |
| Drug |
acyclovir 800 mg |
1 |
2018 |
| Drug |
ad.hifn-î² (bg00001, idec-201) |
1 |
2005 |
| Biological |
adagloxad simolenin |
1 |
2018 |
| Biological |
adagloxad simolenin/obi-821 |
1 |
2018 |
| Radiation |
adaptative radiotherapy |
1 |
2013 |
| Drug |
adct-301 |
1 |
2018 |
| Other |
additional rmis |
1 |
2013 |
| Biological |
adgmcaix-transduced autologous dendritic cells |
1 |
2013 |
| Drug |
adi-peg 20 (arginine deiminase formulated with polyethylene glycol) |
1 |
2011 |
| Other |
adjuvant |
1 |
2016 |
| Drug |
adjuvant chemotherapy using pf (5-fluorouracil ) |
1 |
2006 |
| Drug |
adjuvant chemotherapy) |
1 |
2017 |
| Drug |
adjuvant group |
1 |
2010 |
| Radiation |
adjuvant hypofractionation |
1 |
2020 |
| Other |
adjuvant rt |
1 |
2016 |
| Procedure |
adjuvant tace |
1 |
2016 |
| Procedure |
adjuvant transarterial chemoinfusion (tai) |
1 |
2017 |
| Combination Product |
adjuvant treatment |
1 |
2019 |
| Biological |
adoptive immunotherapy |
1 |
2016 |
| Drug |
adt (androgen deprivation therapy) (i.e. leuprolide) |
1 |
2015 |
| Drug |
adt (androgen deprivation therapy) (i.e. leuprolide)/an androgen receptor inhibitor (i.e. bicalutamide) |
1 |
2015 |
| Biological |
adv |
1 |
2016 |
| Genetic |
adv-tk (adenovirus-thymidine kinase enzyme) gene therapy |
1 |
2006 |
| Biological |
adv/hsv-tk |
1 |
2016 |
| Device |
advanced image guidance |
1 |
2012 |
| Drug |
adxs-503 |
1 |
2019 |
| Biological |
adxs11-001 |
1 |
2014 |
| Biological |
adxs11-001 (adxs-hpv) |
1 |
2013 |
| Drug |
aeg35156 antisense iv infusion |
1 |
2009 |
| Other |
aerobic exercise |
1 |
2018 |
| Drug |
afinitor |
1 |
2012 |
| Drug |
afl-assisted cisplatin |
1 |
2018 |
| Drug |
afl-assisted cisplatin/5-fu |
1 |
2018 |
| Biological |
aflibercept |
1 |
2008 |
| Diagnostic Test |
afp |
1 |
2020 |
| Diagnostic Test |
afp-l3 |
1 |
2020 |
| Biological |
afp specific t cell receptor t cells |
1 |
2019 |
| Drug |
afxl-assisted ingenol mebutate delivery |
1 |
2018 |
| Drug |
ag-013736 |
1 |
2011 |
| Drug |
ag-013736 (axitinib) |
1 |
2012 |
| Drug |
ags-16m8f |
1 |
2010 |
| Drug |
akt inhibitor gsk2141795 |
1 |
2013 |
| Drug |
al101 |
1 |
2018 |
| Drug |
al3818 |
1 |
2015 |
| Drug |
albumin-bound paclitaxel/cisplatin |
1 |
2010 |
| Drug |
albumin infusion |
1 |
2019 |
| Drug |
albumin paclitaxel |
1 |
2010 |
| Drug |
albumin paclitaxel/carboplatin |
1 |
2010 |
| Drug |
aldoxorubicin hcl |
1 |
2017 |
| Drug |
alemtuzumab |
1 |
2012 |
| Drug |
all-trans retinoic acid |
1 |
2020 |
| Procedure |
allogeneic bone marrow transplantation |
1 |
2000 |
| Drug |
allogeneic dcs |
1 |
2002 |
| Drug |
allogeneic dcs/autologous rcc tumor derived cells |
1 |
2002 |
| Procedure |
allogeneic hematopoietic stem cell transplant (hsct) |
1 |
2009 |
| Biological |
allogeneic nk cells therapy |
1 |
2019 |
| Biological |
allostim |
1 |
2015 |
| Biological |
allovax |
1 |
2015 |
| Genetic |
allovectin-7â® |
1 |
2002 |
| Drug |
alpha-tocopheryloxyacetic acid |
1 |
2019 |
| Drug |
alt-803 |
1 |
2017 |
| Drug |
alt-803 / atezolizumab |
1 |
2017 |
| Drug |
alt-803 / avelumab |
1 |
2017 |
| Drug |
alt-803 / nivolumab |
1 |
2017 |
| Drug |
alt-803 / pembrolizumab |
1 |
2017 |
| Device |
aluminium disk |
1 |
2011 |
| Drug |
alvespimycin hydrochloride |
1 |
2004 |
| Drug |
amg 102 at 10 mg |
1 |
2007 |
| Drug |
amg 102 at 10 mg/kg |
1 |
2007 |
| Drug |
amg 102 at 20 mg |
1 |
2007 |
| Drug |
amg 102 at 20 mg/kg |
1 |
2007 |
| Drug |
amg 172 |
1 |
2011 |
| placebo |
amg 386 placebo |
1 |
2008 |
| placebo |
amg 386 placebo iv |
1 |
2007 |
| Drug |
amg386 |
1 |
2009 |
| Drug |
aminolevulinic acid %20 topical solution |
1 |
2012 |
| Drug |
an androgen receptor inhibitor (i.e. bicalutamide) |
1 |
2015 |
| Dietary Supplement |
an iso-caloric, iso-nitrogenous control feed |
1 |
2011 |
| Procedure |
anesthetic methods |
1 |
2018 |
| Biological |
anetumab ravtansine |
1 |
2018 |
| Biological |
ank (nk-92) |
1 |
2015 |
| Drug |
anlotinib hydrochloride, paclitaxel, cisplatin |
1 |
2019 |
| Drug |
anlotinib/gemcitabine/cisplatin |
1 |
2018 |
| Drug |
anlotinib/sintilimab injection |
1 |
2019 |
| Biological |
antagonist |
1 |
2016 |
| Drug |
anti-axl fusion protein avb-s6-500 |
1 |
2019 |
| Biological |
anti-cea car-t cells |
1 |
2018 |
| Biological |
anti-endoglin chimeric monoclonal antibody trc105 |
1 |
2012 |
| Drug |
anti-gitr agonistic monoclonal antibody bms-986156 |
1 |
2019 |
| Biological |
anti-influenza vaccine |
1 |
2015 |
| Biological |
anti-muc1 vaccine |
1 |
2015 |
| Radiation |
anti-pd-1 antibody |
1 |
2019 |
| Drug |
anti-pd-1 antibody shr-1210 |
1 |
2017 |
| Biological |
anti-pd-1 therapy |
1 |
2017 |
| Biological |
anti-sema4d monoclonal antibody vx15 |
1 |
2017 |
| Biological |
anti-sema4d monoclonal antibody vx15/2503 |
1 |
2017 |
| Biological |
anti-thymocyte globulin |
1 |
1999 |
| Drug |
anti-transforming growth factor-beta (gc 1008) |
1 |
2009 |
| Biological |
anti cd45 monoclonal antibody |
1 |
2004 |
| Drug |
antibody tf2 |
1 |
2010 |
| Drug |
apatinib mesylate tablets |
1 |
2017 |
| Combination Product |
apatinib s-1 radiotherapy |
1 |
2017 |
| Drug |
apatinib tablet |
1 |
2009 |
| Drug |
apatinib/with shr-1210 injection |
1 |
2020 |
| Drug |
api 31510 |
1 |
2008 |
| Drug |
api 31510 1.5% topical cream |
1 |
2008 |
| Drug |
api 31510 3% topical cream |
1 |
2008 |
| Drug |
apl-101 |
1 |
2018 |
| Drug |
apx005m |
1 |
2018 |
| Radiation |
arcon |
1 |
2005 |
| Biological |
arg1-18,19,20 |
1 |
2018 |
| Drug |
arimidex (anastrozole) |
1 |
2005 |
| Drug |
arm 2 |
1 |
2016 |
| Drug |
arm 3 |
1 |
2016 |
| Other |
arm 4 |
1 |
2016 |
| Drug |
arm cisplatin |
1 |
2017 |
| Drug |
arm cisplatin / gemcitabine (arm b) |
1 |
2017 |
| Drug |
arm nai-iri |
1 |
2017 |
| Drug |
arm nai-iri / 5-fu / leucovorin (arm a) |
1 |
2017 |
| Drug |
arm1 |
1 |
2016 |
| Drug |
aro-hif2 |
1 |
2019 |
| Drug |
aromatase inhibition therapy |
1 |
2011 |
| Radiation |
arrest-study |
1 |
2016 |
| Drug |
arsenic trioxide |
1 |
2013 |
| Procedure |
arterial embolization |
1 |
2016 |
| Other |
arterial spin labeling magnetic resonance imaging |
1 |
2008 |
| Drug |
artesunate |
1 |
2014 |
| Drug |
as1409 |
1 |
2008 |
| Drug |
ascorbic acid / sorafenib |
1 |
2012 |
| Drug |
aslan001 |
1 |
2018 |
| Biological |
asn-002 |
1 |
2015 |
| Procedure |
aspiration of breast |
1 |
2018 |
| Other |
assessment of dietary intake |
1 |
2013 |
| Drug |
association of bevacizumab (bvc) |
1 |
2010 |
| Drug |
association of bevacizumab (bvc)/ pazopanib (pzp) |
1 |
2010 |
| Drug |
ast-008 |
1 |
2018 |
| Drug |
atezolizumab 1200 mg in 20 ml injection |
1 |
2019 |
| Combination Product |
atezolizumab injection, bevacizumab injection |
1 |
2019 |
| Drug |
atorvastatin calcium |
1 |
2008 |
| Drug |
atovaquone |
1 |
2015 |
| Drug |
atr-101 |
1 |
2013 |
| Drug |
atr kinase inhibitor azd6738 |
1 |
2018 |
| Biological |
attenuated live listeria encoding hpv 16 e7 vaccine adxs11-001 |
1 |
2010 |
| Drug |
auranofin |
1 |
2012 |
| Biological |
autologous anti-psca-car-4-1bb |
1 |
2019 |
| Biological |
autologous anti-psca-car-4-1bb/tcrzeta-cd19t-expressing t-lymphocytes |
1 |
2019 |
| Biological |
autologous c-tcr055 |
1 |
2020 |
| Biological |
autologous ebv specific cytotoxic t cells |
1 |
2015 |
| Genetic |
autologous genetically modified mage a10á¶œâ·â¹â¶t cells |
1 |
2016 |
| Drug |
autologous human tumor-derived hsppc-96 |
1 |
2002 |
| Biological |
autologous ny-eso-1-specific cd8-positive t lymphocytes |
1 |
2018 |
| Drug |
autologous rcc tumor derived cells |
1 |
2002 |
| Combination Product |
autologous tcm immunotherapy |
1 |
2018 |
| Biological |
autologous tumor infiltrating lymphocytes ln-145 |
1 |
2018 |
| Biological |
autologous tumor infiltrating lymphocytes mda-til |
1 |
2018 |
| Behavioral |
automated reminders |
1 |
2016 |
| Device |
automatic imaging fusion of ultrasonography |
1 |
2015 |
| Device |
automatic imaging fusion of ultrasonography/mri |
1 |
2015 |
| Biological |
av-299 |
1 |
2009 |
| Biological |
av-299 / gefitinib |
1 |
2009 |
| Drug |
avastin (bevacizumab) |
1 |
2004 |
| Drug |
avastin in combination with roferon-a |
1 |
2012 |
| Drug |
avb-620 |
1 |
2017 |
| Drug |
avb-s6-500 |
1 |
2019 |
| Drug |
avelumab (msb0010718c) |
1 |
2017 |
| Combination Product |
avelumab 10mg |
1 |
2017 |
| Combination Product |
avelumab 10mg/kg with carboplatin/gemcitabine |
1 |
2017 |
| Combination Product |
avelumab/radical radiotherapy |
1 |
2018 |
| Drug |
avid100 iv |
1 |
2017 |
| Dietary Supplement |
avmacol |
1 |
2017 |
| Drug |
avmacolâ® |
1 |
2017 |
| Biological |
avova-1 |
1 |
2014 |
| Procedure |
axillary dissection |
1 |
2009 |
| Procedure |
axillary lymph node dissection |
1 |
2016 |
| Procedure |
axillary reverse mapping |
1 |
2008 |
| Drug |
axitinib oral tablet |
1 |
2018 |
| Drug |
axl1717 |
1 |
2012 |
| Drug |
azd1775/carboplatin (cbpt) |
1 |
2016 |
| Drug |
azd2014 |
1 |
2016 |
| Drug |
azd2171 |
1 |
2005 |
| Drug |
azd2281 |
1 |
2008 |
| Drug |
azd4635 |
1 |
2016 |
| Drug |
azd5069 |
1 |
2015 |
| Drug |
azd6244 |
1 |
2011 |
| Drug |
azd6738 |
1 |
2016 |
| Drug |
azd6738/olaparib |
1 |
2016 |
| Drug |
azd8055 |
1 |
2009 |
| Drug |
azd9291 80 mg |
1 |
2015 |
| Drug |
azd9291 80 mg/40 mg |
1 |
2015 |
| Biological |
b |
1 |
2016 |
| Drug |
b (pembrolizumab) |
1 |
2017 |
| Biological |
bacillus calmette-guã©rin (bcg) |
1 |
2017 |
| Procedure |
balloon catheter |
1 |
2009 |
| Device |
bardport titanium implanted port withperitoneal catheter |
1 |
2019 |
| Drug |
bavituximab/sorafenib |
1 |
2010 |
| Drug |
bay 59-8862 |
1 |
2002 |
| Drug |
bay1163877 |
1 |
2017 |
| Drug |
bay59-8862 (cytotoxic taxane) |
1 |
2002 |
| Drug |
bay73-4506 |
1 |
2009 |
| Drug |
bay86-9766 mek inhibitor |
1 |
2010 |
| Drug |
bay86-9766 mek inhibitor / sorafenib |
1 |
2010 |
| Drug |
bazedoxifene |
1 |
2016 |
| Drug |
bb-401 |
1 |
2018 |
| Drug |
bc-819 |
1 |
2013 |
| Drug |
bc-819/pei |
1 |
2013 |
| Drug |
bca101 |
1 |
2020 |
| Procedure |
bcc surgery |
1 |
2011 |
| Drug |
bcg |
1 |
2013 |
| Biological |
bcg tokyo-172 strain solution |
1 |
2017 |
| Biological |
bcg tokyo-172 strain vaccine |
1 |
2017 |
| Drug |
bcg, interferon |
1 |
2007 |
| Other |
bead |
1 |
2007 |
| Other |
bead / dox arm |
1 |
2007 |
| Device |
bead block microspheres |
1 |
2007 |
| Behavioral |
behavioral intervention |
1 |
2013 |
| Other |
behavioral, psychological |
1 |
2013 |
| Other |
behavioral, psychological/informational intervention |
1 |
2013 |
| Drug |
belinostat (pdx101) |
1 |
2007 |
| Drug |
belinostat, carboplatin, paclitaxel |
1 |
2009 |
| Drug |
benadryl |
1 |
2011 |
| Drug |
bevacizumab (avastin) |
1 |
2005 |
| Drug |
bevacizumab/sunitinib |
1 |
2007 |
| Drug |
bf-200 ala |
1 |
2014 |
| Drug |
bgb-a317 |
1 |
2018 |
| Drug |
bgj398 |
1 |
2016 |
| Drug |
bi 754091 |
1 |
2018 |
| Drug |
bi 754111 |
1 |
2018 |
| Drug |
bi 894999 |
1 |
2015 |
| Drug |
bibw 2992 |
1 |
2007 |
| Drug |
bibw2992 |
1 |
2015 |
| Drug |
bicalutamide |
1 |
2005 |
| Drug |
biib022 |
1 |
2009 |
| Radiation |
bilateral radiation |
1 |
2012 |
| Device |
biliary stent/high-intensity focused ultrasound ablation system |
1 |
2019 |
| Radiation |
bimodal irradiation |
1 |
2019 |
| Device |
bimodal optical spectroscopy |
1 |
2016 |
| Biological |
biological collection |
1 |
2020 |
| Other |
biological samples |
1 |
2017 |
| Other |
biological: hbv antigen specific tcr redirected t cell |
1 |
2016 |
| Biological |
biological: tcr-t |
1 |
2016 |
| Other |
biomarker analysis |
1 |
2013 |
| Other |
biopsies |
1 |
2011 |
| Device |
bipolar rfa |
1 |
2019 |
| Drug |
birinapant |
1 |
2019 |
| Drug |
bispecific antibody |
1 |
2007 |
| Drug |
bispecific antibody/di-dtpa-131i |
1 |
2007 |
| Drug |
bkm-120 bevacizumab |
1 |
2011 |
| Drug |
bkm120 |
1 |
2014 |
| Dietary Supplement |
black cohosh |
1 |
2012 |
| Drug |
bleomycin |
1 |
2017 |
| Biological |
bleomycin sulfate |
1 |
2017 |
| Biological |
blood samples (5 ml) will be taken |
1 |
2016 |
| Drug |
bms-247550 |
1 |
2002 |
| Drug |
bms-813160 |
1 |
2019 |
| Drug |
bms-936558 (anti-pd-1) |
1 |
2011 |
| Drug |
bms-986253 |
1 |
2019 |
| Drug |
bnc105p |
1 |
2009 |
| Procedure |
bnp, saag, ascites total protein, echocardiography |
1 |
2010 |
| Procedure |
bold mri test |
1 |
2009 |
| Procedure |
bone marrow biopsy |
1 |
2020 |
| Procedure |
bone scan |
1 |
2017 |
| Radiation |
boost |
1 |
2007 |
| Radiation |
boost irradiation |
1 |
2012 |
| Drug |
bpf-ccrt (randomized) |
1 |
2016 |
| Drug |
bpf-ccrt (run-in) |
1 |
2016 |
| Other |
braf detection on fine needle aspiration biopsy (fnab) |
1 |
2015 |
| Other |
brain x-ray |
1 |
2008 |
| Dietary Supplement |
brb lozenge |
1 |
2011 |
| Procedure |
breast biopsy |
1 |
2009 |
| Procedure |
breast cancer surgery only - arm iii |
1 |
2006 |
| Procedure |
breast conservative surgery |
1 |
2016 |
| Other |
breast reconstruction decision aid |
1 |
2019 |
| Drug |
brivanib (active) |
1 |
2006 |
| Drug |
brivanib 400 mg, bid |
1 |
2018 |
| Drug |
brivanib 800 mg, qd |
1 |
2018 |
| placebo |
brivanib placebo |
1 |
2009 |
| Drug |
broccoli sprout extract |
1 |
2012 |
| Drug |
brontictuzumab |
1 |
2016 |
| Other |
bsc |
1 |
2010 |
| Drug |
bumetanide |
1 |
2017 |
| Drug |
buparlisib |
1 |
2012 |
| Device |
c-arm ct |
1 |
2009 |
| Device |
c-arm ct / dsa as needed |
1 |
2009 |
| Drug |
c225 (cetuximab) |
1 |
2008 |
| Drug |
cabazitaxel 10mg |
1 |
2011 |
| Drug |
cabazitaxel 10mg/m2 |
1 |
2011 |
| Drug |
cabazitaxel 12.5mg |
1 |
2011 |
| Drug |
cabazitaxel 12.5mg/m2 |
1 |
2011 |
| Drug |
cabazitaxel 15mg |
1 |
2011 |
| Drug |
cabazitaxel 15mg/m2 |
1 |
2011 |
| Drug |
cabazitaxel 17.5mg |
1 |
2011 |
| Drug |
cabazitaxel 17.5mg/m2 |
1 |
2011 |
| Drug |
cabazitaxel 20mg |
1 |
2011 |
| Drug |
cabazitaxel 20mg/m2 |
1 |
2011 |
| Drug |
cabiralizumab |
1 |
2018 |
| Drug |
cabometyx |
1 |
2018 |
| placebo |
cabozantinib-matched placebo |
1 |
2019 |
| Drug |
cabozantinib-s-malate |
1 |
2018 |
| Drug |
cabozantinib group |
1 |
2019 |
| Drug |
cabozantinib tablets |
1 |
2013 |
| Drug |
calcio levofolinate |
1 |
2017 |
| Drug |
calcitriol |
1 |
2011 |
| Other |
camrelizumab/sbrt |
1 |
2020 |
| Drug |
canakinumab |
1 |
2019 |
| Drug |
cap-232 |
1 |
2007 |
| Drug |
capecitabine in hcc |
1 |
2007 |
| Drug |
capecitabine, |
1 |
2011 |
| Drug |
capecitabine, interferon-alpha |
1 |
2007 |
| Drug |
capecitabine, nab-paclitaxel |
1 |
2010 |
| Drug |
capecitabine/cisplatin(xp) |
1 |
2011 |
| Drug |
capecitabine/paditaxel(xg) |
1 |
2011 |
| Genetic |
car-bcma t cell |
1 |
2017 |
| Genetic |
car-cd19 t cell |
1 |
2017 |
| Genetic |
car-cld18 t cell |
1 |
2017 |
| Genetic |
car-gpc3 t cell |
1 |
2017 |
| Biological |
car2 anti-cea car-t cells |
1 |
2019 |
| Behavioral |
carbohydrate-restricted, high-fat diet |
1 |
2020 |
| Radiation |
carbon-ion radiotherapy for tumor adjacent to gi |
1 |
2016 |
| Radiation |
carbon-ion radiotherapy for tumor away from gi |
1 |
2016 |
| Radiation |
carbon ion irradiation |
1 |
2019 |
| Radiation |
carbon ion radiotherapy |
1 |
2010 |
| Radiation |
carbon ion radiotherapy (cirt) |
1 |
2016 |
| Radiation |
carboplatin-based concurrent chemoradiotherapy |
1 |
2018 |
| Drug |
carboplatin (cbpt) |
1 |
2016 |
| Drug |
carboplatin (dose level 1) |
1 |
2018 |
| Drug |
carboplatin (dose level 2) |
1 |
2018 |
| Drug |
carboplatin (standard of care) |
1 |
2015 |
| Drug |
carboplatin / etoposide |
1 |
2016 |
| Drug |
carboplatin, paclitaxel |
1 |
2009 |
| Combination Product |
carboplatin/gemcitabine alone |
1 |
2017 |
| Drug |
carboplatin/paclitaxel followed by surgery |
1 |
2014 |
| Drug |
carboplatin/paclitaxel/radiation therapy |
1 |
2005 |
| Other |
carevive software |
1 |
2017 |
| Drug |
carfilzomib |
1 |
2013 |
| Drug |
carrimycin |
1 |
2020 |
| Drug |
catumaxomab |
1 |
2010 |
| Drug |
catumaxomab, fluorouracil, leucovorin, oxaliplatin, docetaxel |
1 |
2012 |
| Drug |
cb-103 |
1 |
2018 |
| Drug |
cb-839/everolimus |
1 |
2017 |
| Drug |
cc-122 |
1 |
2016 |
| Drug |
ccrt alone |
1 |
2020 |
| Drug |
ccrt/ pf |
1 |
2017 |
| Drug |
ccrt/gp |
1 |
2017 |
| Drug |
ccrt/nimotuzumab |
1 |
2020 |
| Biological |
cct301-38 |
1 |
2017 |
| Biological |
cct301-59 |
1 |
2017 |
| Biological |
cd147-cart |
1 |
2019 |
| Drug |
cdx-1140 |
1 |
2017 |
| Drug |
cdx-301 |
1 |
2017 |
| Drug |
cdx-3379 |
1 |
2017 |
| Drug |
cdx-3379/cetuximab |
1 |
2017 |
| placebo |
cediranib placebo |
1 |
2007 |
| Drug |
celecoxib, gefitinib |
1 |
2005 |
| Drug |
cellcept |
1 |
2014 |
| Device |
cellectraâ„¢ 2000 |
1 |
2018 |
| Other |
cellular therapy |
1 |
2018 |
| Drug |
cemiplimab-rwlc |
1 |
2020 |
| Procedure |
central neck dissection |
1 |
2020 |
| Drug |
ceralasertib |
1 |
2017 |
| Procedure |
cervical lymph node dissection |
1 |
2016 |
| Drug |
cetuximab (crc) |
1 |
2010 |
| Biological |
cetuximab (erbitux â®) |
1 |
2008 |
| Drug |
cetuximab (scchn) |
1 |
2010 |
| Biological |
cetuximab / concomitant boost radiotherapy |
1 |
2009 |
| Drug |
cetuximab / nk cells |
1 |
2015 |
| Biological |
cetuximab c225 |
1 |
2004 |
| Biological |
cetuximab induction |
1 |
2012 |
| Biological |
cetuximab iv |
1 |
2011 |
| Biological |
cetuximab radioimmunotherapy |
1 |
2012 |
| Drug |
cetuximab) |
1 |
2010 |
| Drug |
cetuximab, cisplatin, doxorubicin |
1 |
2009 |
| Drug |
cetuximab, cisplatin, doxorubicin/cyclophosphamide |
1 |
2009 |
| Drug |
cetuximab,paclitaxel,cisplatin |
1 |
2009 |
| Drug |
cetuximab/chemotherapy (docetaxel, cisplatin, 5-fluorouracil) |
1 |
2008 |
| Drug |
cetuximab/lenalidomide |
1 |
2010 |
| Drug |
cetuximab/radiotherapy |
1 |
2016 |
| Other |
cetuximab/stereotactic radiosurgery |
1 |
2010 |
| Drug |
cgx1321 |
1 |
2018 |
| Other |
chart abstraction |
1 |
2016 |
| Drug |
chemo |
1 |
2019 |
| Procedure |
chemoembolization ,radiofrequency ablation |
1 |
2007 |
| Procedure |
chemoembolization/response-dependent resection |
1 |
2014 |
| Drug |
chemoprevention |
1 |
2011 |
| Drug |
chemoradiotherapy arm |
1 |
2018 |
| Drug |
chemosensitization |
1 |
2003 |
| Drug |
chemosensitization/potentiation therapy |
1 |
2003 |
| Drug |
chemotherapy (docetaxel, cisplatin, 5-fluorouracil) |
1 |
2008 |
| Drug |
chemotherapy as clinical standard of care |
1 |
2019 |
| Drug |
chemotherapy drug |
1 |
2016 |
| Drug |
chemotherapy in combination with trastuzumab for arm1 |
1 |
2017 |
| Drug |
chemotherapy in combination with trastuzumab for arm2 |
1 |
2017 |
| Drug |
chemotherapy in combination with trastuzumab for arm3 |
1 |
2017 |
| Drug |
chemotherapy in combination with trastuzumab for arm4 |
1 |
2017 |
| Drug |
chemotherapy with endostar |
1 |
2009 |
| Drug |
chemotherapy/apatinib |
1 |
2019 |
| Drug |
chemotherapy/radiotherapy/toripalimab |
1 |
2020 |
| Radiation |
chest radiation |
1 |
2016 |
| Drug |
chiauranib |
1 |
2017 |
| Drug |
chidamide/with cisplatin |
1 |
2018 |
| Dietary Supplement |
chinese herbal formulation phy906 |
1 |
2012 |
| Drug |
chloroquine low dose (250mg |
1 |
2009 |
| Drug |
chloroquine low dose (250mg/week) |
1 |
2009 |
| Drug |
chloroquine standard dose (500mg |
1 |
2009 |
| Drug |
chloroquine standard dose (500mg/week) |
1 |
2009 |
| Procedure |
chpp with cisplatin |
1 |
1999 |
| Procedure |
chpp) |
1 |
2003 |
| Other |
cicaplast balm b5 |
1 |
2018 |
| Drug |
cigb300 |
1 |
2012 |
| Biological |
cik cells |
1 |
2019 |
| Drug |
cilengitide |
1 |
2011 |
| Drug |
cimetidine |
1 |
2007 |
| Drug |
cinacalcet hcl |
1 |
2011 |
| Drug |
ciprofloxacin |
1 |
2005 |
| Radiation |
cisplatin-based concurrent chemoradiotherapy |
1 |
2018 |
| Drug |
cisplatin (ddp) |
1 |
2015 |
| Drug |
cisplatin (dose level 1) |
1 |
2018 |
| Drug |
cisplatin (dose level 2) |
1 |
2018 |
| Drug |
cisplatin (dose level 3) |
1 |
2018 |
| Drug |
cisplatin (dose level 4) |
1 |
2018 |
| Drug |
cisplatin (induction |
1 |
2017 |
| Drug |
cisplatin (or alternative) |
1 |
2014 |
| Drug |
cisplatin (or alternative) - deintensified |
1 |
2017 |
| Drug |
cisplatin (or alternative) - standard |
1 |
2017 |
| Drug |
cisplatin (tp) |
1 |
2007 |
| Drug |
cisplatin / 5-fluorouracil (5fu) |
1 |
2016 |
| Drug |
cisplatin 1 |
1 |
2015 |
| Drug |
cisplatin 100mg |
1 |
2015 |
| Drug |
cisplatin 100mg/mâ² concurrent chemotherapy |
1 |
2015 |
| Drug |
cisplatin 2 |
1 |
2015 |
| Drug |
cisplatin 80mg |
1 |
2015 |
| Drug |
cisplatin 80mg/mâ² concurrent chemotherapy |
1 |
2015 |
| Drug |
cisplatin combine with imrt |
1 |
2016 |
| Drug |
cisplatin(xp) |
1 |
2011 |
| Drug |
cisplatin, capecitabine |
1 |
2018 |
| Drug |
cisplatin, taxotere |
1 |
2006 |
| Drug |
cisplatin/5-fluorouracil |
1 |
2012 |
| Drug |
cisplatin/5-fu/with nimotuzumab |
1 |
2012 |
| Drug |
cisplatin/etoposide |
1 |
2018 |
| Drug |
cisplatin/fluorouracil |
1 |
2019 |
| Drug |
cisplatin/gemcitabine |
1 |
2009 |
| Drug |
cisplatin/placebo |
1 |
2019 |
| Drug |
cisplatin/toripalimab |
1 |
2019 |
| Drug |
cisplatinum/everolimus |
1 |
2016 |
| Drug |
ck-301 (cosibelimab) |
1 |
2017 |
| Drug |
clevudine, adefovir |
1 |
2010 |
| Device |
clinimacs |
1 |
2012 |
| Drug |
clostridium butyricum cbm 588 probiotic strain |
1 |
2019 |
| Drug |
cmf regimen |
1 |
1999 |
| Drug |
cni, mmf, steroids, aza etc. (mtor inhibitor free) |
1 |
2006 |
| Drug |
cnto 328 |
1 |
2005 |
| Procedure |
co2 laser surgery |
1 |
2014 |
| Other |
cognitive assessment |
1 |
2015 |
| Behavioral |
cognitive behavior therapy |
1 |
2017 |
| Other |
cognitive intervention |
1 |
2013 |
| Drug |
colchicine |
1 |
2020 |
| Other |
collaborative care |
1 |
2010 |
| Other |
collection of biospecimens |
1 |
2016 |
| Other |
collection of biospecimens/quality of life (qol) assessment |
1 |
2016 |
| Biological |
colloidal gold-bound tumor necrosis factor |
1 |
2007 |
| Biological |
combig-dc (allogeneic dendritic cells) cancer vaccine |
1 |
2012 |
| Biological |
combig-dc (ilixadencel) |
1 |
2013 |
| Drug |
combination iv gemcitabine |
1 |
2015 |
| Drug |
combination iv gemcitabine/iv carboplatin (auc2) |
1 |
2015 |
| Drug |
combination of everolimus, letrozole |
1 |
2012 |
| Drug |
combination of everolimus, letrozole/leuprolide |
1 |
2012 |
| Drug |
combination of nktr-214 |
1 |
2016 |
| Drug |
combination of nktr-214 / nivolumab |
1 |
2016 |
| Drug |
combination of nktr-214 / nivolumab / ipilimumab |
1 |
2016 |
| Drug |
combination of trabectedin with durvalumab |
1 |
2017 |
| Drug |
combination of varlilumab |
1 |
2014 |
| Drug |
combination of varlilumab/nivolumab |
1 |
2014 |
| Biological |
combinations treatment |
1 |
2018 |
| Other |
combined intervention (chemoembolization |
1 |
2012 |
| Other |
combined intervention (chemoembolization/ablation) |
1 |
2012 |
| Procedure |
combined treatment |
1 |
2017 |
| Behavioral |
commitment therapy |
1 |
2015 |
| Other |
common fundamental management |
1 |
2013 |
| Other |
communication skills training |
1 |
2017 |
| Procedure |
comparison of surgical margins by coe vs. dvfe |
1 |
2013 |
| Behavioral |
compliance monitoring |
1 |
2008 |
| Diagnostic Test |
computed tomography scan - 50% dose reduction |
1 |
2017 |
| Diagnostic Test |
computed tomography scan - 70% dose reduction |
1 |
2017 |
| Biological |
concomitant boost radiotherapy |
1 |
2009 |
| Drug |
concomitant cisplatin chemotherapy |
1 |
2008 |
| Behavioral |
concomitant coaching |
1 |
2016 |
| Radiation |
concurrent chemoradiation |
1 |
2014 |
| Radiation |
concurrent chemoradiation (crt) |
1 |
2015 |
| Combination Product |
concurrent chemoradiotherapy |
1 |
2020 |
| Combination Product |
concurrent chemoradiotherapy/with enteral feeding by percutaneous endoscopic gastrostomy |
1 |
2020 |
| Drug |
concurrent chemotherapy with cisplatin during radiotherapy |
1 |
2013 |
| Drug |
concurrent chemotherapy with paclitaxel |
1 |
2012 |
| Drug |
concurrent chemotherapy with paclitaxel/nedaplatin |
1 |
2012 |
| Radiation |
concurrent crt group |
1 |
2018 |
| Drug |
concurrent nimotuzumab during radiotherapy |
1 |
2013 |
| Radiation |
concurrent sorafenib |
1 |
2018 |
| Radiation |
concurrent sorafenib/imrt, followed sorafenib maintenance |
1 |
2018 |
| Procedure |
conization |
1 |
2012 |
| Drug |
conjugated estrogens |
1 |
2016 |
| Drug |
conjugated estrogens/bazedoxifene |
1 |
2016 |
| Procedure |
continuous hyperthermic peritoneal perfusion (hipec |
1 |
2003 |
| Procedure |
continuous hyperthermic peritoneal perfusion (hipec/chpp) |
1 |
2003 |
| Drug |
continuous pazopanib (arm a) |
1 |
2013 |
| Procedure |
contralateral central lymph node dissection |
1 |
2019 |
| Radiation |
contralateral esophageal sparing technique (cest) |
1 |
2015 |
| Procedure |
contralateral submental flap for tongue cancer defect |
1 |
2018 |
| Procedure |
contrast-enhanced magnetic resonance imaging |
1 |
2008 |
| Diagnostic Test |
contrast-enhanced ultrasound |
1 |
2018 |
| Dietary Supplement |
control |
1 |
2018 |
| Procedure |
conventional laparoscopic partial nephrectomy |
1 |
2014 |
| Procedure |
conventional laparoscopic surgery |
1 |
2017 |
| Other |
conventional medicines (oxygen therapy, alfa interferon via aerosol inhalation,/lopinavir/ritonavir)/traditional chinese medicines (tcms) granules |
1 |
2019 |
| Procedure |
conventional open rectal resection |
1 |
2013 |
| Procedure |
conventional open retropubic radical prostectomy |
1 |
2015 |
| Drug |
conventional photodynamic therapy |
1 |
2010 |
| Drug |
conventional tace |
1 |
2018 |
| Other |
conventional transarterial chemoembolization (ctace) |
1 |
2013 |
| Radiation |
conventionally fractionated imrt |
1 |
2008 |
| Radiation |
conventionally fractionated whole breast irradiation |
1 |
2010 |
| Procedure |
conventionnal chemotherapy |
1 |
2008 |
| Drug |
copaxone |
1 |
2019 |
| Drug |
copper cu 64 tp3805 |
1 |
2017 |
| Drug |
corticosteroid |
1 |
2012 |
| Drug |
cositecan |
1 |
2003 |
| Other |
coxen |
1 |
2016 |
| Drug |
cp-675,206 |
1 |
2006 |
| Biological |
cp 675,206 |
1 |
2009 |
| Device |
cpap machine |
1 |
2017 |
| Drug |
cpg 7909 |
1 |
2002 |
| Drug |
cpt-11 |
1 |
2017 |
| Biological |
crcl |
1 |
2015 |
| Drug |
crlx101 |
1 |
2014 |
| Drug |
crlx101 (cerulean) |
1 |
2012 |
| Drug |
crs-100 |
1 |
2006 |
| Procedure |
crs-hipec, control arm |
1 |
2016 |
| Procedure |
crs-hipec, experimental arm |
1 |
2016 |
| Procedure |
crs extended with dual-modality imaging |
1 |
2018 |
| Drug |
crt group |
1 |
2018 |
| Procedure |
cryoimmunotherapy |
1 |
2010 |
| Procedure |
cryotherapy |
1 |
2007 |
| Procedure |
cryotherapy/photodynamic therapy with methyl aminolevulinate cream |
1 |
2007 |
| Drug |
cs-1008 |
1 |
2009 |
| Drug |
cs1001 |
1 |
2019 |
| Drug |
cs1001/ fluorouracil/cisplatin |
1 |
2019 |
| Drug |
cs1003 |
1 |
2019 |
| placebo |
cs1003 placebo |
1 |
2019 |
| Drug |
cs1003 placebo/lenvatinib |
1 |
2019 |
| Drug |
cs1003/lenvatinib |
1 |
2019 |
| Radiation |
ct-guided brachytherapy |
1 |
2008 |
| Procedure |
ct (computed tomography) |
1 |
2018 |
| Other |
ct / rt |
1 |
2005 |
| Procedure |
ct abdomen |
1 |
2009 |
| Procedure |
ct abdomen/pelvis scan |
1 |
2009 |
| Procedure |
ct abdomen/pelvis scan / whole body pet-ct scan |
1 |
2009 |
| Diagnostic Test |
ct dynamic scan |
1 |
2018 |
| Radiation |
ct perfusion |
1 |
2015 |
| Device |
ct, mri |
1 |
2020 |
| Device |
ct, pet |
1 |
2013 |
| Drug |
ctt1057 |
1 |
2018 |
| Biological |
ctx130 |
1 |
2020 |
| Drug |
cu 64 anti-cea monoclonal antibody m5a iv |
1 |
2014 |
| Drug |
cue-101 |
1 |
2019 |
| Dietary Supplement |
curcumin |
1 |
2013 |
| Dietary Supplement |
curcuphyt |
1 |
2013 |
| Procedure |
current initial staging protocols |
1 |
2015 |
| Procedure |
curretage |
1 |
2005 |
| Drug |
cutaneous cream application |
1 |
2017 |
| Biological |
cv8102 / anti-pd-1 therapy |
1 |
2017 |
| Drug |
cvm-1118 |
1 |
2018 |
| Drug |
cx-4945 |
1 |
2019 |
| Device |
cyanoacrylate tissue glue versus fast absorbing gut |
1 |
2011 |
| Drug |
cyclophosphamide, methotrexate, 5 fu |
1 |
2010 |
| Drug |
cyh33 for tablet |
1 |
2018 |
| Procedure |
cystectomy |
1 |
2019 |
| Procedure |
cystoscopy with biopsy |
1 |
2016 |
| Drug |
cytochlor |
1 |
2004 |
| Biological |
cytokine-based biologic agent irx-2 |
1 |
2018 |
| Biological |
cytokine-induced killer cell (cik) treatment |
1 |
2008 |
| Procedure |
cytoreductive surgery (crs)/postoperative intraperitoneal chemotherapy (5-fluorouracil, isovorin) |
1 |
2012 |
| Procedure |
cytoreductive surgery / gastrecomy |
1 |
2017 |
| Procedure |
cytoreductive surgery/hipec |
1 |
2010 |
| Device |
da vinci firefly imaging system |
1 |
2018 |
| Other |
da vinci surgical system model is4000 |
1 |
2017 |
| Drug |
dacarbazine |
1 |
2007 |
| Drug |
dacarbazine/bortezomib |
1 |
2007 |
| Drug |
dacomitinib |
1 |
2012 |
| Biological |
dactinomycin |
1 |
2006 |
| Other |
daily log |
1 |
2013 |
| Drug |
dalantercept/axitinib |
1 |
2012 |
| Drug |
dalantercept/sorafenib |
1 |
2013 |
| Drug |
dalteparin |
1 |
2010 |
| Drug |
danggui buxue tang |
1 |
2018 |
| Drug |
danvatirsen |
1 |
2016 |
| Biological |
daratumumab |
1 |
2018 |
| Drug |
day |
1 |
2003 |
| Biological |
dc-ova |
1 |
2007 |
| Biological |
dc-tc |
1 |
2013 |
| Biological |
dc-tc/gm-csf |
1 |
2013 |
| Device |
dc bead with doxorubicin |
1 |
2005 |
| Biological |
dc ova with cyclophosphamide |
1 |
2007 |
| Biological |
dc vaccine |
1 |
2014 |
| Drug |
dca (dichloroacetate) |
1 |
2011 |
| Device |
dce-mri |
1 |
2010 |
| Device |
dce-mri/quantitative doppler ultrasound |
1 |
2010 |
| Procedure |
dce mri |
1 |
2007 |
| Radiation |
de-escalation radio(chemo)therapy - level 1 |
1 |
2017 |
| Radiation |
de-escalation radio(chemo)therapy - level 2 |
1 |
2017 |
| Drug |
deb |
1 |
2017 |
| Procedure |
deb tace |
1 |
2013 |
| Device |
debdox |
1 |
2013 |
| Procedure |
debdox tace |
1 |
2011 |
| Drug |
debio 1143 |
1 |
2013 |
| Other |
decision aid |
1 |
2016 |
| Drug |
decitabine (dac) |
1 |
2017 |
| Drug |
decitabine; oxaliplatin |
1 |
2019 |
| Drug |
defactinib |
1 |
2015 |
| Drug |
defactinib hydrochloride |
1 |
2015 |
| Drug |
deferoxamine |
1 |
2018 |
| Drug |
deferoxamine/conventional tace |
1 |
2018 |
| Radiation |
definitive external beam radiation in the ipsilateral neck |
1 |
2005 |
| Radiation |
definitive hypofractionation |
1 |
2020 |
| Procedure |
definitive surgical resection |
1 |
2008 |
| Drug |
definity |
1 |
2010 |
| Radiation |
delineating the gtv according to the pretreatment |
1 |
2020 |
| Radiation |
delineating the gtv according to the pretreatment/post-ic tumor extension |
1 |
2020 |
| Drug |
demethylated drug decitabine |
1 |
2018 |
| Biological |
denileukin diftitox |
1 |
2006 |
| Drug |
denosumab |
1 |
2017 |
| Drug |
denosumab inj 120 mg |
1 |
2019 |
| Drug |
denosumab inj 120 mg/1.7ml |
1 |
2019 |
| Drug |
depot octreotide |
1 |
2008 |
| Other |
detecton of circulating tumor dna |
1 |
2019 |
| Device |
device: radiation: diffusing alpha radiation emitters therapy (dart) |
1 |
2019 |
| Other |
dexeryl |
1 |
2018 |
| Drug |
di-dtpa-131i |
1 |
2007 |
| Procedure |
diagnostic lymphadenectomy |
1 |
2006 |
| Procedure |
diagnostic microscopy |
1 |
2017 |
| Drug |
diammonium glycyrrhizinate |
1 |
2012 |
| Drug |
diclofenac |
1 |
2011 |
| Drug |
diclofenac / calcitriol |
1 |
2011 |
| Radiation |
diffusing alpha radiation emitters therapy (dart) |
1 |
2017 |
| Other |
diffusion-weighted mri |
1 |
2016 |
| Drug |
diprosone |
1 |
2009 |
| Procedure |
distal ureterectomy |
1 |
2016 |
| Drug |
dkn-01 |
1 |
2015 |
| Drug |
dkn-01 300 mg |
1 |
2018 |
| Drug |
dkn-01 600 mg |
1 |
2018 |
| Drug |
dky709 |
1 |
2019 |
| Other |
dna extraction determination of mc1r genotypes |
1 |
2018 |
| Biological |
dna plasmid-encoding interleukin-12 |
1 |
2018 |
| Biological |
dna plasmid-encoding interleukin-12/hpv dna plasmids therapeutic vaccine medi0457 |
1 |
2018 |
| Drug |
dnajb1-prkaca peptide vaccine |
1 |
2020 |
| Biological |
dnazyme targeting ebv-lmp1 (dz1) |
1 |
2011 |
| Biological |
dnr.npc-specific t cells |
1 |
2014 |
| Biological |
dnr.npc-specific t cells / cyclophosphamide / fludarabine |
1 |
2014 |
| Drug |
docetaxel (doc) |
1 |
2015 |
| Drug |
docetaxel oxaliplatin 5-fu cf |
1 |
2014 |
| Drug |
docetaxel xrp6976 |
1 |
2014 |
| Drug |
docetaxel(xrp6976) |
1 |
2009 |
| Drug |
docetaxel, |
1 |
2018 |
| Drug |
docetaxel, cisplatin |
1 |
2014 |
| Drug |
docetaxel, cisplatin, 5-fu |
1 |
2011 |
| Drug |
docetaxel, cisplatin, 5-fu/cetuximab |
1 |
2011 |
| Drug |
docetaxel, cisplatin/5-fluorouracil |
1 |
2014 |
| Drug |
docetaxel, nedaplatin, fluorouracil |
1 |
2020 |
| Drug |
docetaxel,carboplatin |
1 |
2018 |
| Drug |
docetaxel,cisplatin |
1 |
2018 |
| Drug |
docetaxel,cisplatin,fluorouracil |
1 |
2015 |
| Drug |
docetaxel/cisplatin (induction chemotherapy) |
1 |
2015 |
| Drug |
docetaxel/cisplatin/nimotuzumab |
1 |
2018 |
| Drug |
docetaxel/gemcitabine |
1 |
2005 |
| Drug |
donafenib |
1 |
2016 |
| Procedure |
donor hematopoietic stem cell harvest |
1 |
2009 |
| Procedure |
donor lymphocyte harvest |
1 |
2009 |
| Radiation |
dose-deescalated treatment |
1 |
2017 |
| Drug |
dose dense mvac with pegylated gcsf |
1 |
2019 |
| Dietary Supplement |
double-brewed green tea |
1 |
2008 |
| Drug |
dovitinib (tki258) |
1 |
2012 |
| Other |
dox arm |
1 |
2007 |
| Drug |
doxorubicin-eluting beads |
1 |
2009 |
| Drug |
doxorubicin, superabsorbent polymer microspheres, embolotherapy |
1 |
2010 |
| Drug |
doxorubicin, vincristine, |
1 |
1999 |
| Drug |
doxorubicin, vincristine,/etoposide with mitotane |
1 |
1999 |
| Drug |
doxorubicin/bortezomib |
1 |
2007 |
| Drug |
doxorubicin/placebo |
1 |
2005 |
| Drug |
doxorubin |
1 |
2014 |
| Other |
drug: cisplatin |
1 |
2016 |
| Other |
drug: cisplatin/5-fluorouracil |
1 |
2016 |
| Biological |
drug: hyperacute lung cancer cell vaccine |
1 |
2003 |
| Other |
drug: taxol,cisplatin |
1 |
2016 |
| Other |
drug: taxol,cisplatin/capecitabine |
1 |
2016 |
| Procedure |
dsa-guided implantation of hepatic artery infusion pump |
1 |
2019 |
| Device |
dsa as needed |
1 |
2009 |
| Device |
dsa only |
1 |
2009 |
| Device |
dsm |
1 |
2018 |
| Drug |
dsp-7888 dosing emulsion |
1 |
2017 |
| Drug |
dtx |
1 |
2019 |
| Procedure |
dual x-ray absorptiometry |
1 |
2015 |
| Drug |
dummy infusion |
1 |
2014 |
| Procedure |
during surgery |
1 |
2018 |
| Drug |
durvalumab (regimen 1) |
1 |
2017 |
| Drug |
durvalumab (regimen 2) |
1 |
2017 |
| Biological |
durvalumab / bevacizumab |
1 |
2015 |
| Diagnostic Test |
dwi mri of the pelvis, abdomen |
1 |
2019 |
| Diagnostic Test |
dwi mri of the pelvis, abdomen/thorax |
1 |
2019 |
| Procedure |
dynamic contrast-enhanced ultrasound imaging |
1 |
2017 |
| Other |
e-mail |
1 |
2019 |
| Drug |
e7050 |
1 |
2011 |
| Drug |
e7070 |
1 |
2003 |
| Behavioral |
early palliative care |
1 |
2015 |
| Behavioral |
early palliative care/symptom control |
1 |
2015 |
| Other |
early tumor response evaluation by mri volumetry |
1 |
2011 |
| Biological |
ebv-specific cytotoxic t lymphocytes |
1 |
2009 |
| Biological |
ebv specific ctl infusion |
1 |
2004 |
| Other |
ecg |
1 |
2019 |
| Device |
echopulse |
1 |
2019 |
| Drug |
edaravone |
1 |
2013 |
| Biological |
edodekin alfa |
1 |
2011 |
| Biological |
edp1503 |
1 |
2018 |
| Other |
educational program |
1 |
2016 |
| Other |
educational website |
1 |
2019 |
| Biological |
efficacy of escalating doses |
1 |
2007 |
| Biological |
efficacy of escalating doses. |
1 |
2007 |
| Biological |
egfr antisense dna |
1 |
2012 |
| Drug |
ekb-569 |
1 |
2003 |
| Device |
ektotherix |
1 |
2015 |
| Drug |
elbasvir |
1 |
2016 |
| Drug |
elbasvir/grazoprevir |
1 |
2016 |
| Procedure |
elective neck dissection |
1 |
2011 |
| Radiation |
elective neck irradiation |
1 |
2015 |
| Procedure |
electrocautery block resection |
1 |
2020 |
| Procedure |
electrochemotherapy |
1 |
2017 |
| Biological |
electrofusion dc vaccine |
1 |
2008 |
| Other |
electron microscopy |
1 |
2007 |
| Radiation |
electronic brachytherapy |
1 |
2008 |
| Device |
electronic brachytherapy (6,1 gy) |
1 |
2016 |
| Device |
electronic brachytherapy (7 gy) |
1 |
2016 |
| Other |
electronic pro in daily clinical practice |
1 |
2017 |
| Radiation |
electronic skin surface brachytherapy |
1 |
2014 |
| Device |
electroporation |
1 |
2019 |
| Drug |
elesclomol sodium |
1 |
2009 |
| Biological |
emactuzumab |
1 |
2016 |
| Drug |
embolic agent |
1 |
2016 |
| Drug |
embolic agents |
1 |
2016 |
| Drug |
emd 1201081 |
1 |
2009 |
| Other |
empty control |
1 |
2015 |
| Drug |
encorafenib |
1 |
2019 |
| Drug |
endocrine therapy |
1 |
2015 |
| Procedure |
endometrial biopsy |
1 |
2015 |
| Diagnostic Test |
endoscopic examination using white light, nbi |
1 |
2019 |
| Diagnostic Test |
endoscopic examination using white light, nbi/iodine staining |
1 |
2019 |
| Procedure |
endoscopic robot-assisted simple enucleation |
1 |
2018 |
| Procedure |
endoscopic surgery |
1 |
2017 |
| Procedure |
endoscopy |
1 |
2018 |
| Drug |
endostar |
1 |
2019 |
| Drug |
endostatins |
1 |
2015 |
| Drug |
endoxana, ima901, leukine |
1 |
2007 |
| Drug |
endoxana, leukine, ima910 |
1 |
2008 |
| Drug |
endoxana, leukine, ima910, aldara |
1 |
2008 |
| Drug |
entecavir 0.5 mg |
1 |
2020 |
| Drug |
enteral nutrition |
1 |
2015 |
| Drug |
enzalutamide with sorafenib |
1 |
2015 |
| Other |
enzyme-linked immunosorbent assay |
1 |
2006 |
| Drug |
enzyme inhibitor therapy |
1 |
2017 |
| Diagnostic Test |
eob-mri |
1 |
2018 |
| Biological |
ep2101 |
1 |
2003 |
| Dietary Supplement |
epa supplementation |
1 |
2015 |
| Genetic |
epidermal growth factor receptor status |
1 |
2012 |
| Drug |
epidoxorubicin |
1 |
2017 |
| Drug |
epidoxorubicin/cisplatin/lipiodol |
1 |
2017 |
| Drug |
epidural anesthesia |
1 |
2014 |
| Drug |
epirubicin, cisplatin, capecitabine |
1 |
2005 |
| Drug |
epirubicin, cyclophosphamide |
1 |
2010 |
| Biological |
epoetin alfa |
1 |
2001 |
| Biological |
epstein-barr virus-specific adoptive t-cells immunotherapy |
1 |
2007 |
| Biological |
epstein-barr virus specific immunotherapy |
1 |
2009 |
| Procedure |
er:yag afl-pdt |
1 |
2013 |
| Biological |
erbitux (cetuximab) |
1 |
2002 |
| Drug |
eribulin |
1 |
2017 |
| Drug |
erivedge |
1 |
2016 |
| Drug |
erlotinib (tarceva) |
1 |
2009 |
| Drug |
erlotinib / rosuvastatin |
1 |
2009 |
| Drug |
erlotinib chlorhydrate |
1 |
2007 |
| Drug |
erlotinib, |
1 |
2011 |
| Drug |
erlotinib/sulindac |
1 |
2012 |
| Drug |
esk981 |
1 |
2018 |
| Procedure |
esophageal variceal ligation |
1 |
2013 |
| Biological |
et140202 autologous t cell product |
1 |
2019 |
| Biological |
et1402l1-artemisâ„¢ t cells -intra-hepatic artery |
1 |
2019 |
| Biological |
et1402l1-artemisâ„¢ t cells -intratumoral injections |
1 |
2019 |
| Biological |
et1402l1-artemisâ„¢ t cells -iv |
1 |
2019 |
| Biological |
etbx-011 |
1 |
2017 |
| Biological |
etbx-021 |
1 |
2017 |
| Biological |
etbx-051 |
1 |
2017 |
| Biological |
etbx-061 |
1 |
2017 |
| Drug |
etoposide (dose level 1) |
1 |
2018 |
| Drug |
etoposide (dose level 2) |
1 |
2018 |
| Drug |
etoposide phosphate |
1 |
2017 |
| Drug |
etoposide with mitotane |
1 |
1999 |
| Drug |
etoposide, carboplatin |
1 |
2019 |
| Drug |
etoposide, cisplatin |
1 |
2019 |
| Other |
evaluation of the hepatic fibrosis |
1 |
2017 |
| Drug |
everolimus (afinitorâ®) |
1 |
2014 |
| Drug |
everolimus , temozolomide |
1 |
2014 |
| Drug |
everolimus 10 mg |
1 |
2006 |
| placebo |
everolimus placebo |
1 |
2009 |
| Drug |
everolimus/bevacizumab |
1 |
2011 |
| Procedure |
everted suture technique |
1 |
2013 |
| Procedure |
examination |
1 |
2013 |
| Device |
exatherm-tbh system |
1 |
2015 |
| Other |
exercise counseling |
1 |
2018 |
| Other |
exercise programme |
1 |
2016 |
| Behavioral |
experimental: prt |
1 |
2014 |
| Behavioral |
experimental: prt/a healthy diet,/weight loss |
1 |
2014 |
| Device |
explorer air camera |
1 |
2018 |
| Radiation |
external-beam radiation |
1 |
2018 |
| Radiation |
external beam proton radiation therapy. |
1 |
2017 |
| Radiation |
external beam radiation (dose level 1) |
1 |
2018 |
| Radiation |
external beam radiation (dose level 2) |
1 |
2018 |
| Radiation |
external beam radiation (hyperfractionated) |
1 |
2018 |
| Radiation |
external beam radiation (standard) |
1 |
2018 |
| Radiation |
external beam rt |
1 |
2013 |
| Radiation |
external fractionated radiotherapy |
1 |
2013 |
| Procedure |
extra imaging |
1 |
2011 |
| Procedure |
extraperitoneal laparoscopic lymphadenectomy (eplnd) |
1 |
2011 |
| Drug |
f-18 fluoro-deoxi-glucose |
1 |
2007 |
| Diagnostic Test |
f-fmiso pet |
1 |
2017 |
| Diagnostic Test |
f-fmiso pet/ct scan |
1 |
2017 |
| Drug |
f-miso pet scan coupled with mri |
1 |
2019 |
| Behavioral |
facial morphing intervention |
1 |
2017 |
| Other |
fact-h&n |
1 |
2018 |
| Other |
fact h&n |
1 |
2018 |
| Drug |
famotidine |
1 |
2017 |
| Drug |
fate-nk100 |
1 |
2017 |
| Drug |
faza |
1 |
2015 |
| Other |
fch positron emission tomography |
1 |
2016 |
| Drug |
fdg |
1 |
2009 |
| Procedure |
fdg pet |
1 |
2012 |
| Procedure |
fdg pet ct |
1 |
2007 |
| Procedure |
fdg pet/mr |
1 |
2012 |
| Other |
fdg positron emission tomography |
1 |
2016 |
| Radiation |
fdgâ€pet guided gradient dose prescription |
1 |
2015 |
| Drug |
fecal microbiota transplantation |
1 |
2019 |
| Drug |
fenretinide |
1 |
2012 |
| Drug |
fenretinide/lxs / ketoconazole |
1 |
2012 |
| Drug |
ferumoxtran-10 |
1 |
2006 |
| Other |
fibroscan |
1 |
2013 |
| Radiation |
fiducials |
1 |
2010 |
| Drug |
filgrastim injection |
1 |
2019 |
| Device |
first oe |
1 |
2018 |
| Device |
first wli |
1 |
2018 |
| Device |
fis-00 fluorescence imaging system (fis) |
1 |
2018 |
| Drug |
fisogatinib (blu-554) |
1 |
2015 |
| Drug |
fisogatinib in combination with cs1001 |
1 |
2019 |
| Drug |
fk228 (romidepsin) |
1 |
2005 |
| Other |
flow cytometry |
1 |
2006 |
| Drug |
floxuridine (fudr) |
1 |
2013 |
| Drug |
flt |
1 |
2009 |
| Drug |
flt3l |
1 |
2018 |
| Drug |
fluorescein sodium injection |
1 |
2017 |
| Procedure |
fluorescence imaging |
1 |
2013 |
| Drug |
fluorine f 18 ara-g |
1 |
2019 |
| Other |
fluorine f 18 fluorothymidine |
1 |
2010 |
| Radiation |
fluorine f 18 fluorthanatrace |
1 |
2018 |
| Drug |
fluorine f18 ef5 |
1 |
2009 |
| Drug |
fluorouracil, leucovorin, oxaliplatin, docetaxel |
1 |
2012 |
| Drug |
flutamide |
1 |
2005 |
| Drug |
fluvastatin sodium |
1 |
2006 |
| Radiation |
focal radiotherapy |
1 |
2017 |
| Drug |
folfiri-bevacizumab |
1 |
2016 |
| Drug |
folfiri / bevacizumab |
1 |
2012 |
| Drug |
folfiri / cetuximab |
1 |
2012 |
| Drug |
folfiri. |
1 |
2011 |
| Drug |
folfirinox |
1 |
2019 |
| Drug |
folfirinox, |
1 |
2011 |
| Drug |
folfox |
1 |
2018 |
| Drug |
folfox (oxaliplatin |
1 |
2013 |
| Drug |
folfox (oxaliplatin/leucovorin/5-fluorouracil) |
1 |
2013 |
| Drug |
folfox regimen |
1 |
2017 |
| Drug |
folfox, |
1 |
2011 |
| Drug |
folinic acid) |
1 |
2016 |
| Procedure |
follow-up |
1 |
2016 |
| Other |
follow up visit |
1 |
2012 |
| Drug |
foretinib |
1 |
2009 |
| Drug |
foretinib (formerly gsk1363089 |
1 |
2008 |
| Drug |
foretinib (formerly gsk1363089/xl880) |
1 |
2008 |
| Drug |
fosbretabulin tromethamine |
1 |
2011 |
| Drug |
fostamatinib disodium |
1 |
2009 |
| Drug |
fractional co2 laser assisted pdt |
1 |
2010 |
| Device |
free-breathing mri |
1 |
2014 |
| Biological |
fresolimumab |
1 |
2015 |
| Drug |
ft500 |
1 |
2019 |
| Procedure |
full bilateral laparoscopic lymphadenectomy |
1 |
2015 |
| Procedure |
full bilateral laparoscopic lymphadenectomy/hysterectomy |
1 |
2015 |
| Drug |
g-csf (granulocyte-colony stimulating factor) |
1 |
2003 |
| Biological |
g-csf/peg-gcsf |
1 |
2009 |
| Drug |
ga-68 labeled psma-11 |
1 |
2020 |
| Drug |
gabapentin |
1 |
2018 |
| Drug |
gadolinium-dtpa |
1 |
2007 |
| Drug |
gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid |
1 |
2020 |
| Drug |
gadoxetate disodium |
1 |
2015 |
| Drug |
gadoxetic acid |
1 |
2012 |
| Drug |
gallium ga 68-dotatate |
1 |
2018 |
| Radiation |
gallium ga 68 fapi-46 |
1 |
2019 |
| Drug |
galunisertib 150mg by mouth twice a day |
1 |
2016 |
| Drug |
gamma-secretase |
1 |
2010 |
| Drug |
gamma-secretase/notch signalling pathway inhibitor ro4929097 |
1 |
2010 |
| Drug |
ganciclovir |
1 |
2014 |
| Procedure |
gasless single-port laparoscopic surgery |
1 |
2017 |
| Procedure |
gastrecomy |
1 |
2017 |
| Procedure |
gastrectomy |
1 |
2014 |
| Drug |
gc |
1 |
2017 |
| Biological |
gc1008 human anti transforming growth factor _beta (tgfî² ) monoclonal antibody |
1 |
2006 |
| Biological |
gc1008 human anti transforming growth factor _beta (tgfî²) monoclonal antibody |
1 |
2006 |
| Drug |
gc33 |
1 |
2012 |
| Drug |
gc33(ro5137382) |
1 |
2009 |
| Drug |
gc4419 |
1 |
2013 |
| Drug |
gefitinib (iressa) |
1 |
2005 |
| Drug |
gefitinib / sunitinib |
1 |
2005 |
| Drug |
gefitinib, raltitrexed |
1 |
2005 |
| Drug |
gelaspan |
1 |
2017 |
| Drug |
gemcitabine (arm b) |
1 |
2017 |
| Drug |
gemcitabine / carboplatin |
1 |
2016 |
| Combination Product |
gemcitabine alone |
1 |
2017 |
| Drug |
gemcitabine, |
1 |
2011 |
| Drug |
gemcitabine, capecitabine |
1 |
2007 |
| Drug |
gemcitabine, capecitabine/sorafenib (6 cycles) |
1 |
2007 |
| Drug |
gemcitabine, gemcitabine-capecitabine, gemcitabine-erlotinib, folfoxiri, folfox, folfiri |
1 |
2011 |
| Drug |
gemcitabine, ifosfamide |
1 |
2005 |
| Drug |
gemcitabine,/gemcitabine/capecitabine,/gemcitabine/erlotinib,/folfirinox,/folfox,/folfiri. |
1 |
2011 |
| Drug |
gemcitabine/cisplatin (induction/adjuvant chemotherapy) |
1 |
2017 |
| Drug |
gemcitabine/docetaxel |
1 |
2011 |
| Drug |
gemcitabine/nab-paclitaxel |
1 |
2013 |
| Drug |
gemcitabine/oxaliplatin |
1 |
2010 |
| Drug |
gemcitabine/oxaliplatin with erlotinib (tarceva) |
1 |
2010 |
| Drug |
gemcitabine/oxaliplatin. |
1 |
2019 |
| Drug |
gemcitabine/with aptinib/toripalimab |
1 |
2019 |
| Drug |
gemox |
1 |
2017 |
| Biological |
gen-009 adjuvanted vaccine |
1 |
2018 |
| Biological |
gen1046 |
1 |
2019 |
| Drug |
gen2 (hsv-thymidine kinase-m2 |
1 |
2020 |
| Drug |
gen2 (hsv-thymidine kinase-m2/hgm-csf genes) |
1 |
2020 |
| Genetic |
gene expression analysis |
1 |
2011 |
| Biological |
genetically engineered ny-eso-1-specific t lymphocytes |
1 |
2016 |
| Biological |
genetically modified ctls |
1 |
2007 |
| Drug |
genexol-pm |
1 |
2016 |
| Drug |
gevokizumab |
1 |
2019 |
| Biological |
gi-4000 |
1 |
2017 |
| Biological |
gi-6207 |
1 |
2017 |
| Biological |
gi-6301 |
1 |
2017 |
| Drug |
gl-0817 |
1 |
2016 |
| Biological |
gl-onc1 |
1 |
2011 |
| Biological |
gl-onc1 alone, |
1 |
2016 |
| Biological |
gl-onc1 alone,/in combination with chemotherapy with/without bevacizumab |
1 |
2016 |
| Biological |
gla-se |
1 |
2014 |
| Drug |
gleevec (imatinib) |
1 |
2006 |
| Drug |
glivec |
1 |
2010 |
| Genetic |
glycar t cells |
1 |
2016 |
| Genetic |
gm-csf) |
1 |
2007 |
| Drug |
gm-csf, ifn alpha |
1 |
2010 |
| Drug |
gm-csf, ifn alpha/il-2 |
1 |
2010 |
| Biological |
gnrh agonist |
1 |
2016 |
| Biological |
gnrh agonist/antagonist |
1 |
2016 |
| Drug |
goserelin |
1 |
2014 |
| Drug |
gp/ccrt |
1 |
2018 |
| Biological |
gpc3 and |
1 |
2017 |
| Biological |
gpc3 and/or tgfî² targeting car-t cells |
1 |
2017 |
| Drug |
gr-md-02 |
1 |
2015 |
| Biological |
granulocyte-macrophage colony-stimulating factor |
1 |
2019 |
| Drug |
grazoprevir |
1 |
2016 |
| Drug |
gsk2118436 |
1 |
2012 |
| Drug |
gsk3359609 |
1 |
2019 |
| Drug |
gsk525762 |
1 |
2012 |
| Drug |
gt90001 |
1 |
2019 |
| Drug |
gt90001/nivolumab |
1 |
2019 |
| Drug |
gti-2040 |
1 |
2003 |
| Biological |
gv1001 |
1 |
2007 |
| Biological |
gvax |
1 |
2005 |
| Procedure |
gvhd prophylaxis |
1 |
2009 |
| Drug |
gw786034 |
1 |
2005 |
| Drug |
gz17-6.02 |
1 |
2018 |
| Drug |
h3b-6527 |
1 |
2016 |
| Drug |
haic of oxa |
1 |
2019 |
| Drug |
haic regimen |
1 |
2016 |
| Procedure |
haled |
1 |
2017 |
| Biological |
hank for infusion |
1 |
2017 |
| Biological |
hankâ„¢ |
1 |
2019 |
| Device |
harmonic generation microscopy |
1 |
2013 |
| Drug |
hbi-8000 in combination with nivolumab |
1 |
2016 |
| Drug |
hd il2 |
1 |
2007 |
| Radiation |
hdr brachytherapy of 7 gy in 3 fractions |
1 |
2016 |
| Radiation |
hdr brachytherapy of 9 gy in 2 fractions |
1 |
2016 |
| Dietary Supplement |
healing elements,methuselah medical technology |
1 |
2016 |
| Other |
health telemonitoring |
1 |
2011 |
| Procedure |
hemihepatic vascular clamping |
1 |
2009 |
| Device |
hepasphere |
1 |
2011 |
| Device |
hepasphere/quadrasphere microspheres |
1 |
2011 |
| Procedure |
hepatectomy/transcatheter arterial chemoembolization |
1 |
2008 |
| Procedure |
hepatectomy/with lymphadenectomy |
1 |
2014 |
| Drug |
hepatic |
1 |
2015 |
| Combination Product |
hepatic arterial infusion/with apatinib/camrelizumab |
1 |
2019 |
| Procedure |
hepatic artery embolization |
1 |
2009 |
| Procedure |
hepatic artery embolization (hae) |
1 |
2017 |
| Other |
hepatobiliary iminodiacetic acid scan |
1 |
2019 |
| Biological |
hepcortespenlisimut-l |
1 |
2014 |
| Device |
her-2 testing |
1 |
2017 |
| Biological |
her2bi-armed activated t cells |
1 |
2017 |
| Drug |
herceptin (trastuzumab) |
1 |
2007 |
| Drug |
hf10 |
1 |
2009 |
| Drug |
hgm-csf genes) |
1 |
2020 |
| Device |
high-intensity focused ultrasound ablation system |
1 |
2019 |
| Procedure |
high-resolution microendoscopy (hrme) imaging |
1 |
2014 |
| Procedure |
high frequency ultrasound imaging |
1 |
2005 |
| Radiation |
higher dose (50.4gy |
1 |
2017 |
| Radiation |
higher dose (50.4gy/28f) of neoadjuvant chemoradiation |
1 |
2017 |
| Drug |
hiltonol |
1 |
2016 |
| Biological |
hla-a02 restricted hig2 |
1 |
2010 |
| Drug |
hlx04 |
1 |
2019 |
| Drug |
hlx10 |
1 |
2019 |
| Drug |
hlx10 100 mg in 10 ml injection |
1 |
2019 |
| Drug |
hlx10/hlx04 |
1 |
2019 |
| Device |
holmium-166 radioembolization |
1 |
2017 |
| Biological |
hpv-16 vaccine |
1 |
2005 |
| Biological |
hpv dna plasmids therapeutic vaccine medi0457 |
1 |
2018 |
| Drug |
hpv e6-specific tcr-t cell with anti-pd1 auto-secreted element |
1 |
2019 |
| Drug |
hpv e6-specific tcr-t cells |
1 |
2018 |
| Genetic |
hpv specific t cells |
1 |
2015 |
| Procedure |
hr |
1 |
2012 |
| Biological |
hsv-tk |
1 |
2016 |
| Drug |
hu5f9-g4 |
1 |
2019 |
| Drug |
huachansu |
1 |
2015 |
| Device |
human intravital microscopy |
1 |
2018 |
| Drug |
human recombinated interleukin-2 |
1 |
2019 |
| Biological |
humanized anti-pd-1 monoclonal antibody toripalimab |
1 |
2017 |
| Radiation |
hydrea |
1 |
2010 |
| Drug |
hydroxyurea pill |
1 |
2019 |
| Biological |
hyperacuteâ®-renal (har) immunotherapy |
1 |
2014 |
| Procedure |
hyperfractionated accelerated radiotherapy |
1 |
2005 |
| Radiation |
hyperfractionated radiation therapy |
1 |
2013 |
| Radiation |
hyperfractionated radiotherapy with concomitant cetuximab |
1 |
2010 |
| Radiation |
hyperfractionation |
1 |
2013 |
| Procedure |
hyperthermia |
1 |
2015 |
| Radiation |
hyperthermia after tace |
1 |
2013 |
| Drug |
hyperthermic intraperitoneal chemotherapy (hipec) |
1 |
2017 |
| Procedure |
hyperthermic intraperitoneal chemotherapy with mmc |
1 |
2014 |
| Radiation |
hypofraction radiation |
1 |
2018 |
| Procedure |
hypofractionated external beam |
1 |
2007 |
| Procedure |
hypofractionated image-guided radiation therapy |
1 |
2018 |
| Radiation |
hypofractionated image guided radaition therapy |
1 |
2018 |
| Radiation |
hypofractionated radiotherapy |
1 |
2016 |
| Radiation |
hypofractionated rt |
1 |
2013 |
| Radiation |
hypofractionated rth with platinol |
1 |
2018 |
| Radiation |
hypofractionated whole breast irradiation |
1 |
2010 |
| Procedure |
hysterectomy |
1 |
2015 |
| Dietary Supplement |
î²-glucan |
1 |
2020 |
| Biological |
ibi308 |
1 |
2017 |
| Drug |
ibrutinib 560mg po daily (imbruvica) |
1 |
2018 |
| Biological |
icg |
1 |
2013 |
| Biological |
icrucumab |
1 |
2011 |
| Drug |
idarubicin/lipiodol |
1 |
2018 |
| Other |
idiographic |
1 |
2015 |
| Drug |
ifn-alpha |
1 |
2007 |
| Drug |
ifn-î±2b |
1 |
2005 |
| Biological |
ifx-hu2.0 |
1 |
2019 |
| Device |
igp-elvis-v4 macroscopic specimen imager |
1 |
2018 |
| Drug |
ik-175 |
1 |
2019 |
| Drug |
il-2/nivolumab |
1 |
2019 |
| Biological |
ilixadencel |
1 |
2018 |
| Device |
illuminating using red light-emitting diode lamps |
1 |
2016 |
| Drug |
ilx651 |
1 |
2004 |
| Diagnostic Test |
ima_detect |
1 |
2017 |
| Biological |
ima201 product |
1 |
2017 |
| Drug |
ima901/leukine |
1 |
2007 |
| Drug |
ima970a |
1 |
2017 |
| Drug |
ima970a/cv8102/cyclophosphamide |
1 |
2017 |
| Radiation |
image-guided adaptive radiation therapy |
1 |
2015 |
| Radiation |
image-guided radiation therapy |
1 |
2014 |
| Drug |
imatinib |
1 |
2005 |
| Drug |
imc-12 |
1 |
2009 |
| Drug |
imc-a12 |
1 |
2009 |
| Biological |
imc-a12 (cixutumumab) |
1 |
2008 |
| Biological |
imc-a12 (cixutumumab) - 10 milligrams |
1 |
2009 |
| Biological |
imc-a12 (cixutumumab) - 10 milligrams/kilogram (mg/kg) |
1 |
2009 |
| Biological |
imc-a12 (cixutumumab) - 20 mg |
1 |
2009 |
| Biological |
imc-a12 (cixutumumab) - 20 mg/kg |
1 |
2009 |
| Drug |
imiquimod 5% cream with prior curettage |
1 |
2014 |
| Biological |
imiquimod/interferon alpha |
1 |
2007 |
| Drug |
immediate instillation of intravesical chemotherapy-epirubicin- |
1 |
2015 |
| Procedure |
immediate resection |
1 |
2014 |
| Drug |
immu-132 |
1 |
2012 |
| Drug |
immune checkpoint inhibitor |
1 |
2018 |
| Biological |
immune killer cells (ikc) |
1 |
2018 |
| Procedure |
immunocryosurgery |
1 |
2010 |
| Other |
immunohistochemistry |
1 |
2010 |
| Dietary Supplement |
immunomodulating oral supplementation |
1 |
2019 |
| Drug |
immunotherapy / radiotherapy arm |
1 |
2018 |
| Drug |
imo-2055 |
1 |
2008 |
| Radiation |
imp-288-indium |
1 |
2010 |
| Radiation |
imp-288-lutetium |
1 |
2010 |
| Dietary Supplement |
impact |
1 |
2011 |
| Radiation |
impt) |
1 |
2018 |
| Radiation |
imrt radiation |
1 |
2017 |
| Radiation |
imrt using individualized ctv |
1 |
2015 |
| Radiation |
imrt using traditional ctv |
1 |
2015 |
| Radiation |
imrt, followed sorafenib maintenance |
1 |
2018 |
| Device |
imrt/sbrt |
1 |
2019 |
| Radiation |
imrt/tomo |
1 |
2016 |
| Drug |
imuran |
1 |
2014 |
| Biological |
in combination with chemotherapy with |
1 |
2016 |
| Drug |
inbrx-105 - pdl1x41bb antibody |
1 |
2019 |
| Drug |
inbrx-106 - hexavalent ox40 agonist antibody |
1 |
2019 |
| Drug |
inc280 (capmatinib) |
1 |
2015 |
| Biological |
incagn02385 |
1 |
2018 |
| Drug |
incagn02390 |
1 |
2018 |
| Drug |
incb062079 |
1 |
2017 |
| Drug |
incmga0012 |
1 |
2020 |
| Drug |
indium-111-dota-girentuximab-irdye800cw |
1 |
2015 |
| Drug |
indium-111-dota-labetuzumab-irdye800cw injection |
1 |
2018 |
| Other |
individualized risk assessment |
1 |
2019 |
| Drug |
indocyanine-green(icg) |
1 |
2019 |
| Procedure |
induction chemotherapy |
1 |
2008 |
| Radiation |
induction chemotherapy followed by ccrt |
1 |
2012 |
| Drug |
induction chemotherapy using pf (5-fluorouracil) |
1 |
2006 |
| Drug |
induction ct |
1 |
2018 |
| Drug |
induction ct/ crt group |
1 |
2018 |
| Drug |
induction ctx(tpf) |
1 |
2010 |
| Drug |
induction ctx(tpf)/(rt/cddp/5-fu) |
1 |
2010 |
| Drug |
induction ctx(tpf)/(rt/cetuximab) |
1 |
2010 |
| Procedure |
induction therapy |
1 |
2009 |
| Drug |
induction trichemotherapy - folfirinox regimen |
1 |
2011 |
| Drug |
infigratinib |
1 |
2019 |
| Other |
infusion of anticancer agent |
1 |
2010 |
| Other |
infusion of mixture of anticancer agent |
1 |
2010 |
| Other |
infusion of mixture of anticancer agent/lipiodol |
1 |
2010 |
| Drug |
infusional 5-fluorouracil |
1 |
2008 |
| Other |
injected ct-scan |
1 |
2018 |
| Biological |
inkt cells |
1 |
2019 |
| Biological |
ino-5401 |
1 |
2018 |
| Biological |
ino-9012 |
1 |
2018 |
| Other |
inspection of covered areas |
1 |
2008 |
| Other |
institutional standard of care |
1 |
2018 |
| Device |
integrated pet |
1 |
2018 |
| Device |
integrated pet/mri |
1 |
2018 |
| Radiation |
intensity-modulated radiotherapy (imrt) |
1 |
2014 |
| Radiation |
intensity modulated-radiotherapy |
1 |
2020 |
| Radiation |
intensity modulated proton therapy |
1 |
2018 |
| Radiation |
intensity modulated radiotherapy |
1 |
2017 |
| Radiation |
intensity modulated radiotherapy (imrt) - deintensified |
1 |
2017 |
| Radiation |
intensity modulated radiotherapy (imrt) - standard |
1 |
2017 |
| Radiation |
intensity modulated radiotherapy treatments |
1 |
2015 |
| Procedure |
intercostal uniportal vats |
1 |
2017 |
| Drug |
interferon |
1 |
2005 |
| Drug |
interferon-alfa |
1 |
2004 |
| Drug |
interferon-alfa-2b |
1 |
2006 |
| Drug |
interferon-alfa-2b/ribavirin |
1 |
2006 |
| Drug |
interferon-alfa 9mu |
1 |
2008 |
| Drug |
interferon alfa-2b |
1 |
2014 |
| Drug |
interferon alfa/cci-779 |
1 |
2003 |
| Biological |
interferon alpha |
1 |
2007 |
| Drug |
interferon alpha-2a |
1 |
2008 |
| Drug |
interferon alpha 2a |
1 |
2012 |
| Drug |
interleukin-2 (il2) |
1 |
2017 |
| Drug |
intermittent pazopanib (arm b) |
1 |
2013 |
| Procedure |
interstitial illumination photodynamic therapy |
1 |
2018 |
| Device |
interstitial light emitting diodes |
1 |
2006 |
| Procedure |
interstitial radiation therapy |
1 |
2017 |
| Behavioral |
interviews |
1 |
2011 |
| Device |
intra-operative mri |
1 |
2014 |
| Radiation |
intra-operative radiation therapy - iort |
1 |
2012 |
| Drug |
intra-operative sn mapping with indocyanin green |
1 |
2015 |
| Drug |
intra-operative sn mapping with patent v blue dye |
1 |
2015 |
| Radiation |
intra operative radiotherapy |
1 |
2015 |
| Drug |
intraarterial cetxuimab (erbitux) |
1 |
2015 |
| Radiation |
intracavitary accelerated partial breast irradiation |
1 |
2008 |
| Procedure |
intraoperative dual-modality imaging |
1 |
2015 |
| Device |
intraoperative fluorescence imaging system |
1 |
2015 |
| Device |
intraoperative ultrasound |
1 |
2015 |
| Procedure |
intraperitoneal administration |
1 |
2006 |
| Drug |
intraperitoneal docetaxel |
1 |
2013 |
| Drug |
intravenous (iv) sea-cd40 |
1 |
2015 |
| Drug |
intravenous infusion ofvit k1 |
1 |
2014 |
| placebo |
intravenousinfusion of placebo |
1 |
2014 |
| Drug |
intravesical 2000mg |
1 |
2017 |
| Drug |
intravesical 2000mg/52.6ml gemcitabine instillation |
1 |
2017 |
| Biological |
intuvax (ilixadencel) |
1 |
2015 |
| Device |
investigational imaging device |
1 |
2017 |
| Drug |
investigator choice (ic) chemotherapy |
1 |
2017 |
| Drug |
investigator choice of chemotherapy |
1 |
2015 |
| Radiation |
iodine |
1 |
2012 |
| Drug |
iodine-124 |
1 |
2018 |
| Other |
iodine i 124 |
1 |
2014 |
| Other |
iodine i 124 chimeric monoclonal antibody g250 |
1 |
2010 |
| Biological |
iodine i 124 monoclonal antibody m5a |
1 |
2019 |
| Diagnostic Test |
iodine staining |
1 |
2019 |
| Drug |
iop injection (mpb-1523) |
1 |
2018 |
| Drug |
ipatasertib |
1 |
2015 |
| Drug |
iph2201 |
1 |
2017 |
| Drug |
ipilimumab 1mg |
1 |
2017 |
| Drug |
ipilimumab 1mg/kg |
1 |
2017 |
| Drug |
ipilimumab/nivolumab |
1 |
2017 |
| Radiation |
ipsilateral radiation |
1 |
2012 |
| Drug |
iressa |
1 |
2003 |
| Drug |
irinotecan/capecitabine |
1 |
2008 |
| Radiation |
irradiation |
1 |
2015 |
| Drug |
irx-2 regimen |
1 |
2017 |
| Drug |
irx 2 |
1 |
2018 |
| Drug |
isolated perfusion |
1 |
2001 |
| Drug |
ispinesib |
1 |
2004 |
| Drug |
itacitinib (incb039110) |
1 |
2020 |
| Drug |
itraconazole 200 mg |
1 |
2019 |
| Drug |
iv carboplatin (auc2) |
1 |
2015 |
| Drug |
iv injection of icg |
1 |
2013 |
| placebo |
iv placebo |
1 |
2020 |
| Drug |
ixazomib |
1 |
2018 |
| Drug |
ixazomib citrate |
1 |
2018 |
| Drug |
jab-3312 |
1 |
2019 |
| Drug |
jiu-wei-zhen-xiao granule |
1 |
2019 |
| Drug |
jnj-42756493 (erdafitinib) |
1 |
2015 |
| Drug |
js001 |
1 |
2019 |
| Drug |
js001(pd-1 inhibitor) |
1 |
2019 |
| Drug |
jx-594 followed by sorafenib |
1 |
2010 |
| Biological |
jx-594 recombinant vaccina gm-csf |
1 |
2011 |
| Genetic |
jx-594: recombinant vaccinia virus (tk-deletion |
1 |
2007 |
| Genetic |
jx-594: recombinant vaccinia virus (tk-deletion/gm-csf) |
1 |
2007 |
| Drug |
karenitecin (bnp1350) |
1 |
2004 |
| Biological |
kg anti-pd-1 mab js001 q2w |
1 |
2016 |
| Drug |
kg bevacizumab alternating with cisplatin |
1 |
2011 |
| Combination Product |
kg with carboplatin |
1 |
2017 |
| Biological |
kg) |
1 |
2009 |
| Drug |
khk2455 |
1 |
2019 |
| Drug |
khk7580 |
1 |
2017 |
| Biological |
kilogram (mg |
1 |
2009 |
| Drug |
klonidin |
1 |
2014 |
| Drug |
krt-232 |
1 |
2018 |
| Drug |
ky1044 |
1 |
2019 |
| Drug |
ky1044/atezolizumab |
1 |
2019 |
| Biological |
l-blp25 |
1 |
2011 |
| Drug |
l-folinic |
1 |
2015 |
| Drug |
l-lv |
1 |
2019 |
| Dietary Supplement |
l-lysine |
1 |
2010 |
| Drug |
l-nmma |
1 |
2017 |
| Procedure |
la |
1 |
2016 |
| Drug |
ladiratuzumab vedotin |
1 |
2019 |
| Drug |
lamivudine |
1 |
2016 |
| Drug |
lanreotide |
1 |
2015 |
| Drug |
lanreotide (microparticle formulation) |
1 |
2005 |
| Drug |
lanreotide autogel 120mg |
1 |
2011 |
| Procedure |
laparoscopic-assisted rectal resection |
1 |
2013 |
| Procedure |
laparoscopic assisted resection of colorectal carcinoma |
1 |
2007 |
| Procedure |
laparoscopic hepatectomy |
1 |
2015 |
| Procedure |
laparoscopic hepatectomy (surgery) |
1 |
2018 |
| Procedure |
laparoscopic liver resection |
1 |
2013 |
| Procedure |
laparoscopic microwave ablation-assisted enucleation |
1 |
2014 |
| Procedure |
laparoscopic partial nephrectomy |
1 |
2017 |
| Procedure |
laparoscopic surgery(ls) |
1 |
2015 |
| Drug |
lapatinib oral tablets |
1 |
2006 |
| Drug |
larotrectinib |
1 |
2015 |
| Drug |
larotrectinib sulfate |
1 |
2015 |
| Device |
laryngoscope with nbi system |
1 |
2015 |
| Procedure |
laser ablation (la) |
1 |
2012 |
| Other |
laser speckle imaging |
1 |
2011 |
| Procedure |
laser treatment |
1 |
2014 |
| Radiation |
late-course accelerated hyperfractionated imrt |
1 |
2008 |
| Procedure |
lavage of the cavum uteri |
1 |
2014 |
| Procedure |
lavage of the cavum uteri/proximal fallopian tubes, performed in the luteal phase of the female cycle |
1 |
2014 |
| Procedure |
lavage of the uterus |
1 |
2015 |
| Drug |
lbh589 |
1 |
2007 |
| Procedure |
lc bead-tace |
1 |
2009 |
| Drug |
lc bead loaded with doxorubicin |
1 |
2009 |
| Drug |
lde225 0.25% |
1 |
2009 |
| Drug |
lde225 0.75% |
1 |
2009 |
| Drug |
lee011 |
1 |
2015 |
| Device |
leica fluorescence microscope |
1 |
2018 |
| Drug |
lenvatinib 4 mg oral |
1 |
2020 |
| Drug |
lenvatinib mesylate |
1 |
2016 |
| Drug |
lenvima 4 mg oral capsule |
1 |
2020 |
| Drug |
letrozole/leuprolide |
1 |
2012 |
| Drug |
leucovorin (arm a) |
1 |
2017 |
| Drug |
leucovorin (calcium folinate |
1 |
2016 |
| Procedure |
leukapheresis |
1 |
2015 |
| Drug |
leukine |
1 |
2007 |
| Drug |
leuprolide |
1 |
2012 |
| Drug |
leuprolide acetate |
1 |
2005 |
| Drug |
leuprolide mesylate |
1 |
2014 |
| Drug |
levofolinate |
1 |
2011 |
| Drug |
levoleucovorin |
1 |
2019 |
| Biological |
li |
1 |
2010 |
| Other |
liberal group |
1 |
2014 |
| Drug |
licartin |
1 |
2008 |
| Drug |
lidocaine-prilocaine 5% cream application |
1 |
2016 |
| Procedure |
limited surgical evaluation |
1 |
2012 |
| Drug |
linagliptin |
1 |
2019 |
| Radiation |
linear energy transfer-optimized intensity modulated proton therapy |
1 |
2018 |
| Drug |
liposomal paclitaxel |
1 |
2016 |
| Drug |
liposomal t4n5 lotion |
1 |
2004 |
| Drug |
lipotecan |
1 |
2013 |
| Drug |
lirilumab |
1 |
2017 |
| Combination Product |
litt |
1 |
2019 |
| Combination Product |
litt / pembrolizumab |
1 |
2019 |
| Procedure |
liver biopsy |
1 |
2014 |
| Biological |
liver nk cell inoculation |
1 |
2010 |
| Procedure |
liver resection/placement of hepatic artery infusion pump |
1 |
2013 |
| Procedure |
liver resection/thrombectomy |
1 |
2013 |
| Drug |
lmp2 antigen-specific tcr t cells |
1 |
2019 |
| Drug |
lmwh |
1 |
2009 |
| Biological |
ln-145-s1 |
1 |
2017 |
| Biological |
ln-145 / pembrolizumab |
1 |
2017 |
| Procedure |
lnd only for lymph nodes enlargement found in preoperative image |
1 |
2018 |
| Procedure |
lnd only for lymph nodes enlargement found in preoperative image/during surgery |
1 |
2018 |
| Drug |
lobaplatin |
1 |
2017 |
| Drug |
local anesthesia |
1 |
2007 |
| Procedure |
local consolidation therapy |
1 |
2018 |
| Radiation |
loco-regional radiotherapy |
1 |
2014 |
| Other |
locoregional treatments |
1 |
2007 |
| Device |
logiq e9 scanner (contrast-enhanced ultrasound) |
1 |
2016 |
| Drug |
long-chain triglyceride |
1 |
2006 |
| Drug |
low-dose tamoxifen |
1 |
2019 |
| Radiation |
low-let cobalt-60 gamma ray therapy |
1 |
2008 |
| Radiation |
low-let electron therapy |
1 |
2008 |
| Radiation |
low-let photon therapy |
1 |
2008 |
| Other |
low dose chest ctscan |
1 |
2018 |
| Other |
low dose ct contrast media - lean body weight |
1 |
2019 |
| Other |
low fat diet |
1 |
2016 |
| Device |
low intensity amplitude-moduled electromagnetic fields |
1 |
2012 |
| Procedure |
low level laser therapy |
1 |
2013 |
| Device |
low level laser therapy- (dmc, sã£o paulo, brazil) |
1 |
2011 |
| Radiation |
lower dose (41.4gy |
1 |
2017 |
| Radiation |
lower dose (41.4gy/23f) of neoadjuvant chemoradiation |
1 |
2017 |
| Drug |
ltx-315 |
1 |
2010 |
| Drug |
lu-177-dota-girentuximab |
1 |
2013 |
| Biological |
lucanixâ„¢ |
1 |
2008 |
| Procedure |
lugol chromoendoscopy |
1 |
2015 |
| Procedure |
lugol upper gastrointestinal endoscopy |
1 |
2018 |
| Procedure |
lumbar puncture |
1 |
2012 |
| Drug |
lurbinectedin (pm01183) |
1 |
2015 |
| Drug |
lutetium-177-psma-i&t |
1 |
2020 |
| Drug |
lutetium lu 177-psma-617 |
1 |
2019 |
| Drug |
lv5fu |
1 |
2016 |
| Drug |
lv5fu/folfiri |
1 |
2016 |
| Drug |
lxs |
1 |
2012 |
| Drug |
ly2510924 |
1 |
2011 |
| Drug |
ly3143921 hydrate |
1 |
2017 |
| Procedure |
lymph node dissection |
1 |
2017 |
| Drug |
m-tor inhibitor free |
1 |
2011 |
| Drug |
m-vac protocol |
1 |
2016 |
| Drug |
m^2 |
1 |
2018 |
| Drug |
mâ² concurrent chemotherapy |
1 |
2015 |
| Biological |
mage-a3 |
1 |
2005 |
| Procedure |
magnetic resonance whole body diffusion-weighted imaging |
1 |
2017 |
| Drug |
maintainance therapy of intravesical chemotherapy-epirubicin- |
1 |
2015 |
| Drug |
maintenance instillations |
1 |
2018 |
| Dietary Supplement |
maintenance vitamin d3 |
1 |
2018 |
| Procedure |
mal-pdt |
1 |
2013 |
| Drug |
mal-pdt re-treatment |
1 |
2011 |
| Procedure |
mammography |
1 |
2010 |
| Device |
mammosite ml |
1 |
2011 |
| Procedure |
management of therapy complications |
1 |
2010 |
| Device |
manual imaging fusion of ultrasonography |
1 |
2015 |
| Device |
manual imaging fusion of ultrasonography/mri |
1 |
2015 |
| Other |
margin-based radiotherapy planning |
1 |
2018 |
| Other |
massage of maxillofacial |
1 |
2018 |
| Other |
massage of maxillofacial/oral cavity |
1 |
2018 |
| Biological |
mb-002 |
1 |
2004 |
| Drug |
mb07133 1200 mg |
1 |
2003 |
| Drug |
mb07133 1200 mg/m2/day |
1 |
2003 |
| Drug |
mb07133 1800 mg |
1 |
2003 |
| Drug |
mb07133 1800 mg/m2/day |
1 |
2003 |
| Drug |
mb07133 2400 mg |
1 |
2003 |
| Drug |
mb07133 2400 mg/m2/day |
1 |
2003 |
| Drug |
mb07133 300mg |
1 |
2003 |
| Drug |
mb07133 300mg/m2/day |
1 |
2003 |
| Drug |
mb07133 600 mg |
1 |
2003 |
| Drug |
mb07133 600 mg/m2/day |
1 |
2003 |
| Biological |
mc |
1 |
2014 |
| Biological |
mcpyv tag-specific polyclonal autologous cd8-positive t cells |
1 |
2015 |
| Drug |
mcs110 |
1 |
2016 |
| Other |
md anderson dysphagia inventory |
1 |
2018 |
| Biological |
mdx-1106 |
1 |
2007 |
| Biological |
mdx-1203 |
1 |
2009 |
| Drug |
me-344 |
1 |
2016 |
| Other |
measuring hemodynamic parameters heart beat to heart beat during single-frequency exposure |
1 |
2018 |
| Drug |
meclizine oral tablet |
1 |
2017 |
| Drug |
medi-573 (1 of 3 doses) |
1 |
2011 |
| Drug |
medi0457 |
1 |
2019 |
| Drug |
medi0562 |
1 |
2017 |
| Radiation |
medial group retropharyngeal node(mrln) sparing |
1 |
2017 |
| Other |
medical chart review |
1 |
2017 |
| Drug |
medroxyprogesterone |
1 |
2003 |
| Drug |
medroxyprogesterone acetate |
1 |
2006 |
| Drug |
megestrol(yining) |
1 |
2015 |
| Drug |
mehd7945a |
1 |
2010 |
| Drug |
mek162 |
1 |
2013 |
| Drug |
melatonin 20 mg oral capsule |
1 |
2019 |
| Drug |
mep |
1 |
2014 |
| Drug |
merestinib |
1 |
2017 |
| Procedure |
mesenchymal stem cell transplantation |
1 |
2014 |
| Other |
message |
1 |
2019 |
| Drug |
met-4 |
1 |
2019 |
| Drug |
methadone |
1 |
2018 |
| Drug |
methoxyamine |
1 |
2015 |
| Drug |
methoxyamine hydrochloride |
1 |
2015 |
| Drug |
methyl-5-aminolevulinate hydrochloride cream |
1 |
2011 |
| Drug |
methyl-aminolevulinate |
1 |
2014 |
| Drug |
methyl-aminolevulinate application |
1 |
2016 |
| Drug |
mfolfiri |
1 |
2019 |
| Drug |
mfolfirinox |
1 |
2016 |
| Drug |
mfolfox6 |
1 |
2015 |
| Drug |
mfolfox6 regimen |
1 |
2018 |
| Biological |
mga271 |
1 |
2011 |
| Drug |
mgd007 |
1 |
2014 |
| Dietary Supplement |
mgn-3 |
1 |
2009 |
| Biological |
mgn1601 |
1 |
2010 |
| Drug |
mgn1703 |
1 |
2010 |
| Dietary Supplement |
micronutrient-fortified probiotic yogurt |
1 |
2016 |
| Drug |
milciclib maleate |
1 |
2017 |
| Behavioral |
mindfulness intervention |
1 |
2017 |
| Procedure |
minimally invasive esophagectomy |
1 |
2016 |
| Drug |
minnelideâ„¢capsules |
1 |
2017 |
| Drug |
minocycline |
1 |
2016 |
| Drug |
mitogelâ„¢ instillations |
1 |
2016 |
| Drug |
mitomycin c,epirubicin,cisplatin,5-fluorouracil,leucovorin |
1 |
2005 |
| Drug |
mitomycins |
1 |
2015 |
| Biological |
mixed bacterial vaccine |
1 |
2008 |
| Drug |
mk-1454 |
1 |
2020 |
| Biological |
mk-3475 (adjuvant) |
1 |
2014 |
| Biological |
mk-3475 (neoadjuvant) |
1 |
2014 |
| Drug |
mk-3475(pembrolizumab) |
1 |
2016 |
| Drug |
mk-6482 |
1 |
2019 |
| Drug |
mln0128 (rp2d) |
1 |
2015 |
| Drug |
mln1117 |
1 |
2016 |
| Drug |
moc31-pe |
1 |
2010 |
| Drug |
moc31pe immunotoxin |
1 |
2014 |
| Drug |
mocetinostat |
1 |
2014 |
| Combination Product |
moderately hypofractionated conformal radiation |
1 |
2018 |
| Combination Product |
moderately hypofractionated conformal radiation/with s-1 |
1 |
2018 |
| Drug |
modified folfox6 |
1 |
2019 |
| Procedure |
modified radical neck dissection |
1 |
2018 |
| Other |
module completion of the prepare to care kit |
1 |
2017 |
| Biological |
mogamulizumab |
1 |
2016 |
| Biological |
mogamulizumab / nivolumab |
1 |
2016 |
| Procedure |
mohs micrographic surgery |
1 |
2007 |
| Procedure |
mohs surgery |
1 |
2012 |
| Procedure |
molecular breast imaging |
1 |
2007 |
| Procedure |
molecular profiling |
1 |
2011 |
| Device |
monitoring device |
1 |
2018 |
| Biological |
montanide isa 51 vaccine |
1 |
2016 |
| Drug |
motexafin gadolinium |
1 |
2005 |
| Drug |
motexafin gadolinium injection |
1 |
2005 |
| Drug |
mpdl3280a |
1 |
2016 |
| Drug |
mpdl3280a dose level 1 |
1 |
2015 |
| Drug |
mpdl3280a dose level 2 |
1 |
2015 |
| Drug |
mpdl3280a dose level 3 |
1 |
2015 |
| Procedure |
mr colonography |
1 |
2006 |
| Procedure |
mri scan |
1 |
2013 |
| Device |
mri, mpmri |
1 |
2013 |
| Procedure |
mriâ±biopsy |
1 |
2010 |
| Device |
mucipliq |
1 |
2013 |
| Biological |
multi-epitope folate receptor alpha-loaded dendritic cell vaccine |
1 |
2014 |
| Biological |
multi-epitope her2 peptide vaccine h2nvac |
1 |
2019 |
| Procedure |
multi-pronged ethanol ablation |
1 |
2009 |
| Drug |
multimodal treatment |
1 |
2011 |
| Biological |
mv |
1 |
2015 |
| Biological |
mv-nis |
1 |
2017 |
| Drug |
mvac protocol |
1 |
2018 |
| Other |
mvx-onco-1 |
1 |
2016 |
| Procedure |
mwa |
1 |
2017 |
| Device |
mwa system |
1 |
2017 |
| Procedure |
mwv |
1 |
2016 |
| Biological |
mycobacterium w |
1 |
2008 |
| Drug |
myfortic |
1 |
2014 |
| Drug |
nab-paclitaxel (paclitaxel-albumin) |
1 |
2016 |
| Drug |
nab-paclitaxel (paclitaxel-albumin) / carboplatin |
1 |
2016 |
| Drug |
nab-paclitaxel (paclitaxel-albumin) / gemcitabine |
1 |
2016 |
| Drug |
nab-paclitaxel, 100mg |
1 |
2018 |
| Drug |
nab-paclitaxel, 100mg/m^2 |
1 |
2018 |
| Drug |
nab-paclitaxel, 80mg |
1 |
2018 |
| Drug |
nab-paclitaxel, 80mg/m^2 |
1 |
2018 |
| Drug |
nab-paclitaxel/cisplatin |
1 |
2019 |
| Drug |
nab-rapamycin |
1 |
2017 |
| Drug |
nab paclitaxel |
1 |
2014 |
| Drug |
naltrexone |
1 |
2014 |
| Drug |
nanodoce (direct injection) |
1 |
2018 |
| Drug |
nanodoce (intravesical instillation) - induction |
1 |
2018 |
| Drug |
nanodoce (intravesical instillation) - induction/maintenance instillations |
1 |
2018 |
| Drug |
nanodoce (intravesical instillation) - visit 2 instillation |
1 |
2018 |
| Device |
nanoknife |
1 |
2015 |
| Device |
nanoknife ledc system |
1 |
2015 |
| Drug |
nanoparticle albumin-bound rapamycin |
1 |
2016 |
| Drug |
naptumomab estafenatox |
1 |
2007 |
| Other |
narrow band imaging (nbi) |
1 |
2010 |
| Procedure |
nasofibroscopy |
1 |
2018 |
| Drug |
natriumfolinate |
1 |
2014 |
| Procedure |
nbi |
1 |
2014 |
| Drug |
nbtxr3 |
1 |
2018 |
| Drug |
nc-6004 |
1 |
2017 |
| Device |
nd:yag laser |
1 |
2015 |
| Procedure |
near-infrared (nir) dye indocyanin green (icg) |
1 |
2014 |
| Other |
neck dissection impairment index |
1 |
2018 |
| Procedure |
neck dissection of at least the ipsilateral sub-level 1b |
1 |
2008 |
| Device |
needle guiding robot |
1 |
2016 |
| Drug |
nelfinavir |
1 |
2017 |
| Drug |
nelfinavir (viraceptâ®) 1250 mg |
1 |
2014 |
| Drug |
neo-201 |
1 |
2018 |
| Biological |
neo-pv-01 |
1 |
2016 |
| Procedure |
neo-tace-haic |
1 |
2020 |
| Procedure |
neo-tace-haic/surgery |
1 |
2020 |
| Drug |
neoadjuvant chemoradiation |
1 |
2017 |
| Radiation |
neoadjuvant chemoradiation therapy |
1 |
2019 |
| Procedure |
neoadjuvant chemoradiotherapy |
1 |
2016 |
| Radiation |
neoadjuvant radiotherapy |
1 |
2019 |
| Biological |
neoantigen vaccines |
1 |
2018 |
| Drug |
neratinib |
1 |
2017 |
| Drug |
neribas fatty ointment |
1 |
2010 |
| Drug |
nerison fatty ointment sorafenib (nexavar, bay43-9006) |
1 |
2010 |
| Drug |
nexavar (sorafenib) |
1 |
2008 |
| Drug |
ngr-htnf |
1 |
2007 |
| Drug |
nhs-il-12 |
1 |
2011 |
| Drug |
nicotinamide |
1 |
2018 |
| Drug |
nicotine replacement |
1 |
2015 |
| Drug |
nimorazole |
1 |
2013 |
| Drug |
nimorazole. |
1 |
2019 |
| Drug |
nimotuzumab/chemotherapy |
1 |
2011 |
| Drug |
nintedanib high dose |
1 |
2012 |
| Drug |
nintedanib low dose |
1 |
2012 |
| Drug |
nintedanib medium dose |
1 |
2012 |
| Drug |
nirapaib |
1 |
2018 |
| Drug |
nivolimumab |
1 |
2017 |
| Drug |
nivolimumab/carboplatin/paclitaxel/radiation |
1 |
2017 |
| Drug |
nivolumab 240 mg |
1 |
2017 |
| Drug |
nivolumab 360mg |
1 |
2017 |
| Drug |
nivolumab 3mg |
1 |
2017 |
| Drug |
nivolumab 3mg/kg |
1 |
2017 |
| Drug |
nivolumab 480mg |
1 |
2019 |
| Drug |
nivolumab 480mg/surgical resection |
1 |
2019 |
| Drug |
nivolumab in combination with urelumab |
1 |
2016 |
| Drug |
nivolumab monotherapy |
1 |
2016 |
| placebo |
nivolumab placebo |
1 |
2017 |
| Drug |
nivolumab, ipilimumab |
1 |
2017 |
| Drug |
nivolumab/relatlimab |
1 |
2020 |
| Drug |
nktr-214 |
1 |
2017 |
| Drug |
nktr-262 |
1 |
2018 |
| Procedure |
no-touch rfa |
1 |
2016 |
| Procedure |
non-everted suture technique |
1 |
2013 |
| Other |
non-icu specialty ward |
1 |
2017 |
| Drug |
norepinephrine intra-arteriel |
1 |
2015 |
| Drug |
norepinephrine intra-arteriel/hepatic |
1 |
2015 |
| Drug |
nortriptyline hydrochloride |
1 |
2016 |
| Drug |
notch signalling pathway inhibitor ro4929097 |
1 |
2010 |
| Device |
novottf-100l(p) device |
1 |
2018 |
| Drug |
nt-i7 |
1 |
2019 |
| Dietary Supplement |
nutrison |
1 |
2016 |
| Behavioral |
nutrition counseling |
1 |
2015 |
| Dietary Supplement |
nutritional supplementation |
1 |
2020 |
| Drug |
obi-3424 |
1 |
2018 |
| Biological |
obi-821 |
1 |
2018 |
| Biological |
obp-301 |
1 |
2014 |
| Other |
observation (no treatment) |
1 |
2008 |
| Other |
observation/mitotane |
1 |
2018 |
| Other |
obtaining human tissue |
1 |
2013 |
| Drug |
octreotide |
1 |
2005 |
| Drug |
octreotide-lar, lanreotide autogel |
1 |
2007 |
| Drug |
octreotide (immediate release) |
1 |
2006 |
| Drug |
octreotide lar |
1 |
2006 |
| Device |
odyssey clx imaging system |
1 |
2018 |
| Drug |
ogx-427 |
1 |
2013 |
| Drug |
oleclumab |
1 |
2016 |
| Dietary Supplement |
oligo fucoidan |
1 |
2019 |
| Drug |
omega-3 fatty acid |
1 |
2013 |
| Drug |
omega-3 fatty acids |
1 |
2014 |
| Drug |
omega-3 fish oil emulsion (omegaven ) |
1 |
2006 |
| Dietary Supplement |
omega 3 group |
1 |
2018 |
| Radiation |
omit radiation to pn0 neck |
1 |
2019 |
| Drug |
onalespib lactate |
1 |
2015 |
| Drug |
onartuzumab |
1 |
2013 |
| Procedure |
oncologically radical margin-free (r0) resection |
1 |
2018 |
| Device |
oncosec medical system (oms) |
1 |
2011 |
| Dietary Supplement |
oncoxin-viusidâ® |
1 |
2018 |
| Drug |
onivyde |
1 |
2018 |
| Drug |
onm-100 |
1 |
2018 |
| Biological |
ont-10, varlilumab combination |
1 |
2014 |
| Drug |
ontak |
1 |
2009 |
| Drug |
opb-31121 |
1 |
2011 |
| Drug |
opb-31121 phase2 |
1 |
2011 |
| Drug |
opc-18 |
1 |
2007 |
| Biological |
opdivo |
1 |
2017 |
| Procedure |
open hepatectomy |
1 |
2015 |
| Procedure |
open liver resection |
1 |
2013 |
| Procedure |
open, traditional approach |
1 |
2012 |
| Other |
operation;tace |
1 |
2009 |
| Other |
operation;tace/pei |
1 |
2009 |
| Device |
opsite(tm) disk |
1 |
2011 |
| Device |
optical molecular imaging |
1 |
2013 |
| Drug |
optimal turb |
1 |
2010 |
| Drug |
optison |
1 |
2015 |
| Device |
optonuclear probe |
1 |
2016 |
| Procedure |
or radiotherapy |
1 |
2005 |
| Biological |
or tgfî² targeting car-t cells |
1 |
2017 |
| Other |
oral cavity |
1 |
2018 |
| Drug |
oral pentamidine |
1 |
2014 |
| Drug |
oral rigosertib |
1 |
2014 |
| Procedure |
oral rinse collection |
1 |
2017 |
| Drug |
oral sorafenib |
1 |
2016 |
| Drug |
oral vancomycin |
1 |
2018 |
| Drug |
orantinib (tsu-68) |
1 |
2008 |
| Procedure |
orchiectomy |
1 |
2018 |
| Drug |
osi-906 |
1 |
2009 |
| Drug |
otl38 |
1 |
2015 |
| Device |
outcomes4me mobile app |
1 |
2020 |
| Behavioral |
outreach with patient education |
1 |
2015 |
| Behavioral |
outreach with patient education/patient navigation services |
1 |
2015 |
| Drug |
oxaliplatin (oxa), levofolinate calcium (l-lv), 5-fu, panitumumab |
1 |
2014 |
| Drug |
oxaliplatin / 5-fluorouracil (5fu) / leucovorin (calcium folinate/folinic acid) |
1 |
2016 |
| Drug |
oxaliplatin / 5-fluorouracil/leucovorin |
1 |
2007 |
| Drug |
oxaliplatin capecitabine |
1 |
2012 |
| Drug |
oxaliplatin s-1 |
1 |
2012 |
| Drug |
oxaliplatin with erlotinib (tarceva) |
1 |
2010 |
| Drug |
oxaliplatin) |
1 |
2018 |
| Drug |
oxaliplatin. |
1 |
2019 |
| Drug |
oxaliplatin/nivolumab |
1 |
2017 |
| Drug |
oxybutynin chloride |
1 |
2016 |
| Drug |
oxygen |
1 |
2007 |
| Drug |
p1101 (ropeginterferon alfa-2b) |
1 |
2019 |
| Drug |
paclitaxel (standard of care) |
1 |
2015 |
| Drug |
paclitaxel (taxol) |
1 |
2007 |
| Drug |
paclitaxel / carboplatin |
1 |
2016 |
| Drug |
paclitaxel followed by surgery |
1 |
2014 |
| Drug |
paclitaxel for injection (albumin-bound) |
1 |
2019 |
| Drug |
paclitaxel, |
1 |
2018 |
| Drug |
paclitaxel, albumin-bound |
1 |
2019 |
| Drug |
paclitaxel, cisplatin |
1 |
2019 |
| Drug |
paclitaxel, cisplatin, 5-fluorouracil |
1 |
2005 |
| Drug |
paclitaxel,/docetaxel,/irinotecan |
1 |
2018 |
| Drug |
paclitaxel/ irinotecan |
1 |
2017 |
| Drug |
paclitaxel/5-fluorouracil |
1 |
2012 |
| Drug |
paclitaxel/carboplatin |
1 |
2015 |
| Drug |
paclitaxel/docetaxel/carboplatin/cisplatin |
1 |
2013 |
| Drug |
paclitaxel/fluorouracil |
1 |
2015 |
| Combination Product |
paclitaxel/tak-228 |
1 |
2018 |
| Drug |
paclitaxel; cisplatin; 5-fluorouracil |
1 |
2010 |
| Drug |
paclitaxel; cisplatin; 5-fluorouracil; capecitabine |
1 |
2010 |
| Drug |
paclitaxelpaclitaxel (albumin bound),bleomycin |
1 |
2019 |
| Drug |
paclitaxelpaclitaxel (albumin bound),bleomycin/with cisplatin/carboplatin |
1 |
2019 |
| Biological |
pacox |
1 |
2014 |
| Drug |
paditaxel(xg) |
1 |
2011 |
| Radiation |
palliative radiation therapy |
1 |
2015 |
| Radiation |
palliative radiotherapy |
1 |
2019 |
| Radiation |
palliative rt |
1 |
2009 |
| Other |
palliative therapy |
1 |
2015 |
| Other |
palliative therapy / idiographic |
1 |
2015 |
| Procedure |
pancreaticoduodenectomy |
1 |
2018 |
| Drug |
panitumumab-irdye800 |
1 |
2018 |
| Drug |
panitumumab (abx-egf) |
1 |
2007 |
| Drug |
panitumumab, mytomicin c, 5-fu, radiation |
1 |
2011 |
| Drug |
panzemâ® ncd |
1 |
2007 |
| Drug |
para-toluenesulfonamide |
1 |
2018 |
| Diagnostic Test |
parametric pet |
1 |
2019 |
| Diagnostic Test |
parametric pet/ct |
1 |
2019 |
| Drug |
part 1 tpst-1120 |
1 |
2019 |
| Drug |
part 1: pt2385 tablets |
1 |
2014 |
| Drug |
part 2: pt2385 tablets in combination with nivolumab |
1 |
2014 |
| Drug |
part 2a tpst-1120 |
1 |
2019 |
| Drug |
part 2a tpst-1120 / nivolumab |
1 |
2019 |
| Drug |
part 2b tpst-1120 |
1 |
2019 |
| Drug |
part 2b tpst-1120 / docetaxel |
1 |
2019 |
| Drug |
part 2c tpst-1120 |
1 |
2019 |
| Drug |
part 2c tpst-1120 / cetuximab |
1 |
2019 |
| Drug |
part 3 tpst-1120 |
1 |
2019 |
| Drug |
part 3: pt2385 tablets in combination with cabozantinib |
1 |
2014 |
| Drug |
part 4a tpst-1120 |
1 |
2019 |
| Drug |
part 4a tpst-1120 / nivolumab |
1 |
2019 |
| Drug |
part 4b tpst-1120 |
1 |
2019 |
| Drug |
part 4b tpst-1120 / docetaxel |
1 |
2019 |
| Drug |
part 4c tpst-1120 |
1 |
2019 |
| Drug |
part 4c tpst-1120 / cetuximab |
1 |
2019 |
| Radiation |
partial breast irradiation |
1 |
2017 |
| Radiation |
partial breast irradiation prior to surgery |
1 |
2019 |
| Procedure |
partial mastectomy |
1 |
2018 |
| Radiation |
particle therapy |
1 |
2016 |
| Drug |
pasireotide |
1 |
2011 |
| Drug |
pasireotide lar |
1 |
2012 |
| Drug |
pasireotide lar / everolimus |
1 |
2012 |
| Drug |
pasireotide lon acting release formulation |
1 |
2012 |
| Drug |
pasireotide sub-cutaneous formulation |
1 |
2012 |
| Behavioral |
patient navigation |
1 |
2016 |
| Behavioral |
patient navigation services |
1 |
2015 |
| Other |
patients receiving best supportive care |
1 |
2011 |
| Drug |
patients with sunitinib |
1 |
2015 |
| Drug |
patients with sunitinib/pazopanib |
1 |
2015 |
| Drug |
patritumab |
1 |
2015 |
| Drug |
patupilone |
1 |
2006 |
| Drug |
pazopanib (pzp) |
1 |
2010 |
| Drug |
pazopanib / interferon alpha 2a |
1 |
2012 |
| Drug |
pazopanib 2 week |
1 |
2009 |
| Drug |
pazopanib 3 week |
1 |
2009 |
| Drug |
pazopanib/sorafenib |
1 |
2012 |
| Drug |
pd-0332991 |
1 |
2011 |
| Drug |
pd-1 antibody |
1 |
2019 |
| Biological |
pd-1 knockout engineered t cells |
1 |
2020 |
| Combination Product |
pd-1 mab/with tace/lenvatinib |
1 |
2020 |
| Biological |
pd-l1 |
1 |
2018 |
| Drug |
pd0332991 |
1 |
2011 |
| Combination Product |
pd1 |
1 |
2019 |
| Device |
pde-neo ii camera |
1 |
2018 |
| Procedure |
pdl treatment |
1 |
2010 |
| Drug |
pdt |
1 |
2018 |
| Procedure |
pdt prior to mohs surgery |
1 |
2009 |
| Procedure |
pdt with metvix 160 mg/g cream |
1 |
2007 |
| Procedure |
pdt with metvix 160 mg/g cream/placebo cream |
1 |
2007 |
| placebo |
pdt with placebo cream |
1 |
2007 |
| Device |
pearl triology imaging system |
1 |
2018 |
| Biological |
peg-gcsf |
1 |
2009 |
| Biological |
pegifn-2b |
1 |
2014 |
| Drug |
pegilodecakin |
1 |
2013 |
| Drug |
peginterferon alfa-2a |
1 |
2015 |
| Biological |
peginterferon alfa-2b |
1 |
2008 |
| Drug |
pegylated interferon alfa-2a |
1 |
2016 |
| Drug |
pegylated interferon alpha-2b |
1 |
2014 |
| Drug |
pegylated liposomal doxorubicin (pld) |
1 |
2016 |
| Biological |
pelareorep |
1 |
2010 |
| Radiation |
pelvic ebrt |
1 |
2017 |
| Radiation |
pelvic ebrt/brachytherapy |
1 |
2017 |
| Radiation |
pelvic radiation |
1 |
2007 |
| Procedure |
pelvis scan |
1 |
2009 |
| Drug |
pembrolizumab (200 mg) |
1 |
2016 |
| Biological |
pembrolizumab (keytrudaâ®) |
1 |
2019 |
| Biological |
pembrolizumab 400 mg |
1 |
2019 |
| Drug |
pembrolizumab injection |
1 |
2017 |
| Drug |
pembrolizumab injection [keytruda] |
1 |
2020 |
| Drug |
pembrolizumab, cetuximab |
1 |
2017 |
| Drug |
pembrolizumab/denosumab |
1 |
2017 |
| Drug |
pembrolizumab/nivolumab |
1 |
2018 |
| Drug |
pembrolizumab/nivolumab/js001 |
1 |
2019 |
| Drug |
pen-221 |
1 |
2016 |
| Drug |
pen-866 sodium |
1 |
2017 |
| Radiation |
pencil beam scanning radiation |
1 |
2013 |
| Drug |
pentostatin |
1 |
2009 |
| Drug |
pep005 (ingenol mebutate) gel, 0.05% |
1 |
2011 |
| Procedure |
percutaneous ethanol alcohol injection |
1 |
2017 |
| Procedure |
percutaneous laser ablation |
1 |
2010 |
| Procedure |
percutaneous local abalation |
1 |
2018 |
| Procedure |
percutaneous microwave ablation, laparoscopic hepatectomy |
1 |
2020 |
| Procedure |
percutaneous placement of device in the liver |
1 |
2006 |
| Procedure |
percutaneous radiationfrequency ablation |
1 |
2008 |
| Procedure |
percutaneous radiofrequency ablation |
1 |
2010 |
| Drug |
perflutren lipid microspheres |
1 |
2015 |
| Drug |
perflutren protein-type a microspheres |
1 |
2017 |
| Radiation |
perfusion computed tomography |
1 |
2018 |
| Procedure |
perfusion ct scan |
1 |
2010 |
| Drug |
perifosine |
1 |
2007 |
| Combination Product |
perioperative capox-bevacizumab |
1 |
2016 |
| Drug |
perioperative chemotherapy |
1 |
2015 |
| Drug |
perioperative chemotherapy/bevacizumab |
1 |
2015 |
| Combination Product |
perioperative folfiri-bevacizumab |
1 |
2016 |
| Combination Product |
perioperative folfox-bevacizumab |
1 |
2016 |
| Other |
perioperative systemic therapy |
1 |
2016 |
| Other |
peripheral blood collection |
1 |
2017 |
| Procedure |
peripheral blood sample (optional) |
1 |
2016 |
| Other |
personalised treatment |
1 |
2016 |
| Behavioral |
personalized information |
1 |
2018 |
| Biological |
personalized mrna tumor vaccine |
1 |
2018 |
| Drug |
pertuzumab, trastuzumab |
1 |
2014 |
| Diagnostic Test |
pet-ct |
1 |
2019 |
| Device |
pet mri |
1 |
2019 |
| Diagnostic Test |
pet/ct dynamic scan |
1 |
2018 |
| Device |
pet/ct scan |
1 |
2018 |
| Device |
pet/ct, pet/mri, mpmri |
1 |
2013 |
| Diagnostic Test |
pet/mr |
1 |
2018 |
| Diagnostic Test |
pet/mri |
1 |
2019 |
| Biological |
pexastimogene devacirepvec (pexa-vec) |
1 |
2017 |
| Drug |
pf-05082566 |
1 |
2011 |
| Drug |
pf-06940434 |
1 |
2019 |
| Drug |
pf-3512676 |
1 |
2002 |
| Drug |
pf-ccrt (randomized) |
1 |
2016 |
| Drug |
pf804 |
1 |
2012 |
| Other |
pharmacodynamic study |
1 |
2014 |
| Other |
pharmacokinetics |
1 |
2015 |
| Drug |
phase 1 : avelumab |
1 |
2018 |
| Drug |
phase 1 : regorafenib |
1 |
2018 |
| Drug |
phase 2 : avelumab |
1 |
2018 |
| Drug |
phase 2 : regorafenib |
1 |
2018 |
| Behavioral |
phone call |
1 |
2013 |
| Procedure |
photoacoustic imaging |
1 |
2019 |
| Device |
photodynamic diagnostic |
1 |
2016 |
| Device |
photodynamic diagnostic/therapy |
1 |
2016 |
| Combination Product |
photodynamic therapy (pdt) (ala-pdt, ameluzâ®-pdt) |
1 |
2018 |
| Procedure |
photodynamic therapy with methyl aminolevulinate cream |
1 |
2007 |
| Drug |
photofrin |
1 |
2011 |
| Radiation |
photon radiotherapy |
1 |
2007 |
| Radiation |
photon therapy |
1 |
2009 |
| Radiation |
photon therapy (radiation therapy) |
1 |
2017 |
| Drug |
phy906 |
1 |
2004 |
| Other |
physical activity |
1 |
2018 |
| Procedure |
physical examination |
1 |
2015 |
| Behavioral |
physical exercise |
1 |
2015 |
| Procedure |
physical therapy |
1 |
2019 |
| Drug |
physician’s choice |
1 |
2013 |
| Other |
physiological support |
1 |
2018 |
| Drug |
pi-88 |
1 |
2005 |
| Drug |
pi3k-beta inhibitor gsk2636771 |
1 |
2015 |
| Drug |
pi3kbeta inhibitor azd8186 |
1 |
2017 |
| Device |
pinpoint ir ir9000 flourescence imaging system (fis) |
1 |
2018 |
| Drug |
pipac with abraxane |
1 |
2017 |
| Drug |
pivanex |
1 |
2003 |
| Diagnostic Test |
pivka-ii |
1 |
2020 |
| placebo |
placebo-containing mna |
1 |
2018 |
| placebo |
placebo (dmc, sã£o paulo, brazil) |
1 |
2011 |
| placebo |
placebo (for bavituximab) |
1 |
2013 |
| placebo |
placebo (for pregabalin) |
1 |
2013 |
| placebo |
placebo (for ruxolitinib) |
1 |
2016 |
| placebo |
placebo (laser low level energy nonfunctional) |
1 |
2013 |
| placebo |
placebo (saline solution) |
1 |
2017 |
| placebo |
placebo azd9291 80 mg |
1 |
2015 |
| Drug |
placebo azd9291 80 mg/40 mg |
1 |
2015 |
| placebo |
placebo cream |
1 |
2007 |
| placebo |
placebo cutaneous cream application |
1 |
2017 |
| placebo |
placebo for lenvatinib |
1 |
2019 |
| placebo |
placebo gel |
1 |
2009 |
| placebo |
placebo infusion |
1 |
2016 |
| placebo |
placebo matching zd6474 |
1 |
2008 |
| placebo |
placebo normal saline |
1 |
2017 |
| placebo |
placebo of afatinib |
1 |
2011 |
| placebo |
placebo photodynamic therapy (pdt) (vehicle to bf-200 ala containing no active ingredient) |
1 |
2018 |
| placebo |
placebo sachets |
1 |
2013 |
| placebo |
placebo tablets |
1 |
2013 |
| placebo |
placebo testosterone |
1 |
2009 |
| placebo |
placebo, vehicle control |
1 |
2009 |
| Drug |
placebo/ fluorouracil/cisplatin |
1 |
2019 |
| Drug |
placebo/axitinib |
1 |
2012 |
| Drug |
placebo/cisplatin/carboplatin / 5-fluorouracil (5-fu) |
1 |
2019 |
| Dietary Supplement |
placebo/control group |
1 |
2018 |
| Drug |
placebo/everolimus |
1 |
2017 |
| Drug |
placebo/sorafenib |
1 |
2019 |
| Drug |
placebo/with chemoradiotherapy |
1 |
2019 |
| Drug |
placebos/chemo |
1 |
2019 |
| Procedure |
placement of hepatic artery infusion pump |
1 |
2013 |
| Procedure |
planar imaging |
1 |
2017 |
| Procedure |
plasma radiofrequency ablation |
1 |
2020 |
| Drug |
platinum-based drug |
1 |
2019 |
| Drug |
platinum (cisplatin |
1 |
2018 |
| Drug |
platinum (cisplatin/oxaliplatin) / capecitabine |
1 |
2018 |
| Drug |
platinum (cisplatin/oxaliplatin) / fluorouracil (5-fu) |
1 |
2018 |
| Drug |
platinum (cisplatin/oxaliplatin) / paclitaxel |
1 |
2018 |
| Drug |
platinum doublet |
1 |
2019 |
| Biological |
pneumococcal 13-valent conjugate vaccine |
1 |
2019 |
| Drug |
polyic |
1 |
2018 |
| Genetic |
polymerase chain reaction |
1 |
2010 |
| Genetic |
polymorphism of il-1 beta |
1 |
2008 |
| Genetic |
polymorphism of il-1 beta/tnf-alpha |
1 |
2008 |
| Genetic |
polymorphisms of hsp70 |
1 |
2008 |
| Genetic |
polymorphisms of hsp70/tnf promoter |
1 |
2008 |
| Drug |
porfiromycin |
1 |
1999 |
| Procedure |
portal irradiation stent placement |
1 |
2018 |
| Procedure |
positron emission tomography (pet) |
1 |
2018 |
| Other |
positron emission tomography with fludeoxyglucose f 18 |
1 |
2010 |
| Procedure |
possible liver biopsy for locoregional therapy group |
1 |
2020 |
| Radiation |
post-ic tumor extension |
1 |
2020 |
| Radiation |
post-surgical radiation |
1 |
2010 |
| Drug |
post anti-pd-1 therapy. |
1 |
2017 |
| Procedure |
postoperative intraperitoneal chemotherapy (5-fluorouracil, isovorin) |
1 |
2012 |
| Drug |
postoperative tace |
1 |
2016 |
| Drug |
potentiation therapy |
1 |
2003 |
| Drug |
pralatrexate injection |
1 |
2008 |
| Drug |
pralsetinib |
1 |
2020 |
| Drug |
pralsetinib (blu-667) |
1 |
2017 |
| Biological |
prame |
1 |
2007 |
| Drug |
pramlintide |
1 |
2020 |
| Drug |
pravastatin pill |
1 |
2017 |
| Drug |
pre-operative sn mapping with radionucleide |
1 |
2015 |
| Procedure |
precise hepatectomy |
1 |
2012 |
| Procedure |
precise segmental renal arterial clamping |
1 |
2017 |
| Drug |
prednisone 5mg |
1 |
2017 |
| Drug |
pregabalin |
1 |
2013 |
| Drug |
premetrexed (alimta) |
1 |
2005 |
| Radiation |
preoperative radiotherapy |
1 |
2014 |
| Procedure |
preoprative tace |
1 |
2013 |
| Other |
preventative dietary intervention |
1 |
2011 |
| Other |
preventive intervention |
1 |
2016 |
| Drug |
prexasertib |
1 |
2010 |
| Biological |
prgn-3005 ultracar-t cells |
1 |
2019 |
| Procedure |
primary closure for tongue cancer defect |
1 |
2018 |
| Procedure |
pringle’s maneuver |
1 |
2009 |
| Drug |
prn1371 |
1 |
2015 |
| Dietary Supplement |
probiotic |
1 |
2013 |
| Dietary Supplement |
probiotics |
1 |
2011 |
| Drug |
proflavine |
1 |
2014 |
| Behavioral |
prone positioning |
1 |
2009 |
| Behavioral |
prone/supine position |
1 |
2009 |
| Radiation |
prophylactic cranial irradiation |
1 |
2019 |
| Radiation |
prophylactic cranial irradiation (pci) |
1 |
2008 |
| Procedure |
prophylactic selective lateral neck dissection |
1 |
2010 |
| Drug |
propofol |
1 |
2013 |
| Drug |
propranolol hydrochloride |
1 |
2012 |
| Device |
prosenseâ„¢ |
1 |
2015 |
| Drug |
prospective midazolam |
1 |
2007 |
| Procedure |
protective therapy |
1 |
2016 |
| Radiation |
proton |
1 |
2007 |
| Radiation |
proton radiotherapy |
1 |
2015 |
| Radiation |
proton therapy (radiation therapy) |
1 |
2017 |
| Radiation |
proton/photon radiotherapy |
1 |
2007 |
| Procedure |
proximal fallopian tubes, performed in the luteal phase of the female cycle |
1 |
2014 |
| Device |
proxiscan |
1 |
2016 |
| Drug |
prv111 (cisplatin transmucosal system) |
1 |
2018 |
| Drug |
ps-341 |
1 |
2003 |
| Biological |
psma |
1 |
2007 |
| Diagnostic Test |
psma-pet |
1 |
2017 |
| Diagnostic Test |
psma-pet/ct scan |
1 |
2017 |
| Biological |
psma/prame |
1 |
2007 |
| Other |
psychosocial support for caregiver |
1 |
2012 |
| Drug |
pt-112 |
1 |
2018 |
| Drug |
pt2385 tablets |
1 |
2017 |
| Drug |
pt2977 in combination with cabozantinib tablets |
1 |
2018 |
| Biological |
ptvg-hp plasmid dna vaccine |
1 |
2015 |
| Drug |
ptx-9908 injection |
1 |
2019 |
| Drug |
pv-10 (10% rose bengal disodium) |
1 |
2009 |
| Drug |
pv-10 (rose bengal disodium 10%) |
1 |
2005 |
| Procedure |
pva, lipiodol, doxorubicin |
1 |
2011 |
| Procedure |
pve |
1 |
2009 |
| Procedure |
pve with coils |
1 |
2020 |
| Procedure |
pve with coils/tagm |
1 |
2020 |
| Procedure |
pve with multiple coils |
1 |
2020 |
| Drug |
px-866 (crc) |
1 |
2010 |
| Drug |
px-866 (scchn) |
1 |
2010 |
| Procedure |
quadrantectomy |
1 |
2009 |
| Procedure |
quadrantectomy / sentinel node biopsy |
1 |
2009 |
| Procedure |
quadrantectomy/axillary dissection |
1 |
2009 |
| Device |
quadrasphere microspheres |
1 |
2011 |
| Other |
quality of life |
1 |
2012 |
| Other |
quality of life (qol) assessment |
1 |
2016 |
| Other |
quality of life questionnaires |
1 |
2017 |
| Device |
quantitative doppler ultrasound |
1 |
2010 |
| Drug |
quercetin (dietary supplement) |
1 |
2018 |
| Drug |
r-(-)-gossypol acetic acid |
1 |
2009 |
| Drug |
rad001(everolimus) |
1 |
2008 |
| Drug |
rad001, sunitinib |
1 |
2007 |
| Drug |
rad001/sorafenib |
1 |
2006 |
| Radiation |
radiation (post induction) |
1 |
2008 |
| Radiation |
radiation (standard of care) |
1 |
2015 |
| Radiation |
radiation doses |
1 |
2017 |
| Radiation |
radiation segmentectomy |
1 |
2017 |
| Radiation |
radiation therapy (imrt |
1 |
2018 |
| Radiation |
radiation therapy (imrt/impt) |
1 |
2018 |
| Radiation |
radiation therapy (rt) |
1 |
2014 |
| Radiation |
radiation therapy of the pelvis |
1 |
2018 |
| Other |
radiation, surgery |
1 |
2019 |
| Other |
radiation, surgery/radiofrequency ablation |
1 |
2019 |
| Radiation |
radiation/immunotherapy |
1 |
2016 |
| Device |
radiation: diffusing alpha radiation emitters therapy (dart) |
1 |
2017 |
| Radiation |
radiation(imrt) |
1 |
2011 |
| Procedure |
radical colectomy |
1 |
2020 |
| Procedure |
radical cystectomy with standardized pelvic lymphadenectomy |
1 |
2018 |
| Procedure |
radical nephroureterectomy |
1 |
2016 |
| Procedure |
radical proctectomy with total mesorectal excision |
1 |
2011 |
| Procedure |
radical surgery-peritonectomy |
1 |
2016 |
| Radiation |
radio-ablation |
1 |
2014 |
| Procedure |
radio frequency ablation (rfa) |
1 |
2018 |
| Drug |
radiochemotherapy |
1 |
2012 |
| Radiation |
radiochemotherapy cap 50 |
1 |
2011 |
| Radiation |
radiochemotherapy cap 60 |
1 |
2011 |
| Radiation |
radiochemotherapy with 70 gy |
1 |
2015 |
| Radiation |
radiochemotherapy with 77 gy |
1 |
2015 |
| Device |
radioembolisation (sir-spheresâ® microspheres) |
1 |
2009 |
| Procedure |
radioembolization (sirt) |
1 |
2010 |
| Procedure |
radioembolization with y-90 |
1 |
2016 |
| Device |
radiofrequency ablation/microwave ablation |
1 |
2018 |
| Procedure |
radiofrequency ablation; interferon-alpha |
1 |
2009 |
| Procedure |
radiofrequency ablation; sunitinib maleate |
1 |
2009 |
| Procedure |
radiomammography |
1 |
2009 |
| Device |
radiomics |
1 |
2019 |
| Device |
radiomics/watson artificial intelligence |
1 |
2019 |
| Procedure |
radionuclide imaging |
1 |
2014 |
| Drug |
radiotherapy arm |
1 |
2018 |
| Radiation |
radiotherapy to all dissected areas |
1 |
2019 |
| Combination Product |
radiotherapy/chemotherapy |
1 |
2018 |
| Drug |
radium-223 |
1 |
2015 |
| Drug |
radspherin |
1 |
2018 |
| Biological |
ramucirumab (imc-1121b) |
1 |
2011 |
| Biological |
ramucirumab dp |
1 |
2011 |
| Biological |
ramucirumab dp (imc-1121b) |
1 |
2010 |
| Drug |
randomized midazolam |
1 |
2007 |
| Drug |
ranitidine |
1 |
2002 |
| Procedure |
rate of remission |
1 |
2006 |
| Procedure |
re-transcatheter arterial chemoembolization (re-tace) |
1 |
2016 |
| Procedure |
re-turbt |
1 |
2017 |
| Drug |
rebastinib |
1 |
2016 |
| Drug |
recombinant anti-egfr monoclonal antibody |
1 |
2019 |
| Biological |
recombinant fowlpox-cea(6d) |
1 |
2002 |
| Biological |
recombinant fowlpox-cea(6d)/tricom vaccine |
1 |
2002 |
| Biological |
recombinant fowlpox gm-csf vaccine adjuvant |
1 |
2002 |
| Biological |
recombinant human egf-rp64k |
1 |
2016 |
| Biological |
recombinant human egf-rp64k/montanide isa 51 vaccine |
1 |
2016 |
| Drug |
recombinant human endostatin injection (endostar) |
1 |
2015 |
| Drug |
recombinant human interleukin-11 |
1 |
2018 |
| Biological |
recombinant human interleukin-15 |
1 |
2012 |
| Drug |
recombinant human lactoferrin |
1 |
2004 |
| Biological |
recombinant interferon alfa |
1 |
2003 |
| Drug |
recombinant interferon alfa 2a |
1 |
2016 |
| Biological |
recombinant interferon beta |
1 |
2015 |
| Biological |
recombinant interleukin-12 |
1 |
1999 |
| Drug |
recombinant interleukin-21 |
1 |
2008 |
| Biological |
recombinant vesicular stomatitis virus-expressing interferon-beta |
1 |
2012 |
| Radiation |
reduced target delineation |
1 |
2017 |
| Radiation |
reduced target delineation/radiation doses |
1 |
2017 |
| Radiation |
reducing ctv |
1 |
2019 |
| Drug |
reference147609 |
1 |
2009 |
| Drug |
regorafenib (stivarga, bay73-4506) |
1 |
2013 |
| Drug |
regorafenib(stivarga, bay73-4506) |
1 |
2017 |
| Drug |
regorafenib/nivolumab |
1 |
2020 |
| Drug |
relacorilant, 100mg qd |
1 |
2018 |
| Drug |
relacorilant, 150mg qd |
1 |
2018 |
| Drug |
relatlimab |
1 |
2020 |
| Procedure |
relaxation therapy |
1 |
2019 |
| Behavioral |
relaxation therapy 1 |
1 |
2006 |
| Behavioral |
relaxation therapy 2 |
1 |
2006 |
| Behavioral |
relaxation therapy 3 |
1 |
2006 |
| Biological |
reolysinâ® |
1 |
2008 |
| Combination Product |
repetitive epipac-ox |
1 |
2017 |
| Other |
research blood draws |
1 |
2013 |
| Procedure |
resection for primary lesion |
1 |
2016 |
| Procedure |
resection for primary lesion/cervical lymph node dissection |
1 |
2016 |
| Procedure |
resection of mucoeidermoid carcinoma |
1 |
2019 |
| Drug |
resminostat |
1 |
2015 |
| Radiation |
respiratory gated proton beam radiotherapy |
1 |
2008 |
| Procedure |
response-dependent resection |
1 |
2014 |
| Other |
restrictive group |
1 |
2014 |
| Drug |
retinoid 9cuab30 |
1 |
2016 |
| Procedure |
rfta |
1 |
2006 |
| Combination Product |
rgd pet |
1 |
2019 |
| Combination Product |
rgd pet/ct |
1 |
2019 |
| Drug |
rhenium (re 188 p2045, bay86-5284) |
1 |
2004 |
| Drug |
rhil-15 |
1 |
2019 |
| Drug |
rigosertib |
1 |
2013 |
| Drug |
rigosertib intravenous |
1 |
2018 |
| Drug |
rigosertib oral capsules |
1 |
2018 |
| Drug |
rigosertib oral capsules / rigosertib oral liquid solution / rigosertib intravenous |
1 |
2018 |
| Drug |
rigosertib oral liquid solution |
1 |
2018 |
| Drug |
ril-21 |
1 |
2006 |
| Drug |
ril-21 / sorafenib |
1 |
2006 |
| Drug |
ril-21 only |
1 |
2006 |
| Procedure |
rnu |
1 |
2016 |
| Drug |
ro5323441 |
1 |
2011 |
| Drug |
ro6874281 |
1 |
2017 |
| Drug |
ro7070179 |
1 |
2015 |
| Procedure |
robotic assisted radical prostatectomy |
1 |
2015 |
| Other |
robust radiotherapy planning |
1 |
2018 |
| Drug |
rosuvastatin |
1 |
2009 |
| Procedure |
routine central neck dissection |
1 |
2010 |
| Other |
routine medical care |
1 |
2020 |
| Procedure |
routine template-based lymphadenectomy |
1 |
2018 |
| Biological |
rp1 |
1 |
2019 |
| Biological |
rp1, intra-tumoral injection, oncolytic virus |
1 |
2020 |
| Drug |
rrx-001 |
1 |
2015 |
| Drug |
rsifn-co |
1 |
2015 |
| Radiation |
rt (70 gy in 35 fractions) |
1 |
2013 |
| Combination Product |
rt) |
1 |
2017 |
| Drug |
rt/cddp/5-fu |
1 |
2010 |
| Drug |
rt/cetuximab |
1 |
2010 |
| Radiation |
rt/hyperthermia after tace |
1 |
2013 |
| Other |
rtc |
1 |
2011 |
| Drug |
ruxolitinib |
1 |
2016 |
| Drug |
ruxolitinib phosphate |
1 |
2017 |
| Combination Product |
s-1 radiotherapy |
1 |
2017 |
| Radiation |
sabr |
1 |
2016 |
| Radiation |
sabr treatment of lesions |
1 |
2016 |
| Drug |
sacituzumab govitecan |
1 |
2020 |
| Biological |
safety |
1 |
2007 |
| Biological |
safety/efficacy of escalating doses |
1 |
2007 |
| Biological |
safety/efficacy of escalating doses. |
1 |
2007 |
| Other |
salivary cortisol collection |
1 |
2017 |
| Drug |
salvage chemotherapy |
1 |
2012 |
| Drug |
samitalâ® |
1 |
2013 |
| Procedure |
sampling peritoneal tissue |
1 |
2018 |
| Drug |
saracatinib |
1 |
2007 |
| Radiation |
sbrt/tace/sorafenib |
1 |
2020 |
| Other |
scale of subjective total taste acuity |
1 |
2018 |
| Other |
scannographic evaluation of the tumor response performed with mrecist criteria after 3 months of treatment with sorafenib |
1 |
2017 |
| Drug |
scb-313 |
1 |
2019 |
| Other |
scoring acute toxicity |
1 |
2011 |
| Other |
scoring of late toxicity |
1 |
2011 |
| Other |
scoring quality of life (qol) |
1 |
2011 |
| Other |
scqolit questionnaire |
1 |
2015 |
| Procedure |
screening |
1 |
2016 |
| Procedure |
screening mammography |
1 |
2007 |
| Other |
screening questionnaire administration |
1 |
2012 |
| Drug |
sct-i10a |
1 |
2019 |
| Drug |
sct-i10a/chemo |
1 |
2019 |
| Drug |
sct200 |
1 |
2019 |
| Procedure |
secondary cytoreductive surgery |
1 |
2012 |
| Drug |
selective intra-arterial floxuridine |
1 |
2012 |
| Drug |
selective intra-arterial floxuridine/systemic gemcitabine/cisplatin |
1 |
2012 |
| Procedure |
selective tace via microsphere loaded with doxorubicin |
1 |
2009 |
| Procedure |
selective traditional tace |
1 |
2009 |
| Drug |
selenomethionine (slm) |
1 |
2015 |
| Device |
self-expandable 125i radioactive seeds-loaded-stent |
1 |
2011 |
| Device |
self-expandable biliary nitinol alloys stent |
1 |
2011 |
| Drug |
selinexor |
1 |
2013 |
| Drug |
selumetinib sulfate |
1 |
2007 |
| Drug |
semaxanib |
1 |
2000 |
| Other |
semi-structured interviews |
1 |
2019 |
| Procedure |
sentinel node biopsy/mastectomy |
1 |
2012 |
| Drug |
sephb4-hsa with cetuximab |
1 |
2019 |
| Drug |
sephb4-hsa with cetuximab/radiation |
1 |
2019 |
| Procedure |
sequentially |
1 |
2016 |
| Procedure |
set-back suture |
1 |
2013 |
| Drug |
sevoflurane |
1 |
2013 |
| Drug |
sf1126 |
1 |
2017 |
| Drug |
sgi-110 |
1 |
2012 |
| Drug |
sgn-15 |
1 |
2003 |
| Drug |
sgn-15, docetaxel |
1 |
2004 |
| Drug |
sgn-75 |
1 |
2009 |
| Drug |
sgn-cd47m |
1 |
2019 |
| Drug |
sgx942 |
1 |
2017 |
| Device |
sham-treatment |
1 |
2014 |
| Procedure |
sham intervention |
1 |
2017 |
| Radiation |
shorter wb fractionation |
1 |
2007 |
| Radiation |
shorter wb fractionation / boost |
1 |
2007 |
| Drug |
shr-1701 |
1 |
2020 |
| Radiation |
sib-imrt |
1 |
2013 |
| Procedure |
sigmoidoscopy |
1 |
2012 |
| Drug |
silybin |
1 |
2010 |
| Drug |
simmtecan, 5-fu |
1 |
2019 |
| Drug |
simmtecan, 5-fu/l-lv |
1 |
2019 |
| Radiation |
simultaneous integrated boost intensity-modulated chemoradiotherapy |
1 |
2019 |
| Procedure |
simultaneously |
1 |
2016 |
| Drug |
sinecatechins 10% |
1 |
2013 |
| Radiation |
single-fraction radiotherapy with concomitant 5fu |
1 |
2010 |
| Radiation |
single-fraction radiotherapy with concomitant 5fu/hydrea |
1 |
2010 |
| Drug |
single arm dose dense mvac |
1 |
2009 |
| Drug |
sintilimab/chemotherapy |
1 |
2019 |
| Drug |
sintilimab/ibi305 |
1 |
2019 |
| Drug |
sintilimab/with gemcitabine/carboplatin |
1 |
2020 |
| Dietary Supplement |
sip feed control |
1 |
2019 |
| Biological |
sipuleucel-t |
1 |
2014 |
| Drug |
sir-sphere |
1 |
2011 |
| Device |
sir-spheres yttrium-90 microspheres |
1 |
2008 |
| Biological |
sirna-transfected peripheral blood mononuclear cells apn401 |
1 |
2017 |
| Procedure |
sirt |
1 |
2013 |
| Drug |
sitravatinib/tislelizumab |
1 |
2018 |
| Other |
skin biopsy |
1 |
2013 |
| Other |
skin cancer screening training |
1 |
2015 |
| Drug |
sl-279252 |
1 |
2019 |
| Procedure |
sln mapping |
1 |
2009 |
| Procedure |
sln mapping/biopsy |
1 |
2009 |
| Device |
sm-rfa |
1 |
2019 |
| Radiation |
smart |
1 |
2015 |
| Device |
smart matrix scaffold |
1 |
2018 |
| Drug |
sndx-275 |
1 |
2008 |
| Drug |
sns-301 |
1 |
2019 |
| Drug |
so-c101 |
1 |
2019 |
| Drug |
sodium acetate c11 |
1 |
2011 |
| Other |
sodium chloride 0.9 % |
1 |
2010 |
| Other |
solar simulator |
1 |
2017 |
| Drug |
solu medrol |
1 |
2010 |
| Other |
solvent with specific gravity equivalent to lipiodol |
1 |
2010 |
| Other |
solvent with specific gravity less than lipiodol |
1 |
2010 |
| Biological |
som230 |
1 |
2012 |
| Drug |
somatostatin (octreotide) |
1 |
2006 |
| Drug |
somatostatin infusion |
1 |
2016 |
| Other |
sonazoid-enhanced ultrasonography |
1 |
2014 |
| Diagnostic Test |
sonography |
1 |
2020 |
| Drug |
sorafenib (6 cycles) |
1 |
2007 |
| Drug |
sorafenib (bay-43-9006) |
1 |
2007 |
| Drug |
sorafenib (bay 43-9006) |
1 |
2008 |
| Drug |
sorafenib (bay43-9006) |
1 |
2013 |
| Drug |
sorafenib (nexavar) |
1 |
2008 |
| Drug |
sorafenib (nexavar, bay43-9006) sorafenib (nexavar, bay43-9006) |
1 |
2010 |
| Drug |
sorafenib (nexavar, bay43-9006) sorafenib (nexavar, bay43-9006) / nerison fatty ointment sorafenib (nexavar, bay43-9006)/neribas fatty ointment |
1 |
2010 |
| Drug |
sorafenib (nexavar, bay43-9006)/doxorubicin |
1 |
2005 |
| Drug |
sorafenib (nexavar,bay43-9006) |
1 |
2014 |
| Drug |
sorafenib 200mg tab |
1 |
2017 |
| Drug |
sorafenib 400 mg twice daily |
1 |
2014 |
| Drug |
sorafenib 400 mg twice daily / intravenousinfusion of placebo |
1 |
2014 |
| Drug |
sorafenib 400mg twice daily |
1 |
2014 |
| Drug |
sorafenib 400mg twice daily / intravenous infusion ofvit k1 |
1 |
2014 |
| Drug |
sorafenib ramp-up regimen |
1 |
2010 |
| Drug |
sorafenib standard dosing regimen |
1 |
2010 |
| Drug |
sorafenib with temsirolimus |
1 |
2009 |
| Drug |
sorafenib, ts-1 |
1 |
2010 |
| Drug |
sorafenib/gemcitabine |
1 |
2008 |
| Drug |
sorafenib/pazopanib |
1 |
2012 |
| Drug |
sorafenib: |
1 |
2012 |
| Drug |
sox |
1 |
2017 |
| Drug |
sparc147609 |
1 |
2009 |
| Device |
spect-ct |
1 |
2016 |
| Procedure |
spect imaging |
1 |
2017 |
| Radiation |
spect/ct |
1 |
2015 |
| Radiation |
spect/ct scan |
1 |
2018 |
| Drug |
spi-1620 |
1 |
2008 |
| Drug |
spleen tyrosine kinase inhibitor tak-659 |
1 |
2018 |
| Other |
split bolus dual energy ct |
1 |
2014 |
| Device |
sponge |
1 |
2017 |
| Device |
spy-phi ir9000 flourescence imaging system (fis) |
1 |
2018 |
| Drug |
sr57746a |
1 |
2006 |
| Drug |
srf388 |
1 |
2020 |
| Device |
ssm |
1 |
2018 |
| Drug |
st. john’s wort |
1 |
2016 |
| Drug |
sta-9090 |
1 |
2010 |
| Radiation |
standard chemoradiotherapy |
1 |
2017 |
| Other |
standard dose ct contrast media |
1 |
2019 |
| Radiation |
standard dose imrt |
1 |
2018 |
| Radiation |
standard dose prescription |
1 |
2015 |
| Radiation |
standard fractionation (sfx) radiotherapy |
1 |
2017 |
| Radiation |
standard fractionation radiotherapy |
1 |
2007 |
| Behavioral |
standard information |
1 |
2018 |
| Other |
standard multiphase ct |
1 |
2014 |
| Drug |
standard of care (investigator choice) |
1 |
2014 |
| Drug |
standard of care pd-1 therapy |
1 |
2019 |
| Radiation |
standard radiation treatment |
1 |
2017 |
| Radiation |
standard radio(chemotherapy) |
1 |
2017 |
| Radiation |
standard radiochemotherapy (hart) |
1 |
2010 |
| Procedure |
standard robot-assisted partial nephrectomy |
1 |
2018 |
| Radiation |
standard rt |
1 |
2013 |
| Procedure |
standard surgery |
1 |
2007 |
| Procedure |
standard surgical excision |
1 |
2014 |
| Radiation |
standard wb fractionation |
1 |
2007 |
| Radiation |
standard wb fractionation/boost |
1 |
2007 |
| Other |
standardized nutrition therapy |
1 |
2020 |
| Procedure |
stem cell transplant |
1 |
2007 |
| Biological |
stem cells |
1 |
2012 |
| Radiation |
stereotactic ablative body radiation (sabr) |
1 |
2016 |
| Radiation |
stereotactic ablative radiotherapy (sabr) |
1 |
2016 |
| Radiation |
stereotactic body radiation then surgery |
1 |
2014 |
| Radiation |
stereotactic radiation |
1 |
2012 |
| Radiation |
stereotatic body radiotherapy (sbrt) |
1 |
2013 |
| Drug |
stp705 |
1 |
2020 |
| Drug |
streptozotocin |
1 |
2004 |
| Drug |
stro-002 |
1 |
2018 |
| Drug |
su011248 (sunitinib) |
1 |
2005 |
| Drug |
su011248 capsule |
1 |
2005 |
| Drug |
suba-itraconazole |
1 |
2015 |
| Drug |
subcutaneous (sc) sea-cd40 |
1 |
2015 |
| Procedure |
subxiphoid uniportal vats |
1 |
2017 |
| Drug |
sulindac |
1 |
2012 |
| Drug |
sunitinib (su011248) |
1 |
2005 |
| Drug |
sunitinib 2 |
1 |
2007 |
| Drug |
sunitinib 2/1 |
1 |
2007 |
| Drug |
sunitinib 4 |
1 |
2007 |
| Drug |
sunitinib 4/2 |
1 |
2007 |
| Drug |
sunitinib malate (su011248) |
1 |
2008 |
| Drug |
sunitinib maleate |
1 |
2009 |
| Procedure |
superficial shave biopsy |
1 |
2013 |
| Other |
supersaturated calcium-phosphate |
1 |
2010 |
| Behavioral |
supine position |
1 |
2009 |
| Procedure |
supportive care |
1 |
2016 |
| Procedure |
surgery alone |
1 |
2020 |
| Procedure |
surgery of resectable lesions |
1 |
2008 |
| Procedure |
surgery, chemotherapy and |
1 |
2005 |
| Procedure |
surgery, chemotherapy and/or radiotherapy |
1 |
2005 |
| Procedure |
surgery/hyperthermic intraperitoneal chemotherapy with mmc |
1 |
2014 |
| Other |
surgery: classic strategy |
1 |
2016 |
| Other |
surgery: gs strategy |
1 |
2016 |
| Procedure |
surgery: spleen-preservation |
1 |
2005 |
| Procedure |
surgery: splenectomy |
1 |
2005 |
| Device |
surgical removal of sinonasal papiloma |
1 |
2013 |
| Procedure |
surgical removal of tumor tissue for t cell production |
1 |
2016 |
| Procedure |
surgical resection (standard of care) |
1 |
2015 |
| Procedure |
surgical tumor resection |
1 |
2009 |
| Drug |
surufatinib |
1 |
2015 |
| Other |
survivorship care plan |
1 |
2019 |
| Behavioral |
survivorship education |
1 |
2015 |
| Drug |
sustained released 5-fu |
1 |
2009 |
| Drug |
sustained released 5-fu/sustained released cisplatin |
1 |
2009 |
| Drug |
sustained released cisplatin |
1 |
2009 |
| Procedure |
sutures |
1 |
2007 |
| Drug |
sym004 |
1 |
2011 |
| Behavioral |
symptom control |
1 |
2015 |
| Drug |
systemic chemotherapy (folfox) |
1 |
2008 |
| Drug |
systemic chemotherapy alone (oxaliplatin, 5-fluorouracil, isovorin) |
1 |
2012 |
| Drug |
systemic gemcitabine |
1 |
2012 |
| Biological |
tabelecleucel |
1 |
2018 |
| Drug |
tac-101 |
1 |
2004 |
| Procedure |
tace-sorafenib group |
1 |
2011 |
| Procedure |
tace (transcatheter arterial chemoembolization ) |
1 |
2009 |
| Other |
tace / rg3 |
1 |
2016 |
| Drug |
tace regimen |
1 |
2016 |
| Procedure |
tace therapy |
1 |
2009 |
| Radiation |
tace transarterial chemoembolization |
1 |
2013 |
| Other |
tace/ rtc |
1 |
2011 |
| Combination Product |
tace/autologous tcm immunotherapy |
1 |
2018 |
| Radiation |
tace/external beam rt |
1 |
2013 |
| Device |
tace/rfa |
1 |
2019 |
| Drug |
tace/sorafenib |
1 |
2015 |
| Procedure |
tace/with iodine-125 seeds implantation |
1 |
2017 |
| placebo |
tadalafil placebo |
1 |
2015 |
| Drug |
taest16001 |
1 |
2017 |
| Procedure |
tagm |
1 |
2020 |
| Combination Product |
tai combine lenvatinib |
1 |
2019 |
| Combination Product |
tai combine sbrt |
1 |
2019 |
| Combination Product |
tai with folfox |
1 |
2019 |
| Combination Product |
tai/pd1 |
1 |
2019 |
| Drug |
talazoparib tosylate |
1 |
2019 |
| Genetic |
talimogene laherparepvec (t-vec) |
1 |
2018 |
| Drug |
talimogene laherparepvec (tvec) |
1 |
2016 |
| Device |
tandem microsphere loaded with epirubicin |
1 |
2017 |
| Device |
tandemâ„¢ |
1 |
2012 |
| Drug |
tandutinib |
1 |
2006 |
| Drug |
tanespimycin |
1 |
2005 |
| Drug |
tarceva (erlotinib hcl) |
1 |
2004 |
| Radiation |
target volume delineation after nact |
1 |
2017 |
| Drug |
tas-102 |
1 |
2016 |
| Biological |
tavokinogene telseplasmid (tavo) |
1 |
2011 |
| Drug |
taxane |
1 |
2015 |
| Drug |
tazarotene |
1 |
2008 |
| Drug |
tazemetostat |
1 |
2019 |
| Drug |
tc99m-sulfur colloid |
1 |
2009 |
| Biological |
tcrzeta-cd19t-expressing t-lymphocytes |
1 |
2019 |
| Procedure |
tea |
1 |
2013 |
| Procedure |
tea with lem |
1 |
2007 |
| Drug |
technetium tc-99m sodium pertechnetate |
1 |
2017 |
| Drug |
technetium tc 99m ec20 |
1 |
2012 |
| Drug |
technetium99 |
1 |
2016 |
| Drug |
tefinostat |
1 |
2014 |
| Drug |
tegafur-gimeracil-oteracil |
1 |
2019 |
| Drug |
tegafur gimeracil oteracil potassium capsules |
1 |
2017 |
| Drug |
tegafur/uracil |
1 |
2007 |
| Drug |
tegafur/uracil (ufurâ®) |
1 |
2007 |
| Drug |
telaglenastat |
1 |
2019 |
| Drug |
telaglenastat hydrochloride |
1 |
2019 |
| Drug |
telapristone acetate |
1 |
2014 |
| Device |
tele-dermatology |
1 |
2016 |
| Drug |
temoporfin |
1 |
2013 |
| Drug |
temsirolimus (cci-779) |
1 |
2007 |
| Drug |
temsirolimus (pre surgery) |
1 |
2011 |
| Drug |
temsirolimus (torisel) |
1 |
2007 |
| Drug |
tenofovir disoproxil fumarate 300mg |
1 |
2020 |
| Drug |
tepotinib 1000 mg |
1 |
2013 |
| Drug |
tepotinib 300 mg |
1 |
2013 |
| Drug |
tepotinib 500 mg |
1 |
2013 |
| Drug |
testosterone enanthate 100 mg |
1 |
2009 |
| Drug |
testosterone enanthate 100 mg/ml |
1 |
2009 |
| Drug |
testosterone undecanoate |
1 |
2017 |
| Drug |
testosterone undecanoate/sunitinib/pazopanib |
1 |
2017 |
| Drug |
tetrahydrouridine |
1 |
2004 |
| Drug |
tetrahydrouridine (thu) |
1 |
2017 |
| Drug |
tetrathiomolybdate (tm) |
1 |
2005 |
| Other |
text message |
1 |
2019 |
| Drug |
tf2 - 68 ga-imp-288: |
1 |
2012 |
| Biological |
tg4001 |
1 |
2017 |
| Biological |
tgfbdnrii-transduced autologous tumor infiltrating lymphocytes |
1 |
2015 |
| Procedure |
th2 rapa cells |
1 |
2009 |
| Drug |
thalidomide, alpha interferon |
1 |
2005 |
| Drug |
thalidomide, interferon, octreotide |
1 |
2005 |
| Drug |
thalidomine |
1 |
2014 |
| Drug |
the ginsenoside rg3 |
1 |
2012 |
| Device |
therabionic device |
1 |
2007 |
| Procedure |
therapeutic |
1 |
2016 |
| Biological |
therapeutic estradiol |
1 |
2019 |
| Procedure |
therapeutic lymphadenectomy |
1 |
2012 |
| Procedure |
therapeutic surgical procedure |
1 |
2015 |
| Device |
therapy |
1 |
2016 |
| Device |
therasphere |
1 |
2012 |
| Radiation |
therasphere hud |
1 |
2008 |
| Procedure |
thermal ablation |
1 |
2019 |
| Procedure |
thermal ablation therapy |
1 |
2016 |
| Drug |
thiotepa |
1 |
2007 |
| Radiation |
thoracic radiation |
1 |
2015 |
| Radiation |
thoracic radiation therapy |
1 |
2019 |
| Procedure |
thoracic surgical procedure |
1 |
2017 |
| Diagnostic Test |
thorax |
1 |
2019 |
| Radiation |
three fraction accelerated partial breast irradiation |
1 |
2018 |
| Procedure |
thrombectomy |
1 |
2013 |
| Drug |
thrombospondin-1 mimetic |
1 |
2003 |
| Drug |
thymalfasin (thymosin alpha-1) |
1 |
2004 |
| Drug |
thymosin a1 |
1 |
2018 |
| Biological |
til infusion |
1 |
2016 |
| Drug |
tilsotolimod |
1 |
2019 |
| Drug |
tiragolumab |
1 |
2019 |
| Drug |
tirapazamine |
1 |
2017 |
| Drug |
tislelizumab(bgb-a317 |
1 |
2019 |
| Drug |
tislelizumab(bgb-a317/with chemoradiotherapy. |
1 |
2019 |
| Drug |
tisotumab vedotin |
1 |
2018 |
| Procedure |
tissue bonding |
1 |
2007 |
| Other |
tissue oxygen measurement |
1 |
2014 |
| Other |
tissues collections |
1 |
2020 |
| Drug |
tivozanib (av-951)/temsirolimus |
1 |
2007 |
| Genetic |
tk99un |
1 |
2009 |
| Drug |
tki: sutent, nexavar |
1 |
2012 |
| Drug |
tki: sutent, nexavar/votrient |
1 |
2012 |
| Drug |
tki258 |
1 |
2012 |
| Drug |
tki258 (dovitinib): |
1 |
2011 |
| Drug |
tlc 388 |
1 |
2015 |
| Procedure |
tme (total mesorectal excision) |
1 |
2013 |
| Drug |
tmx-101 |
1 |
2012 |
| Genetic |
tnf-alpha |
1 |
2008 |
| Genetic |
tnf promoter |
1 |
2008 |
| Drug |
tno155 |
1 |
2019 |
| Other |
tobacco cessation counseling |
1 |
2017 |
| Procedure |
toce |
1 |
2009 |
| Procedure |
toce/peit |
1 |
2009 |
| Procedure |
toce/rfa |
1 |
2009 |
| Drug |
tocilizumab |
1 |
2019 |
| Drug |
tocosol paclitaxel |
1 |
2004 |
| Drug |
tolipalimab |
1 |
2019 |
| Radiation |
tomo |
1 |
2016 |
| Radiation |
tomotherapy |
1 |
2013 |
| Drug |
topical ascorbic acid |
1 |
2020 |
| Drug |
topotecan hydrochloride liposomes |
1 |
2003 |
| Biological |
toripalimab injection(js001 ) |
1 |
2019 |
| Drug |
toripalimab/gemcitabine |
1 |
2020 |
| Drug |
toriplimab |
1 |
2019 |
| Procedure |
total hemihepatic vascular exclusion |
1 |
2009 |
| Procedure |
total thyroidectomy |
1 |
2020 |
| Procedure |
total thyroidectomy/central neck dissection |
1 |
2020 |
| Other |
tourniquet ischemia |
1 |
2011 |
| Other |
toxicities reduced treatment |
1 |
2019 |
| Drug |
tp-0903 |
1 |
2016 |
| Drug |
tpf experimental |
1 |
2010 |
| Drug |
tpf group |
1 |
2014 |
| Drug |
tpf neoadjuvant chemotherapy |
1 |
2013 |
| Drug |
tqb2450 |
1 |
2019 |
| Drug |
tqb2450 injection |
1 |
2019 |
| Drug |
tqb2450/cisplatin/carboplatin / 5-fluorouracil (5-fu) |
1 |
2019 |
| Drug |
trabectedin |
1 |
2002 |
| Procedure |
traditional rfa |
1 |
2016 |
| Combination Product |
trans-arterial chemoembolization |
1 |
2017 |
| Procedure |
trans-arterial chemoembolization (tace) |
1 |
2014 |
| Procedure |
trans arterial chemoembolization (tace) |
1 |
2004 |
| Procedure |
trans oral surgery (tos) |
1 |
2016 |
| Drug |
transarterial chemoembolisation |
1 |
2009 |
| Procedure |
transarterial chemoembolisation with doxorubicin |
1 |
2007 |
| Procedure |
transarterial chemoembolization versus the standard treatment with sorafinib |
1 |
2016 |
| Procedure |
transarterial chemoembolization(tace) |
1 |
2019 |
| Combination Product |
transarterial chemoinfusion (tai) combine toripalimab |
1 |
2019 |
| Procedure |
transarterial infusion |
1 |
2018 |
| Device |
transarterialchemoembolisation (tace) |
1 |
2005 |
| Procedure |
transcatheter hepatic arterial chemoembolization |
1 |
2011 |
| Procedure |
transcervical oropharyngeal ultrasound |
1 |
2017 |
| Procedure |
transcutaneous acupoint electrical stimulation |
1 |
2019 |
| Procedure |
transoral robotic surgery (tors) with neck dissection |
1 |
2019 |
| Procedure |
transoral robotic surgery / neck dissection |
1 |
2012 |
| Procedure |
transoral surgery |
1 |
2012 |
| Drug |
trc 105 |
1 |
2011 |
| Drug |
trc105/axitinib |
1 |
2013 |
| Other |
treatment determined by physician |
1 |
2008 |
| Drug |
treatment duration of cisplatin based chemotherapy |
1 |
2016 |
| Drug |
treatment with bsct |
1 |
2015 |
| Drug |
treatment with cbp |
1 |
2009 |
| Drug |
treatment with cbp/5-fu |
1 |
2009 |
| Drug |
treatment with endostar, cbp |
1 |
2009 |
| Drug |
treatment with endostar, cbp/5-fu |
1 |
2009 |
| Drug |
treatment with vismodegib |
1 |
2018 |
| Drug |
tremelimumab (cohort a dose) |
1 |
2018 |
| Drug |
tremelimumab (cohort b dose) |
1 |
2018 |
| Drug |
tremelimumab (regimen 1) |
1 |
2017 |
| Drug |
tremelimumab (regimen 2) |
1 |
2017 |
| Drug |
tremelimumab (treme) |
1 |
2015 |
| Drug |
trement |
1 |
2006 |
| Drug |
tretinoin |
1 |
2019 |
| Drug |
tretinoin 0.1% cream |
1 |
2000 |
| Drug |
tretinoin 0.1% cream/placebo |
1 |
2000 |
| Biological |
tricom vaccine |
1 |
2002 |
| Drug |
triprizumab |
1 |
2019 |
| Biological |
trovaxâ® |
1 |
2006 |
| Drug |
trpv6 calcium channel inhibitor sor-c13 |
1 |
2018 |
| Other |
tumor-infiltrating lymphocyte therapy |
1 |
2017 |
| Procedure |
tumor-infiltrating lymphocytes (til) |
1 |
2017 |
| Biological |
tumor antigen loaded autologous dendritic cells |
1 |
2005 |
| Procedure |
tumor biopsies |
1 |
2013 |
| Genetic |
tumor tissue collection (optional) |
1 |
2016 |
| Device |
tumor treating fields therapy |
1 |
2019 |
| Procedure |
tumorectomy |
1 |
2015 |
| Device |
twin internally cooled-wet electrodes |
1 |
2019 |
| Biological |
ucb-nk cells |
1 |
2018 |
| Drug |
ugn-102 |
1 |
2018 |
| Drug |
ulixertinib |
1 |
2015 |
| Procedure |
ultrasonographic screening |
1 |
2005 |
| Procedure |
ultrasonography |
1 |
2014 |
| Procedure |
ultrasound-guided transbronchial needle-delivered interstitial photodynamic therapy |
1 |
2018 |
| Drug |
ultrasound contrast agent (contrast-enhanced ultrasound) |
1 |
2016 |
| Procedure |
umbilical cord blood transplantation |
1 |
1999 |
| Other |
university of michigan xerostomia index |
1 |
2018 |
| Drug |
uprosertib |
1 |
2013 |
| Drug |
uracil |
1 |
2007 |
| Drug |
uracil (ufurâ®) |
1 |
2007 |
| Drug |
urea-based cream |
1 |
2013 |
| Drug |
urea cream 20% |
1 |
2017 |
| Diagnostic Test |
urinary malignancy |
1 |
2019 |
| Biological |
urokinase-derived peptide a6 |
1 |
2009 |
| Diagnostic Test |
uspio-enhanced mri |
1 |
2018 |
| Behavioral |
usual dietary care |
1 |
2020 |
| Drug |
usual mal-pdt |
1 |
2011 |
| Procedure |
uterine lavage |
1 |
2017 |
| Device |
uterine lavage catheter |
1 |
2017 |
| Biological |
v934-ep |
1 |
2008 |
| Biological |
v935 |
1 |
2008 |
| placebo |
vaccine placebo |
1 |
2015 |
| Drug |
val201 |
1 |
2014 |
| Drug |
valacyclovir |
1 |
2016 |
| Drug |
valrubicin |
1 |
2012 |
| Drug |
valrubicin, 800 mg |
1 |
2011 |
| Drug |
vandetanib 300mg |
1 |
2012 |
| Drug |
vandetanib/metformin |
1 |
2015 |
| Drug |
varenicline |
1 |
2015 |
| Drug |
varlilumab 3 mg |
1 |
2019 |
| Drug |
varlilumab 3 mg/kg |
1 |
2019 |
| Drug |
vatalanib |
1 |
2008 |
| Genetic |
vcn-01 |
1 |
2018 |
| Biological |
vegf trap |
1 |
2006 |
| Drug |
vegfâ€tki |
1 |
2016 |
| Drug |
vegfr inhibitor |
1 |
2020 |
| Drug |
vehicle |
1 |
2009 |
| Drug |
velcade tm (bortezomib) for injection, |
1 |
2003 |
| Drug |
velcade tm (bortezomib) for injection,/ps-341 |
1 |
2003 |
| Drug |
vemurafenib |
1 |
2017 |
| Drug |
venetoclax |
1 |
2018 |
| Drug |
venlafaxine |
1 |
2018 |
| Drug |
venlafaxine hydrochloride extended release |
1 |
2018 |
| Procedure |
vertical mattress suture |
1 |
2013 |
| Device |
vevo 3100 lazr-x |
1 |
2018 |
| Behavioral |
video-based informed consent |
1 |
2014 |
| Procedure |
video fluoroscopy |
1 |
2011 |
| Procedure |
videoscopic procedure |
1 |
2012 |
| Drug |
vinblastine sulfate |
1 |
2002 |
| Drug |
vinflunine, carboplatin |
1 |
2012 |
| Drug |
vinflunine, gemcitabine |
1 |
2012 |
| Drug |
vinflunine/best supportive care |
1 |
2006 |
| Drug |
vinorelbine ditartrate |
1 |
2010 |
| Drug |
vismodegib (150 mg po daily) |
1 |
2012 |
| Drug |
vismodegib 150 mg |
1 |
2009 |
| Drug |
vistusertib |
1 |
2014 |
| Drug |
vitamin a compound |
1 |
2019 |
| Dietary Supplement |
vitamin b12 |
1 |
2008 |
| Drug |
vitamin b12 injection |
1 |
2016 |
| Dietary Supplement |
vitamin d3 prior to first visit |
1 |
2018 |
| Dietary Supplement |
vitamin d3 prior to second visit |
1 |
2018 |
| Drug |
vitamins |
1 |
2011 |
| Procedure |
vivascope 2500 ex-vivo fluorescent confocal microscope |
1 |
2018 |
| Drug |
vk-2019 |
1 |
2018 |
| Radiation |
vmat |
1 |
2019 |
| Radiation |
vmat with cbct |
1 |
2011 |
| Radiation |
vmat with kv-ray |
1 |
2011 |
| Drug |
vmd-928 300-mg capsules |
1 |
2018 |
| Radiation |
volume modulated arc therapy |
1 |
2014 |
| Drug |
votrient |
1 |
2012 |
| Biological |
vsv-hifnbeta-nis |
1 |
2017 |
| Biological |
vsv-ifnî²-nis |
1 |
2018 |
| Biological |
vv1 |
1 |
2020 |
| Drug |
vx-970 (m6620) |
1 |
2015 |
| Other |
watch video |
1 |
2017 |
| Device |
watson artificial intelligence |
1 |
2019 |
| Drug |
wee1 inhibitor azd1775 |
1 |
2015 |
| Drug |
week) |
1 |
2009 |
| Behavioral |
weight loss |
1 |
2014 |
| Dietary Supplement |
whey protein supplement |
1 |
2015 |
| Other |
whole body pet-ct |
1 |
2018 |
| Procedure |
whole body pet-ct scan |
1 |
2009 |
| Radiation |
whole breast radiation |
1 |
2015 |
| Radiation |
whole breast radiotherapy |
1 |
2019 |
| Radiation |
whole neck irradiation |
1 |
2015 |
| Combination Product |
with apatinib |
1 |
2019 |
| Drug |
with aptinib |
1 |
2019 |
| Drug |
with chemoradiotherapy |
1 |
2019 |
| Drug |
with chemoradiotherapy. |
1 |
2019 |
| Other |
with ct with iodinated contrast injection |
1 |
2015 |
| Other |
with ct without injection |
1 |
2015 |
| Combination Product |
with enteral feeding by percutaneous endoscopic gastrostomy |
1 |
2020 |
| Drug |
with gemcitabine |
1 |
2020 |
| Procedure |
with iodine-125 seeds implantation |
1 |
2017 |
| Procedure |
with lymphadenectomy |
1 |
2014 |
| Drug |
with nimotuzumab |
1 |
2012 |
| Combination Product |
with s-1 |
1 |
2018 |
| Drug |
with shr-1210 injection |
1 |
2020 |
| Combination Product |
with tace |
1 |
2020 |
| Biological |
without bevacizumab |
1 |
2016 |
| Procedure |
wl |
1 |
2014 |
| Procedure |
wl/nbi |
1 |
2014 |
| Drug |
wst09 |
1 |
2006 |
| Drug |
wst11 mediated vascular targeted phototherapy (vtp) |
1 |
2018 |
| Drug |
xenetix-ct perfusion imaging |
1 |
2012 |
| Drug |
xl147 (sar245408) |
1 |
2009 |
| Drug |
xl147 (sar245408), |
1 |
2008 |
| Drug |
xl880) |
1 |
2008 |
| Drug |
xl888 |
1 |
2017 |
| Biological |
xmab20717 |
1 |
2018 |
| Biological |
xmabâ®22841 |
1 |
2019 |
| Biological |
xmabâ®23104 |
1 |
2018 |
| Drug |
xofigo |
1 |
2016 |
| Radiation |
xrt |
1 |
2016 |
| Radiation |
y-90 radioembolization |
1 |
2017 |
| Device |
y90 radioembolization |
1 |
2017 |
| Drug |
yang yin fu zheng jie du therapy |
1 |
2020 |
| Biological |
yervoy |
1 |
2017 |
| Drug |
yiv-906 |
1 |
2019 |
| Drug |
yiv-906/sorafenib |
1 |
2019 |
| Drug |
ym155 |
1 |
2006 |
| Procedure |
yoga |
1 |
2005 |
| Biological |
young til |
1 |
2014 |
| Drug |
yttrium-90 (y-90) |
1 |
2009 |
| Device |
yttrium-90 microspheres (therasphere mds nordion) |
1 |
2009 |
| Drug |
z-208 |
1 |
2008 |
| Drug |
z-endoxifen hydrochloride |
1 |
2017 |
| Drug |
z650 |
1 |
2019 |
| Drug |
zavedosâ® |
1 |
2013 |
| Drug |
zd6474 |
1 |
2007 |
| Drug |
zd6474 (vandetanib) |
1 |
2006 |
| Drug |
zd6474, vandetanib |
1 |
2008 |
| Drug |
zirconium-89 girentuximab pet |
1 |
2016 |
| Drug |
zirconium-89 girentuximab pet/ct |
1 |
2016 |
| Drug |
zirconium zr-89 panitumumab |
1 |
2018 |
| Drug |
zkab001 10mg |
1 |
2018 |
| Drug |
zkab001 10mg/kg |
1 |
2018 |
| Drug |
zkab001 15mg |
1 |
2018 |
| Drug |
zkab001 15mg/kg |
1 |
2018 |
| Drug |
zkab001 5mg |
1 |
2018 |
| Drug |
zkab001 5mg/kg |
1 |
2018 |
| Drug |
zoledronate |
1 |
2007 |